[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjhFKuTM3L6XxzXd6IZzSBdNV8FDM7RdisQhDjdcR4IU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of Utah",[4],968,false,217,40,781250,73,629,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Cancer",31,{"name":18,"count":19},"Pain",23,{"name":21,"count":22},"Breast Cancer",20,{"name":24,"count":22},"Chronic Pain",{"name":26,"count":27},"Low Back Pain",17,{"name":29,"count":30},"Contraception",15,{"name":32,"count":30},"Obesity",{"name":34,"count":35},"Stroke",14,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04892251","Ketamine Assisted Psychotherapy for Opioid Use Disorder","2023-12-30","MORE+KAP",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04141644","Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC","2024-01-29","Ipilimumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05292209","RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring","2024-10-30","Riluzole 50 MG",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04106856","Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer (SHAPER)","2024-12-06","Losartan",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04163432","Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC","2025-02-04","Durvalumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03171025","Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer","2025-02-10","Nivolumab",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04409639","Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations","2025-04-02","Cobimetinib",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04754191","Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer","2025-04-22","Enfortumab vedotin",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04315233","Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics","2025-06","Ribociclib",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05201144","A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)","2026-03-31","Sildenafil Oral Suspension",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,123,152,170,280,348,396,432,483,511,539,573,599,625,655,673,699,725,752,773,799,819,844,867,887,905,923,941,969,987,1005,1034,1052,1070,1088,1117,1135,1153,1171,1189,1210,1233,1255,1281,1299,1323,1341,1370,1417,1443,1467,1485,1509,1527,1552,1570,1588,1606,1632,1658,1682,1710,1728,1764,1790,1815,1833,1851,1876,1894,1918,1942,1967,2000,2071,2113,2142,2164,2193,2220,2244,2269,2287,2311,2336,2364,2388,2413,2437,2463,2488,2515,2533,2559,2582,2600,2618,2636,2660,2684,2702,2729,2759,2777,2795,2821,2839,2862,2890,2917,2935,2959,3002,3036,3061,3085,3109,3133,3157,3179,3205,3227,3249,3273,3296,3330,3348,3366,3384,3408,3431,3456,3480,3503,3526,3551,3573,3628,3692,3757,3799,3851,3889,3930,3982,4011,4033,4068,4090,4124,4156,4178,4211,4246,4281,4309,4341,4378,4408,4441,4467,4485,4503,4521,4539,4565,4583,4608,4632,4650,4673,4698,4720,4738,4762,4780,4803,4829,4847,4871,4895,4920,4943,4968,4989,5014,5032,5050,5073,5096,5122,5146,5167,5189,5207,5230,5248,5273,5291,5309,5327,5350,5368,5392,5414,5432,5457,5480,5505,5523,5546,5574,5592,5617,5635,5661,5684,5708,5730,5752,5776,5794,5812,5830,5854,5872,5897,5915,5939,5961,5983,6008,6026,6049,6067,6085,6108,6132,6157,6175,6199,6224,6246,6272,6290,6314,6338,6356,6381,6403,6446,6478,6500,6533,6567,6590,6614,6632,6650,6668,6692,6710,6734,6752,6776,6794,6817,6841,6865,6890,6908,6926,6948,6971,6993,7011,7034,7052,7070,7088,7113,7131,7163,7185,7203,7221,7239,7257,7275,7300,7318,7336,7360,7383,7407,7432,7455,7478,7501,7525,7547,7565,7583,7601,7624,7648,7666,7690,7708,7726,7749,7770,7806,7828,7861,7885,7910,7934,7959,7984,8002,8024,8051,8069,8087,8105,8131,8154,8172,8196,8221,8248,8266,8291,8315,8341,8366,8384,8402,8420,8443,8461,8479,8500,8523,8546,8569,8592,8643,8676,8716,8759,8785,8812,8843,8865,8889,8917,8945,8976,9001,9023,9058,9087,9105,9123,9141,9166,9188,9213,9236,9258,9280,9304,9328,9346,9374,9392,9410,9433,9455,9479,9497,9521,9539,9562,9584,9608,9633,9655,9673,9691,9714,9732,9755,9773,9796],{"intervention":96,"totalTrials":97,"cells":98},"Levonorgestrel 52 MG Intrauterine System",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":121},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT05444582","Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start","RECRUITING",[92],"2027-03-31","2027-07-31","2022-11-07",1404,[29],[96],{"trials":122,"activeCount":101},[],{"intervention":124,"totalTrials":97,"cells":125},"Levonorgestrel 1.5 mg and Piroxicam 40 mg",{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":148,"NA":150},{"trials":127,"activeCount":101},[],{"trials":129,"activeCount":101},[],{"trials":131,"activeCount":101},[],{"trials":133,"activeCount":97,"soonestReadout":139},[134],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":146},"NCT07449299","Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel","NOT_YET_RECRUITING",[91],"2031-06","2031-11","2027-03",1458,[144,29,145],"Emergency Contraception","COX-2 Inhibitor",[124,147],"Oral LNG + Placebo",{"trials":149,"activeCount":101},[],{"trials":151,"activeCount":101},[],{"intervention":147,"totalTrials":97,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":166,"NA":168},{"trials":155,"activeCount":101},[],{"trials":157,"activeCount":101},[],{"trials":159,"activeCount":101},[],{"trials":161,"activeCount":97,"soonestReadout":139},[162],{"nctId":135,"briefTitle":136,"status":137,"phases":163,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":164,"interventions":165},[91],[144,29,145],[124,147],{"trials":167,"activeCount":101},[],{"trials":169,"activeCount":101},[],{"intervention":66,"totalTrials":171,"cells":172},8,{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":229,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":174,"activeCount":101},[],{"trials":176,"activeCount":97,"soonestReadout":182},[177,190,202,216],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT04109729","Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer","ACTIVE_NOT_RECRUITING",[89],"2026-04-28","2026-12","2020-09-16",39,[187],"Metastatic Castration-resistant Prostate Cancer",[66,189],"Radium-223",{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":97,"conditions":198,"interventions":200},"NCT03382886","Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma","TERMINATED",[89],"2018-07-26","2019-07-02","2018-04-11",[199],"Hepatocellular Carcinoma",[66,201],"Bevacizumab",{"nctId":203,"briefTitle":204,"status":205,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":101,"conditions":210,"interventions":212},"NCT04315155","Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic\u002FAdvanced Carcinomas w ARID1A Lof Mutation","WITHDRAWN",[89],"2023-09","2025-09","2020-10",[211],"Metastatic Adenocarcinoma",[213,214,215,214,213],"Belinostat","nivolumab","ipilimumab",{"nctId":217,"briefTitle":218,"status":219,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":35,"conditions":224,"interventions":226},"NCT01998126","Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer","COMPLETED",[89],"2017-05-09","2018-03-29","2013-12-02",[225],"Non-small Cell Lung Cancer",[46,227,228,66],"Erlotinib","Crizotinib",{"trials":230,"activeCount":273,"soonestReadout":65},[231,243,253,261],{"nctId":232,"briefTitle":233,"status":193,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT03259425","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",[90],"2018-09-21","2020-09-25","2018-01-03",7,[240],"Melanoma",[66,242],"HF10",{"nctId":244,"briefTitle":245,"status":113,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":252},"NCT06365619","Neoadjuvant Ipilimumab\u002FNivolumab for Patients With Recurrent, High Risk, Resectable Melanoma",[90],"2027-08","2030-08","2026-06",25,[240],[46,66],{"nctId":63,"briefTitle":64,"status":180,"phases":254,"primaryCompletion":65,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},[90],"2027-10-31","2017-07-10",200,[259],"Bladder Cancer",[66],{"nctId":262,"briefTitle":263,"status":180,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT05723055","Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[90],"2026-05","2028-04","2023-05-03",9,[270],"Hodgkin Lymphoma",[272,66],"Axatilimab",3,{"trials":275,"activeCount":101},[],{"trials":277,"activeCount":101},[],{"trials":279,"activeCount":101},[],{"intervention":281,"totalTrials":282,"cells":283},"Metformin",5,{"EARLY_PHASE1":284,"PHASE1":319,"PHASE2":331,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":285,"activeCount":273,"soonestReadout":313},[286,297,309],{"nctId":287,"briefTitle":288,"status":113,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":296},"NCT06185179","Metformin and Muscle Recovery",[88],"2029-05-31","2030-05-31","2024-09-01",50,[295],"Muscle Atrophy or Weakness",[281],{"nctId":298,"briefTitle":299,"status":300,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":308},"NCT07179042","Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo","ENROLLING_BY_INVITATION",[88],"2030-09","2025-09-04",60,[306,307],"Intertrochanteric Femur Fracture","Muscle Atrophy",[281],{"nctId":310,"briefTitle":311,"status":180,"phases":312,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":318},"NCT03107884","Role of Metformin on Muscle Health of Older Adults",[88],"2026-11-01","2019-08-01",64,[307,317],"Insulin Resistance",[281,281],{"trials":320,"activeCount":101},[321],{"nctId":322,"briefTitle":323,"status":219,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT02682121","Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo",[89],"2017-01","2012-04",55,[329],"Prediabetes",[281],{"trials":332,"activeCount":97,"soonestReadout":115},[333],{"nctId":334,"briefTitle":335,"status":113,"phases":336,"primaryCompletion":115,"completion":115,"start":337,"enrollment":338,"conditions":339,"interventions":341},"NCT05900466","Metformin for Fibromyalgia Symptoms (INFORM Trial)",[90],"2023-04-01",72,[340],"Fibromyalgia Syndrome",[281],{"trials":343,"activeCount":101},[],{"trials":345,"activeCount":101},[],{"trials":347,"activeCount":101},[],{"intervention":61,"totalTrials":273,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":379,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":351,"activeCount":101},[],{"trials":353,"activeCount":378,"soonestReadout":369},[354,365],{"nctId":355,"briefTitle":356,"status":113,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":364},"NCT06124118","Tumor Treating Fields for Locally Advanced NSCLC",[89],"2026-11-15","2027-11-15","2024-04-04",30,[363],"Non Small Cell Lung Cancer",[61],{"nctId":366,"briefTitle":367,"status":180,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":268,"conditions":372,"interventions":377},"NCT05154994","Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma",[89],"2026-08","2028-02","2022-01-14",[373,374,375,376],"Infiltrating Urothelial Carcinoma, Sarcomatoid Variant","Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Unresectable Urothelial Carcinoma",[213,61],2,{"trials":380,"activeCount":97,"soonestReadout":60},[381],{"nctId":58,"briefTitle":59,"status":180,"phases":382,"primaryCompletion":60,"completion":183,"start":383,"enrollment":384,"conditions":385,"interventions":387},[90],"2020-06-16",43,[386],"Non-Small Cell Lung Cancer Metastatic",[61,388,389],"Pemetrexed","Carboplatin",{"trials":391,"activeCount":101},[],{"trials":393,"activeCount":101},[],{"trials":395,"activeCount":101},[],{"intervention":46,"totalTrials":397,"cells":398},4,{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":420,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":97,"soonestReadout":45},[403,412,416],{"nctId":43,"briefTitle":44,"status":180,"phases":404,"primaryCompletion":45,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},[89],"2028-04-30","2020-08-20",24,[409],"Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)",[46,411],"Osimertinib",{"nctId":203,"briefTitle":204,"status":205,"phases":413,"primaryCompletion":207,"completion":208,"start":209,"enrollment":101,"conditions":414,"interventions":415},[89],[211],[213,214,215,214,213],{"nctId":217,"briefTitle":218,"status":219,"phases":417,"primaryCompletion":221,"completion":222,"start":223,"enrollment":35,"conditions":418,"interventions":419},[89],[225],[46,227,228,66],{"trials":421,"activeCount":97,"soonestReadout":247},[422],{"nctId":244,"briefTitle":245,"status":113,"phases":423,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":424,"interventions":425},[90],[240],[46,66],{"trials":427,"activeCount":101},[],{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":101},[],{"intervention":433,"totalTrials":273,"cells":434},"Rituximab",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":453,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":436,"activeCount":101},[],{"trials":438,"activeCount":101},[439],{"nctId":440,"briefTitle":441,"status":442,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":407,"conditions":447,"interventions":449},"NCT06824701","Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","SUSPENDED",[89],"2032-01","2033-01","2025-09-12",[448],"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[450,451,433,452],"Tazemetostat","Zanubrutinib","Obinutuzumab",{"trials":454,"activeCount":378,"soonestReadout":141},[455,466],{"nctId":456,"briefTitle":457,"status":113,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":19,"conditions":462,"interventions":464},"NCT06390956","Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",[90],"2031-12","2032-12","2025-02-20",[463],"Marginal Zone Lymphoma",[465,433],"Pirtobrutinib",{"nctId":467,"briefTitle":468,"status":113,"phases":469,"primaryCompletion":141,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[90],"2030-03","2025-08-25",29,[474],"Relapsed or Refractory Large B-cell Lymphoma",[476,433],"Loncastuximab Tesirine",{"trials":478,"activeCount":101},[],{"trials":480,"activeCount":101},[],{"trials":482,"activeCount":101},[],{"intervention":465,"totalTrials":378,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":486,"activeCount":101},[],{"trials":488,"activeCount":101},[],{"trials":490,"activeCount":378,"soonestReadout":459},[491,495],{"nctId":456,"briefTitle":457,"status":113,"phases":492,"primaryCompletion":459,"completion":460,"start":461,"enrollment":19,"conditions":493,"interventions":494},[90],[463],[465,433],{"nctId":496,"briefTitle":497,"status":137,"phases":498,"primaryCompletion":499,"completion":500,"start":249,"enrollment":250,"conditions":501,"interventions":503},"NCT07548450","Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)",[90],"2034-06","2035-06",[502],"Waldenstrom Macroglobulinemia",[465,504],"Mosunetuzumab",{"trials":506,"activeCount":101},[],{"trials":508,"activeCount":101},[],{"trials":510,"activeCount":101},[],{"intervention":476,"totalTrials":378,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":514,"activeCount":101},[],{"trials":516,"activeCount":101},[],{"trials":518,"activeCount":378,"soonestReadout":141},[519,523],{"nctId":467,"briefTitle":468,"status":113,"phases":520,"primaryCompletion":141,"completion":470,"start":471,"enrollment":472,"conditions":521,"interventions":522},[90],[474],[476,433],{"nctId":524,"briefTitle":525,"status":137,"phases":526,"primaryCompletion":527,"completion":139,"start":249,"enrollment":19,"conditions":528,"interventions":530},"NCT07573436","Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)",[89,90],"2030-06",[529],"Post-transplant Lymphoproliferative Disorder",[531,532],"Loncastuximab tesirine","Rituximab or rituximab biosimilar",{"trials":534,"activeCount":101},[],{"trials":536,"activeCount":101},[],{"trials":538,"activeCount":101},[],{"intervention":540,"totalTrials":378,"cells":541},"Bortezomib",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":567,"PHASE4":569,"NA":571},{"trials":543,"activeCount":101},[],{"trials":545,"activeCount":101},[],{"trials":547,"activeCount":97,"soonestReadout":183},[548,557],{"nctId":549,"briefTitle":550,"status":113,"phases":551,"primaryCompletion":183,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT06029998","Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion",[90],"2028-12","2024-03-11",22,[187],[540],{"nctId":558,"briefTitle":559,"status":193,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":27,"conditions":563,"interventions":566},"NCT00983346","Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients",[90],"2014-09","2009-10",[15,564,565],"Myeloma","Multiple Myeloma",[540],{"trials":568,"activeCount":101},[],{"trials":570,"activeCount":101},[],{"trials":572,"activeCount":101},[],{"intervention":574,"totalTrials":97,"cells":575},"Clomiphene Citrate",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":97,"soonestReadout":586},[582],{"nctId":583,"briefTitle":584,"status":113,"phases":585,"primaryCompletion":586,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT04944836","Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial",[90],"2028-07-01","2029-01-01","2023-03-09",58,[591],"Rotator Cuff Tears",[574],{"trials":594,"activeCount":101},[],{"trials":596,"activeCount":101},[],{"trials":598,"activeCount":101},[],{"intervention":600,"totalTrials":97,"cells":601},"Inebilizumab",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":603,"activeCount":101},[],{"trials":605,"activeCount":101},[],{"trials":607,"activeCount":97,"soonestReadout":612},[608],{"nctId":609,"briefTitle":610,"status":113,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":618},"NCT04372615","The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis",[90],"2028-09-30","2022-03-30",116,[616,617],"Autoimmune Encephalitis","Encephalitis",[600],{"trials":620,"activeCount":101},[],{"trials":622,"activeCount":101},[],{"trials":624,"activeCount":101},[],{"intervention":626,"totalTrials":97,"cells":627},"Atezolizumab",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":629,"activeCount":101},[],{"trials":631,"activeCount":101},[],{"trials":633,"activeCount":97,"soonestReadout":265},[634],{"nctId":635,"briefTitle":636,"status":113,"phases":637,"primaryCompletion":265,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":647},"NCT05168618","Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer",[90],"2027-01","2022-03-29",33,[642,643,644,645,646],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",[626,648],"Cabozantinib S-malate",{"trials":650,"activeCount":101},[],{"trials":652,"activeCount":101},[],{"trials":654,"activeCount":101},[],{"intervention":648,"totalTrials":97,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":101},[],{"trials":662,"activeCount":97,"soonestReadout":265},[663],{"nctId":635,"briefTitle":636,"status":113,"phases":664,"primaryCompletion":265,"completion":638,"start":639,"enrollment":640,"conditions":665,"interventions":666},[90],[642,643,644,645,646],[626,648],{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":101},[],{"trials":672,"activeCount":101},[],{"intervention":674,"totalTrials":97,"cells":675},"Topical Tretinoin",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":677,"activeCount":101},[],{"trials":679,"activeCount":101},[],{"trials":681,"activeCount":97,"soonestReadout":686},[682],{"nctId":683,"briefTitle":684,"status":113,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":250,"conditions":689,"interventions":692},"NCT06358677","Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors",[90],"2027-07","2029-07","2025-02-19",[690,691],"Metastatic Solid Tumor","Locally Advanced Solid Tumor",[674],{"trials":694,"activeCount":101},[],{"trials":696,"activeCount":101},[],{"trials":698,"activeCount":101},[],{"intervention":700,"totalTrials":97,"cells":701},"Nicotinamide",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":719,"PHASE4":721,"NA":723},{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":97,"soonestReadout":369},[708],{"nctId":709,"briefTitle":710,"status":113,"phases":711,"primaryCompletion":369,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":718},"NCT04844528","Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers",[90],"2028-08","2022-02-25",86,[716,717],"Chronic Lymphocytic Leukemia","Non-melanoma Skin Cancer (NMSC)",[700],{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":101},[],{"trials":724,"activeCount":101},[],{"intervention":726,"totalTrials":97,"cells":727},"Transdermal estrogen",{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":729,"activeCount":101},[],{"trials":731,"activeCount":101},[],{"trials":733,"activeCount":97,"soonestReadout":738},[734],{"nctId":735,"briefTitle":736,"status":137,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":589,"conditions":740,"interventions":745},"NCT06318403","Estradiol Supplementation and Rotator Cuff Repair",[90],"2030-12","2028-03",[591,741,742,743,744],"Rotator Cuff Injuries","Rotator Cuff Syndrome","Menopause Related Conditions","Menopause",[726],{"trials":747,"activeCount":101},[],{"trials":749,"activeCount":101},[],{"trials":751,"activeCount":101},[],{"intervention":51,"totalTrials":97,"cells":753},{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":755,"activeCount":101},[],{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":97,"soonestReadout":50},[760],{"nctId":48,"briefTitle":49,"status":113,"phases":761,"primaryCompletion":50,"completion":50,"start":762,"enrollment":763,"conditions":764,"interventions":766},[90],"2022-06-15",78,[765],"Atrial Fibrillation Paroxysmal",[51],{"trials":768,"activeCount":101},[],{"trials":770,"activeCount":101},[],{"trials":772,"activeCount":101},[],{"intervention":774,"totalTrials":97,"cells":775},"Guarana",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":777,"activeCount":101},[],{"trials":779,"activeCount":101},[],{"trials":781,"activeCount":97,"soonestReadout":786},[782],{"nctId":783,"briefTitle":784,"status":113,"phases":785,"primaryCompletion":786,"completion":787,"start":788,"enrollment":714,"conditions":789,"interventions":792},"NCT07151391","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)",[90],"2027-09","2028-09","2025-09-03",[790,791],"Neuroendocrine Tumors","Gynecologic Cancer",[774],{"trials":794,"activeCount":101},[],{"trials":796,"activeCount":101},[],{"trials":798,"activeCount":101},[],{"intervention":71,"totalTrials":97,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":802,"activeCount":101},[],{"trials":804,"activeCount":101},[],{"trials":806,"activeCount":97,"soonestReadout":70},[807],{"nctId":68,"briefTitle":69,"status":180,"phases":808,"primaryCompletion":70,"completion":369,"start":809,"enrollment":35,"conditions":810,"interventions":812},[90],"2021-01-12",[811],"Chronic Myelomonocytic Leukemia (CMML)",[71],{"trials":814,"activeCount":101},[],{"trials":816,"activeCount":101},[],{"trials":818,"activeCount":101},[],{"intervention":820,"totalTrials":97,"cells":821},"Isatuximab",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":823,"activeCount":101},[],{"trials":825,"activeCount":101},[],{"trials":827,"activeCount":97,"soonestReadout":832},[828],{"nctId":829,"briefTitle":830,"status":113,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":9,"conditions":835,"interventions":837},"NCT06517017","Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma",[90],"2026-11","2027-11","2025-10-09",[565,836],"Plasma Cell Leukemia",[820],{"trials":839,"activeCount":101},[],{"trials":841,"activeCount":101},[],{"trials":843,"activeCount":101},[],{"intervention":845,"totalTrials":97,"cells":846},"XL092",{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":848,"activeCount":101},[],{"trials":850,"activeCount":101},[],{"trials":852,"activeCount":97,"soonestReadout":183},[853],{"nctId":854,"briefTitle":855,"status":113,"phases":856,"primaryCompletion":183,"completion":552,"start":857,"enrollment":858,"conditions":859,"interventions":860},"NCT06568562","XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer",[90],"2024-12-09",32,[187],[845],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":101},[],{"trials":866,"activeCount":101},[],{"intervention":76,"totalTrials":97,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":881,"PHASE4":883,"NA":885},{"trials":870,"activeCount":101},[],{"trials":872,"activeCount":101},[],{"trials":874,"activeCount":97,"soonestReadout":75},[875],{"nctId":73,"briefTitle":74,"status":180,"phases":876,"primaryCompletion":75,"completion":638,"start":877,"enrollment":878,"conditions":879,"interventions":880},[90],"2022-06-05",34,[187],[76],{"trials":882,"activeCount":101},[],{"trials":884,"activeCount":101},[],{"trials":886,"activeCount":101},[],{"intervention":388,"totalTrials":97,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":899,"PHASE4":901,"NA":903},{"trials":890,"activeCount":101},[],{"trials":892,"activeCount":101},[],{"trials":894,"activeCount":97,"soonestReadout":60},[895],{"nctId":58,"briefTitle":59,"status":180,"phases":896,"primaryCompletion":60,"completion":183,"start":383,"enrollment":384,"conditions":897,"interventions":898},[90],[386],[61,388,389],{"trials":900,"activeCount":101},[],{"trials":902,"activeCount":101},[],{"trials":904,"activeCount":101},[],{"intervention":389,"totalTrials":97,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":908,"activeCount":101},[],{"trials":910,"activeCount":101},[],{"trials":912,"activeCount":97,"soonestReadout":60},[913],{"nctId":58,"briefTitle":59,"status":180,"phases":914,"primaryCompletion":60,"completion":183,"start":383,"enrollment":384,"conditions":915,"interventions":916},[90],[386],[61,388,389],{"trials":918,"activeCount":101},[],{"trials":920,"activeCount":101},[],{"trials":922,"activeCount":101},[],{"intervention":504,"totalTrials":97,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":926,"activeCount":101},[],{"trials":928,"activeCount":101},[],{"trials":930,"activeCount":97,"soonestReadout":499},[931],{"nctId":496,"briefTitle":497,"status":137,"phases":932,"primaryCompletion":499,"completion":500,"start":249,"enrollment":250,"conditions":933,"interventions":934},[90],[502],[465,504],{"trials":936,"activeCount":101},[],{"trials":938,"activeCount":101},[],{"trials":940,"activeCount":101},[],{"intervention":942,"totalTrials":97,"cells":943},"Defactinib",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":963,"PHASE4":965,"NA":967},{"trials":945,"activeCount":101},[],{"trials":947,"activeCount":101},[],{"trials":949,"activeCount":97,"soonestReadout":954},[950],{"nctId":951,"briefTitle":952,"status":113,"phases":953,"primaryCompletion":954,"completion":955,"start":956,"enrollment":640,"conditions":957,"interventions":960},"NCT06194929","Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",[89,90],"2028-01-15","2030-01-15","2024-03-20",[958,959],"Cutaneous Melanoma","Brain Metastases",[942,961,962],"Avutometinib","Encorafenib",{"trials":964,"activeCount":101},[],{"trials":966,"activeCount":101},[],{"trials":968,"activeCount":101},[],{"intervention":961,"totalTrials":97,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":972,"activeCount":101},[],{"trials":974,"activeCount":101},[],{"trials":976,"activeCount":97,"soonestReadout":954},[977],{"nctId":951,"briefTitle":952,"status":113,"phases":978,"primaryCompletion":954,"completion":955,"start":956,"enrollment":640,"conditions":979,"interventions":980},[89,90],[958,959],[942,961,962],{"trials":982,"activeCount":101},[],{"trials":984,"activeCount":101},[],{"trials":986,"activeCount":101},[],{"intervention":962,"totalTrials":97,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":101},[],{"trials":992,"activeCount":101},[],{"trials":994,"activeCount":97,"soonestReadout":954},[995],{"nctId":951,"briefTitle":952,"status":113,"phases":996,"primaryCompletion":954,"completion":955,"start":956,"enrollment":640,"conditions":997,"interventions":998},[89,90],[958,959],[942,961,962],{"trials":1000,"activeCount":101},[],{"trials":1002,"activeCount":101},[],{"trials":1004,"activeCount":101},[],{"intervention":1006,"totalTrials":97,"cells":1007},"Low Dose 5-hydroxytryptophan",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1009,"activeCount":101},[],{"trials":1011,"activeCount":101},[],{"trials":1013,"activeCount":97,"soonestReadout":1018},[1014],{"nctId":1015,"briefTitle":1016,"status":113,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1024},"NCT05895747","5-HTP and Creatine for Depression R33 Phase",[90],"2026-06-30","2026-07-31","2023-09-28",106,[1023],"Major Depressive Disorder",[1006,1025,1026,1027],"High Dose 5-hydroxytryptophan","Low Dose Creatine Monohydrate","High Dose Creatine Monohydrate",{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":101},[],{"trials":1033,"activeCount":101},[],{"intervention":1025,"totalTrials":97,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":101},[],{"trials":1041,"activeCount":97,"soonestReadout":1018},[1042],{"nctId":1015,"briefTitle":1016,"status":113,"phases":1043,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1044,"interventions":1045},[90],[1023],[1006,1025,1026,1027],{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":101},[],{"trials":1051,"activeCount":101},[],{"intervention":1026,"totalTrials":97,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1055,"activeCount":101},[],{"trials":1057,"activeCount":101},[],{"trials":1059,"activeCount":97,"soonestReadout":1018},[1060],{"nctId":1015,"briefTitle":1016,"status":113,"phases":1061,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1062,"interventions":1063},[90],[1023],[1006,1025,1026,1027],{"trials":1065,"activeCount":101},[],{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":101},[],{"intervention":1027,"totalTrials":97,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1073,"activeCount":101},[],{"trials":1075,"activeCount":101},[],{"trials":1077,"activeCount":97,"soonestReadout":1018},[1078],{"nctId":1015,"briefTitle":1016,"status":113,"phases":1079,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1080,"interventions":1081},[90],[1023],[1006,1025,1026,1027],{"trials":1083,"activeCount":101},[],{"trials":1085,"activeCount":101},[],{"trials":1087,"activeCount":101},[],{"intervention":1089,"totalTrials":97,"cells":1090},"relugolix + ARPI",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1092,"activeCount":101},[],{"trials":1094,"activeCount":101},[],{"trials":1096,"activeCount":97,"soonestReadout":1101},[1097],{"nctId":1098,"briefTitle":1099,"status":113,"phases":1100,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT07216248","Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer",[90],"2030-10","2031-10","2025-10-27",160,[1106],"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[1089,1108,1109,1110],"Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI","relugolix or androgen deprivation therapy (ADT) + ARPI","relugolix + ARPI.",{"trials":1112,"activeCount":101},[],{"trials":1114,"activeCount":101},[],{"trials":1116,"activeCount":101},[],{"intervention":1108,"totalTrials":97,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1120,"activeCount":101},[],{"trials":1122,"activeCount":101},[],{"trials":1124,"activeCount":97,"soonestReadout":1101},[1125],{"nctId":1098,"briefTitle":1099,"status":113,"phases":1126,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1127,"interventions":1128},[90],[1106],[1089,1108,1109,1110],{"trials":1130,"activeCount":101},[],{"trials":1132,"activeCount":101},[],{"trials":1134,"activeCount":101},[],{"intervention":1109,"totalTrials":97,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1138,"activeCount":101},[],{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":97,"soonestReadout":1101},[1143],{"nctId":1098,"briefTitle":1099,"status":113,"phases":1144,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1145,"interventions":1146},[90],[1106],[1089,1108,1109,1110],{"trials":1148,"activeCount":101},[],{"trials":1150,"activeCount":101},[],{"trials":1152,"activeCount":101},[],{"intervention":1110,"totalTrials":97,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":101},[],{"trials":1158,"activeCount":101},[],{"trials":1160,"activeCount":97,"soonestReadout":1101},[1161],{"nctId":1098,"briefTitle":1099,"status":113,"phases":1162,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1163,"interventions":1164},[90],[1106],[1089,1108,1109,1110],{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":101},[],{"intervention":272,"totalTrials":97,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1174,"activeCount":101},[],{"trials":1176,"activeCount":101},[],{"trials":1178,"activeCount":97,"soonestReadout":265},[1179],{"nctId":262,"briefTitle":263,"status":180,"phases":1180,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":1181,"interventions":1182},[90],[270],[272,66],{"trials":1184,"activeCount":101},[],{"trials":1186,"activeCount":101},[],{"trials":1188,"activeCount":101},[],{"intervention":41,"totalTrials":97,"cells":1190},{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1192,"activeCount":101},[],{"trials":1194,"activeCount":101},[],{"trials":1196,"activeCount":97,"soonestReadout":40},[1197],{"nctId":38,"briefTitle":39,"status":113,"phases":1198,"primaryCompletion":40,"completion":1199,"start":1200,"enrollment":304,"conditions":1201,"interventions":1203},[89,90],"2024-05-30","2021-05-20",[1202],"Opioid-use Disorder",[41],{"trials":1205,"activeCount":101},[],{"trials":1207,"activeCount":101},[],{"trials":1209,"activeCount":101},[],{"intervention":1211,"totalTrials":97,"cells":1212},"Budesonide EC",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1214,"activeCount":101},[],{"trials":1216,"activeCount":101},[],{"trials":1218,"activeCount":97,"soonestReadout":1223},[1219],{"nctId":1220,"briefTitle":1221,"status":113,"phases":1222,"primaryCompletion":1223,"completion":786,"start":267,"enrollment":1224,"conditions":1225,"interventions":1226},"NCT05405387","Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant",[90],"2026-05-19",120,[565,836],[1211],{"trials":1228,"activeCount":101},[],{"trials":1230,"activeCount":101},[],{"trials":1232,"activeCount":101},[],{"intervention":86,"totalTrials":97,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1249,"PHASE4":1251,"NA":1253},{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":97,"soonestReadout":85},[1241],{"nctId":83,"briefTitle":84,"status":113,"phases":1242,"primaryCompletion":85,"completion":1243,"start":1244,"enrollment":9,"conditions":1245,"interventions":1248},[90],"2026-09-30","2022-09-15",[1246,1247],"Congenital Diaphragmatic Hernia","Pulmonary Hypertension",[86],{"trials":1250,"activeCount":101},[],{"trials":1252,"activeCount":101},[],{"trials":1254,"activeCount":101},[],{"intervention":1256,"totalTrials":97,"cells":1257},"Pneumococcal 20-valent Conjugate Vaccine",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":101},[],{"trials":1263,"activeCount":97,"soonestReadout":141},[1264],{"nctId":1265,"briefTitle":1266,"status":113,"phases":1267,"primaryCompletion":141,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1273},"NCT05183854","Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial",[90],"2028-06","2022-01-31",61,[716,1272],"Small Lymphocytic Lymphoma",[1256,1274],"Pneumococcal Polyvalent Vaccine",{"trials":1276,"activeCount":101},[],{"trials":1278,"activeCount":101},[],{"trials":1280,"activeCount":101},[],{"intervention":1274,"totalTrials":97,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":101},[],{"trials":1286,"activeCount":101},[],{"trials":1288,"activeCount":97,"soonestReadout":141},[1289],{"nctId":1265,"briefTitle":1266,"status":113,"phases":1290,"primaryCompletion":141,"completion":1268,"start":1269,"enrollment":1270,"conditions":1291,"interventions":1292},[90],[716,1272],[1256,1274],{"trials":1294,"activeCount":101},[],{"trials":1296,"activeCount":101},[],{"trials":1298,"activeCount":101},[],{"intervention":1300,"totalTrials":97,"cells":1301},"Pemigatinib",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":97,"soonestReadout":638},[1308],{"nctId":1309,"briefTitle":1310,"status":113,"phases":1311,"primaryCompletion":638,"completion":738,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1316},"NCT06300528","Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas",[90],"2025-10-03",27,[448,1315,463],"Mantle Cell Lymphoma",[1300],{"trials":1318,"activeCount":101},[],{"trials":1320,"activeCount":101},[],{"trials":1322,"activeCount":101},[],{"intervention":532,"totalTrials":97,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1326,"activeCount":101},[],{"trials":1328,"activeCount":101},[],{"trials":1330,"activeCount":97,"soonestReadout":527},[1331],{"nctId":524,"briefTitle":525,"status":137,"phases":1332,"primaryCompletion":527,"completion":139,"start":249,"enrollment":19,"conditions":1333,"interventions":1334},[89,90],[529],[531,532],{"trials":1336,"activeCount":101},[],{"trials":1338,"activeCount":101},[],{"trials":1340,"activeCount":101},[],{"intervention":213,"totalTrials":273,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1362,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1344,"activeCount":101},[],{"trials":1346,"activeCount":378,"soonestReadout":80},[1347,1354,1358],{"nctId":78,"briefTitle":79,"status":113,"phases":1348,"primaryCompletion":80,"completion":369,"start":1349,"enrollment":878,"conditions":1350,"interventions":1353},[89],"2021-05-03",[1351,1352],"Metastatic Breast Cancer","Recurrent Ovarian Carcinoma",[81,213],{"nctId":203,"briefTitle":204,"status":205,"phases":1355,"primaryCompletion":207,"completion":208,"start":209,"enrollment":101,"conditions":1356,"interventions":1357},[89],[211],[213,214,215,214,213],{"nctId":366,"briefTitle":367,"status":180,"phases":1359,"primaryCompletion":369,"completion":370,"start":371,"enrollment":268,"conditions":1360,"interventions":1361},[89],[373,374,375,376],[213,61],{"trials":1363,"activeCount":101},[],{"trials":1365,"activeCount":101},[],{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":101},[],{"intervention":1371,"totalTrials":273,"cells":1372},"Cabozantinib",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1398,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1374,"activeCount":101},[],{"trials":1376,"activeCount":97,"soonestReadout":1381},[1377,1386],{"nctId":1378,"briefTitle":1379,"status":113,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":640,"conditions":1384,"interventions":1385},"NCT05613894","Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer",[89],"2026-05-01","2028-05-01","2023-07-14",[187],[1371],{"nctId":1387,"briefTitle":1388,"status":219,"phases":1389,"primaryCompletion":1390,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT03200587","Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)",[89],"2020-04-14","2021-11-25","2018-06-21",12,[1395],"Renal Cell Carcinoma",[1397,1371],"Avelumab",{"trials":1399,"activeCount":101},[1400],{"nctId":1401,"briefTitle":1402,"status":219,"phases":1403,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1409},"NCT03534804","Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma",[90],"2023-08-02","2024-04-15","2018-09-18",37,[375,259],[1371,1410],"Pembrolizumab",{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"intervention":1418,"totalTrials":97,"cells":1419},"Anti-CD19 CAR-T cells",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1435,"PHASE3":1437,"PHASE4":1439,"NA":1441},{"trials":1421,"activeCount":101},[],{"trials":1423,"activeCount":97,"soonestReadout":265},[1424],{"nctId":1425,"briefTitle":1426,"status":113,"phases":1427,"primaryCompletion":265,"completion":1428,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1434},"NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies",[89],"2027-05","2024-02-20",10,[1432,1433],"Acute Lymphoblastic Leukemia","Diffuse Large B Cell Lymphoma",[1418],{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":101},[],{"trials":1440,"activeCount":101},[],{"trials":1442,"activeCount":101},[],{"intervention":1444,"totalTrials":97,"cells":1445},"Epcoritamab",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1447,"activeCount":101},[],{"trials":1449,"activeCount":97,"soonestReadout":1454},[1450],{"nctId":1451,"briefTitle":1452,"status":137,"phases":1453,"primaryCompletion":1454,"completion":1455,"start":265,"enrollment":1393,"conditions":1456,"interventions":1457},"NCT07528352","External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed\u002FRefractory DLBCL",[89],"2030-05","2031-05",[1433],[1444,1458],"Glofitamab",{"trials":1460,"activeCount":101},[],{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[],{"intervention":1458,"totalTrials":97,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1470,"activeCount":101},[],{"trials":1472,"activeCount":97,"soonestReadout":1454},[1473],{"nctId":1451,"briefTitle":1452,"status":137,"phases":1474,"primaryCompletion":1454,"completion":1455,"start":265,"enrollment":1393,"conditions":1475,"interventions":1476},[89],[1433],[1444,1458],{"trials":1478,"activeCount":101},[],{"trials":1480,"activeCount":101},[],{"trials":1482,"activeCount":101},[],{"trials":1484,"activeCount":101},[],{"intervention":1486,"totalTrials":97,"cells":1487},"ropeginterferon alfa- 2b",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1489,"activeCount":101},[],{"trials":1491,"activeCount":97,"soonestReadout":1496},[1492],{"nctId":1493,"briefTitle":1494,"status":137,"phases":1495,"primaryCompletion":1496,"completion":1454,"start":265,"enrollment":30,"conditions":1497,"interventions":1499},"NCT07521046","Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)",[89],"2029-05",[1498],"Myelofibrosis",[1486,1500],"Ruxolitinib",{"trials":1502,"activeCount":101},[],{"trials":1504,"activeCount":101},[],{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"intervention":1500,"totalTrials":97,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":97,"soonestReadout":1496},[1515],{"nctId":1493,"briefTitle":1494,"status":137,"phases":1516,"primaryCompletion":1496,"completion":1454,"start":265,"enrollment":30,"conditions":1517,"interventions":1518},[89],[1498],[1486,1500],{"trials":1520,"activeCount":101},[],{"trials":1522,"activeCount":101},[],{"trials":1524,"activeCount":101},[],{"trials":1526,"activeCount":101},[],{"intervention":1528,"totalTrials":97,"cells":1529},"Loncastuximab tesirine and rituximab",{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1544,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1531,"activeCount":101},[],{"trials":1533,"activeCount":97,"soonestReadout":1538},[1534],{"nctId":1535,"briefTitle":1536,"status":113,"phases":1537,"primaryCompletion":1538,"completion":1539,"start":1540,"enrollment":1393,"conditions":1541,"interventions":1543},"NCT06607549","Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)",[89],"2029-11","2030-11","2025-03-18",[1542],"Central Nervous System Lymphoma",[1528],{"trials":1545,"activeCount":101},[],{"trials":1547,"activeCount":101},[],{"trials":1549,"activeCount":101},[],{"trials":1551,"activeCount":101},[],{"intervention":411,"totalTrials":97,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1562,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":97,"soonestReadout":45},[1558],{"nctId":43,"briefTitle":44,"status":180,"phases":1559,"primaryCompletion":45,"completion":405,"start":406,"enrollment":407,"conditions":1560,"interventions":1561},[89],[409],[46,411],{"trials":1563,"activeCount":101},[],{"trials":1565,"activeCount":101},[],{"trials":1567,"activeCount":101},[],{"trials":1569,"activeCount":101},[],{"intervention":81,"totalTrials":97,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":101},[],{"trials":1575,"activeCount":97,"soonestReadout":80},[1576],{"nctId":78,"briefTitle":79,"status":113,"phases":1577,"primaryCompletion":80,"completion":369,"start":1349,"enrollment":878,"conditions":1578,"interventions":1579},[89],[1351,1352],[81,213],{"trials":1581,"activeCount":101},[],{"trials":1583,"activeCount":101},[],{"trials":1585,"activeCount":101},[],{"trials":1587,"activeCount":101},[],{"intervention":189,"totalTrials":97,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1598,"PHASE3":1600,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":101},[],{"trials":1593,"activeCount":97,"soonestReadout":182},[1594],{"nctId":178,"briefTitle":179,"status":180,"phases":1595,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":1596,"interventions":1597},[89],[187],[66,189],{"trials":1599,"activeCount":101},[],{"trials":1601,"activeCount":101},[],{"trials":1603,"activeCount":101},[],{"trials":1605,"activeCount":101},[],{"intervention":1607,"totalTrials":97,"cells":1608},"Vitamin C",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1610,"activeCount":101},[],{"trials":1612,"activeCount":97,"soonestReadout":1617},[1613],{"nctId":1614,"briefTitle":1615,"status":137,"phases":1616,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":273,"conditions":1620,"interventions":1623},"NCT07612345","High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study",[89],"2027-07-15","2027-12-15","2026-07-15",[1621,1622],"Pyruvate Kinase Deficiency","Glucose 6 Phosphate Dehydrogenase Deficiency",[1607],{"trials":1625,"activeCount":101},[],{"trials":1627,"activeCount":101},[],{"trials":1629,"activeCount":101},[],{"trials":1631,"activeCount":101},[],{"intervention":1633,"totalTrials":97,"cells":1634},"FMISO PET CT",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1650,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":97,"soonestReadout":1643},[1639],{"nctId":1640,"briefTitle":1641,"status":113,"phases":1642,"primaryCompletion":1643,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1649},"NCT04846309","Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy",[89],"2026-10","2027-10","2021-10-12",16,[1648],"Esophageal Cancer",[1633],{"trials":1651,"activeCount":101},[],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":101},[],{"intervention":1659,"totalTrials":97,"cells":1660},"Pegylated interferon alpha2a",{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":97,"soonestReadout":1669},[1665],{"nctId":1666,"briefTitle":1667,"status":113,"phases":1668,"primaryCompletion":1669,"completion":1670,"start":1404,"enrollment":1671,"conditions":1672,"interventions":1673},"NCT05535764","Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis",[89],"2026-04","2027-10-30",18,[1498],[1659],{"trials":1675,"activeCount":101},[],{"trials":1677,"activeCount":101},[],{"trials":1679,"activeCount":101},[],{"trials":1681,"activeCount":101},[],{"intervention":56,"totalTrials":97,"cells":1683},{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1685,"activeCount":101},[],{"trials":1687,"activeCount":97,"soonestReadout":55},[1688],{"nctId":53,"briefTitle":54,"status":180,"phases":1689,"primaryCompletion":55,"completion":1690,"start":1691,"enrollment":554,"conditions":1692,"interventions":1700},[89],"2026-08-08","2019-08-08",[1693,1694,1695,1696,1697,1698,1699],"Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Ductal Adenocarcinoma","Locally Advanced Unresectable Pancreatic Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8",[56,1701],"Losartan Potassium",{"trials":1703,"activeCount":101},[],{"trials":1705,"activeCount":101},[],{"trials":1707,"activeCount":101},[],{"trials":1709,"activeCount":101},[],{"intervention":1701,"totalTrials":97,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1713,"activeCount":101},[],{"trials":1715,"activeCount":97,"soonestReadout":55},[1716],{"nctId":53,"briefTitle":54,"status":180,"phases":1717,"primaryCompletion":55,"completion":1690,"start":1691,"enrollment":554,"conditions":1718,"interventions":1719},[89],[1693,1694,1695,1696,1697,1698,1699],[56,1701],{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[],{"trials":1727,"activeCount":101},[],{"intervention":1729,"totalTrials":378,"cells":1730},"Saline",{"EARLY_PHASE1":1731,"PHASE1":1743,"PHASE2":1745,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1732,"activeCount":97,"soonestReadout":739},[1733],{"nctId":1734,"briefTitle":1735,"status":180,"phases":1736,"primaryCompletion":739,"completion":739,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1741},"NCT05037812","Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures",[88],"2019-03-25",150,[1740],"Tibial Plateau Fractures",[1729,1742],"Multimodal injections",{"trials":1744,"activeCount":101},[],{"trials":1746,"activeCount":101},[1747],{"nctId":1748,"briefTitle":1749,"status":219,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":315,"conditions":1753,"interventions":1755},"NCT03669081","Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy",[90],"2018-09-30","2016-09-20",[1754],"Pain, Postoperative",[1756,1757,1729],"Ketorolac","Pregabalin",{"trials":1759,"activeCount":101},[],{"trials":1761,"activeCount":101},[],{"trials":1763,"activeCount":101},[],{"intervention":1765,"totalTrials":97,"cells":1766},"Progesterone",{"EARLY_PHASE1":1767,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1768,"activeCount":97,"soonestReadout":1773},[1769],{"nctId":1770,"briefTitle":1771,"status":113,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":9,"conditions":1776,"interventions":1779},"NCT05128071","PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)",[88],"2026-04-30","2027-04","2022-02-04",[1777,1778],"Methamphetamine-dependence","Postpartum Abstinence",[1765],{"trials":1781,"activeCount":101},[],{"trials":1783,"activeCount":101},[],{"trials":1785,"activeCount":101},[],{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":101},[],{"intervention":1791,"totalTrials":97,"cells":1792},"Hematoma Local Anesthetic Block Procedure with 1% Lidocaine",{"EARLY_PHASE1":1793,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1794,"activeCount":97,"soonestReadout":686},[1795],{"nctId":1796,"briefTitle":1797,"status":180,"phases":1798,"primaryCompletion":686,"completion":686,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT05086224","Hematoma Block Versus Bier Block for Closed Fracture Reduction",[88],"2021-07-15",500,[1802],"Distal Radius Fractures",[1791,1804],"Bier Anesthetic Block Procedure with 1% Lidocaine",{"trials":1806,"activeCount":101},[],{"trials":1808,"activeCount":101},[],{"trials":1810,"activeCount":101},[],{"trials":1812,"activeCount":101},[],{"trials":1814,"activeCount":101},[],{"intervention":1804,"totalTrials":97,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1818,"activeCount":97,"soonestReadout":686},[1819],{"nctId":1796,"briefTitle":1797,"status":180,"phases":1820,"primaryCompletion":686,"completion":686,"start":1799,"enrollment":1800,"conditions":1821,"interventions":1822},[88],[1802],[1791,1804],{"trials":1824,"activeCount":101},[],{"trials":1826,"activeCount":101},[],{"trials":1828,"activeCount":101},[],{"trials":1830,"activeCount":101},[],{"trials":1832,"activeCount":101},[],{"intervention":1742,"totalTrials":97,"cells":1834},{"EARLY_PHASE1":1835,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1847,"NA":1849},{"trials":1836,"activeCount":97,"soonestReadout":739},[1837],{"nctId":1734,"briefTitle":1735,"status":180,"phases":1838,"primaryCompletion":739,"completion":739,"start":1737,"enrollment":1738,"conditions":1839,"interventions":1840},[88],[1740],[1729,1742],{"trials":1842,"activeCount":101},[],{"trials":1844,"activeCount":101},[],{"trials":1846,"activeCount":101},[],{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":101},[],{"intervention":1852,"totalTrials":97,"cells":1853},"Regional anesthesia group",{"EARLY_PHASE1":1854,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1855,"activeCount":97,"soonestReadout":1860},[1856],{"nctId":1857,"briefTitle":1858,"status":180,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":257,"conditions":1862,"interventions":1864},"NCT05019638","Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures",[88],"2028-05","2021-03-15",[1863],"Ankle Fractures",[1852,1865],"Local multimodal analgesia group",{"trials":1867,"activeCount":101},[],{"trials":1869,"activeCount":101},[],{"trials":1871,"activeCount":101},[],{"trials":1873,"activeCount":101},[],{"trials":1875,"activeCount":101},[],{"intervention":1865,"totalTrials":97,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1884,"PHASE2":1886,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":97,"soonestReadout":1860},[1880],{"nctId":1857,"briefTitle":1858,"status":180,"phases":1881,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":257,"conditions":1882,"interventions":1883},[88],[1863],[1852,1865],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"trials":1889,"activeCount":101},[],{"trials":1891,"activeCount":101},[],{"trials":1893,"activeCount":101},[],{"intervention":1895,"totalTrials":97,"cells":1896},"Memantine XR",{"EARLY_PHASE1":1897,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1898,"activeCount":97,"soonestReadout":183},[1899],{"nctId":1900,"briefTitle":1901,"status":180,"phases":1902,"primaryCompletion":183,"completion":183,"start":1903,"enrollment":22,"conditions":1904,"interventions":1907},"NCT02144584","Memantine for Enhanced Stroke Recovery",[88],"2014-01",[1905,1906],"Ischemic Stroke","Upper Extremity Weakness",[1895],{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[],{"trials":1915,"activeCount":101},[],{"trials":1917,"activeCount":101},[],{"intervention":1919,"totalTrials":97,"cells":1920},"Blood Draw or Saliva\u002FCheek Cell Sample:",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[],{"trials":1926,"activeCount":101},[],{"trials":1928,"activeCount":101},[],{"trials":1930,"activeCount":101},[],{"trials":1932,"activeCount":97,"soonestReadout":739},[1933],{"nctId":1934,"briefTitle":1935,"status":300,"phases":1936,"primaryCompletion":739,"completion":739,"start":1937,"enrollment":1738,"conditions":1938,"interventions":1941},"NCT05159739","Genetic Susceptibility to Periprosthetic Joint Infections",[],"2018-03-07",[1939,1940],"Total Joint Arthroplasty","Periprosthetic Joint Infections",[1919],{"intervention":1943,"totalTrials":97,"cells":1944},"Observational",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1946,"activeCount":101},[],{"trials":1948,"activeCount":101},[],{"trials":1950,"activeCount":101},[],{"trials":1952,"activeCount":101},[],{"trials":1954,"activeCount":101},[],{"trials":1956,"activeCount":97,"soonestReadout":1381},[1957],{"nctId":1958,"briefTitle":1959,"status":113,"phases":1960,"primaryCompletion":1381,"completion":1381,"start":1961,"enrollment":1962,"conditions":1963,"interventions":1966},"NCT06866444","Duloxetine Metabolism and Fibromyalgia",[],"2025-05-01",100,[1964,1965],"Fibromyalgia","Duloxetine",[1943],{"intervention":1968,"totalTrials":97,"cells":1969},"Platelet Rich Plasma",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":97,"soonestReadout":1986},[1982],{"nctId":1983,"briefTitle":1984,"status":113,"phases":1985,"primaryCompletion":1986,"completion":1986,"start":1987,"enrollment":1988,"conditions":1989,"interventions":1999},"NCT07231471","Platelet Rich Plasma for Musculoskeletal Conditions",[93],"2035-01-01","2025-12-29",10000,[1990,1991,1992,1993,1994,1995,1996,1997,1998],"Osteoarthritis (OA)","Osteoarthritis (OA) of the Knee","Osteoarthritis (OA) of the Hip","Osteoarthritis (OA) of the Shoulder","Osteoarthritis Ankle","Elbow Osteoarthritis","Epicondylitis of the Elbow","Plantar Fasciitis of Both Feet","Tendinopathy",[1968],{"intervention":2001,"totalTrials":273,"cells":2002},"Celecoxib",{"EARLY_PHASE1":2003,"PHASE1":2014,"PHASE2":2016,"PHASE3":2054,"PHASE4":2056,"NA":2069},{"trials":2004,"activeCount":101},[2005],{"nctId":2006,"briefTitle":2007,"status":193,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":268,"conditions":2011,"interventions":2013},"NCT00585156","The Effects of Celecoxib on Bone Ingrowth",[88],"2008-09","2008-06",[2012,18],"Bone Ingrowth",[2001],{"trials":2015,"activeCount":101},[],{"trials":2017,"activeCount":101},[2018],{"nctId":2019,"briefTitle":2020,"status":193,"phases":2021,"primaryCompletion":2022,"completion":2023,"start":2024,"enrollment":2025,"conditions":2026,"interventions":2053},"NCT04162873","Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer",[90],"2023-02-28","2023-04-26","2019-11-27",13,[2027,2028,2029,2030,2031,2032,2033,2034,2035,2036,2037,2038,2039,2040,2041,2042,2043,2044,2045,2046,2047,2048,2049,2050,2051,2052],"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Nasal Cavity and Paranasal Sinus Carcinoma","Oral Cavity Carcinoma","Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Recurrent Hypopharyngeal Carcinoma","Recurrent Laryngeal Carcinoma","Recurrent Nasal Cavity and Paranasal Sinus Carcinoma","Recurrent Oral Cavity Carcinoma","Recurrent Oropharyngeal Carcinoma","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Hypopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVC Hypopharyngeal Carcinoma AJCC v8","Stage IVC Laryngeal Cancer AJCC v8","Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[2001],{"trials":2055,"activeCount":101},[],{"trials":2057,"activeCount":101},[2058],{"nctId":2059,"briefTitle":2060,"status":219,"phases":2061,"primaryCompletion":2062,"completion":2062,"start":314,"enrollment":1962,"conditions":2063,"interventions":2065},"NCT04015908","A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery",[92],"2023-01-31",[2064],"Opioid Use",[2001,2066,1757,2067,2068],"Acetaminophen","Oxycodone","Percocet",{"trials":2070,"activeCount":101},[],{"intervention":2072,"totalTrials":273,"cells":2073},"Creatine Monohydrate",{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2099,"PHASE4":2101,"NA":2111},{"trials":2075,"activeCount":101},[],{"trials":2077,"activeCount":101},[],{"trials":2079,"activeCount":101},[2080,2091],{"nctId":2081,"briefTitle":2082,"status":219,"phases":2083,"primaryCompletion":2084,"completion":2085,"start":2086,"enrollment":384,"conditions":2087,"interventions":2088},"NCT04395183","5-HTP and Creatine for Depression",[90],"2023-08-01","2024-03-01","2021-03-01",[1023],[2089,2090],"5-Hydroxytryptophan 100 MG","Creatine monohydrate",{"nctId":2092,"briefTitle":2093,"status":219,"phases":2094,"primaryCompletion":2095,"completion":2095,"start":2096,"enrollment":2025,"conditions":2097,"interventions":2098},"NCT00851006","Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram",[90],"2012-12","2009-04",[1023],[2072],{"trials":2100,"activeCount":101},[],{"trials":2102,"activeCount":101},[2103],{"nctId":2104,"briefTitle":2105,"status":205,"phases":2106,"primaryCompletion":2107,"completion":2107,"start":2108,"enrollment":101,"conditions":2109,"interventions":2110},"NCT03202095","Creatine for Treatment of Depression Associated With Type 2 Diabetes",[92],"2024-06-10","2017-08-01",[1023],[2072],{"trials":2112,"activeCount":101},[],{"intervention":1756,"totalTrials":378,"cells":2114},{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2125,"PHASE4":2127,"NA":2140},{"trials":2116,"activeCount":101},[],{"trials":2118,"activeCount":101},[],{"trials":2120,"activeCount":101},[2121],{"nctId":1748,"briefTitle":1749,"status":219,"phases":2122,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":315,"conditions":2123,"interventions":2124},[90],[1754],[1756,1757,1729],{"trials":2126,"activeCount":101},[],{"trials":2128,"activeCount":101},[2129],{"nctId":2130,"briefTitle":2131,"status":193,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":1430,"conditions":2135,"interventions":2137},"NCT03028012","TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone",[92],"2019-05-01","2017-05-02",[2136],"Myofascial Pain",[1756,2138,2139],"Lidocaine","Dexamethasone",{"trials":2141,"activeCount":101},[],{"intervention":1757,"totalTrials":378,"cells":2143},{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2154,"PHASE4":2156,"NA":2162},{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":101},[],{"trials":2149,"activeCount":101},[2150],{"nctId":1748,"briefTitle":1749,"status":219,"phases":2151,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":315,"conditions":2152,"interventions":2153},[90],[1754],[1756,1757,1729],{"trials":2155,"activeCount":101},[],{"trials":2157,"activeCount":101},[2158],{"nctId":2059,"briefTitle":2060,"status":219,"phases":2159,"primaryCompletion":2062,"completion":2062,"start":314,"enrollment":1962,"conditions":2160,"interventions":2161},[92],[2064],[2001,2066,1757,2067,2068],{"trials":2163,"activeCount":101},[],{"intervention":2165,"totalTrials":378,"cells":2166},"dexamethasone",{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2191},{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[],{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":101},[2177,2187],{"nctId":2178,"briefTitle":2179,"status":219,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2186},"NCT00119002","The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis",[92],"2006-04","2004-01",598,[2185],"Bronchiolitis, Viral",[2165],{"nctId":2130,"briefTitle":2131,"status":193,"phases":2188,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":1430,"conditions":2189,"interventions":2190},[92],[2136],[1756,2138,2139],{"trials":2192,"activeCount":101},[],{"intervention":2194,"totalTrials":97,"cells":2195},"Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate",{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2202,"PHASE4":2204,"NA":2218},{"trials":2197,"activeCount":101},[],{"trials":2199,"activeCount":101},[],{"trials":2201,"activeCount":101},[],{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[2206],{"nctId":2207,"briefTitle":2208,"status":219,"phases":2209,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":640,"conditions":2213,"interventions":2217},"NCT04544683","Effectiveness of Cervical Transforaminal Epidural Steroid Injection",[92],"2022-10-31","2023-12-07","2018-10-23",[2214,2215,2216],"Cervical Radiculopathy","Cervical Spondylosis","Disk, Herniated",[2194],{"trials":2219,"activeCount":101},[],{"intervention":2221,"totalTrials":97,"cells":2222},"Terbutaline",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2242},{"trials":2224,"activeCount":101},[],{"trials":2226,"activeCount":101},[],{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"trials":2232,"activeCount":101},[2233],{"nctId":2234,"briefTitle":2235,"status":219,"phases":2236,"primaryCompletion":2237,"completion":2237,"start":2238,"enrollment":250,"conditions":2239,"interventions":2241},"NCT00802230","Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure",[92],"2004-12","2002-09",[2240],"Heart Failure",[2221],{"trials":2243,"activeCount":101},[],{"intervention":2245,"totalTrials":97,"cells":2246},"Triamcinolone Acetonide",{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2255,"NA":2267},{"trials":2248,"activeCount":101},[],{"trials":2250,"activeCount":101},[],{"trials":2252,"activeCount":101},[],{"trials":2254,"activeCount":101},[],{"trials":2256,"activeCount":101},[2257],{"nctId":2258,"briefTitle":2259,"status":193,"phases":2260,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":1646,"conditions":2264,"interventions":2265},"NCT03382925","Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?",[92],"2019-08-19","2020-08-19","2017-12-20",[2214],[2138,2245,2266],"Normal saline",{"trials":2268,"activeCount":101},[],{"intervention":2266,"totalTrials":97,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2285},{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":101},[],{"trials":2276,"activeCount":101},[],{"trials":2278,"activeCount":101},[],{"trials":2280,"activeCount":101},[2281],{"nctId":2258,"briefTitle":2259,"status":193,"phases":2282,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":1646,"conditions":2283,"interventions":2284},[92],[2214],[2138,2245,2266],{"trials":2286,"activeCount":101},[],{"intervention":2288,"totalTrials":97,"cells":2289},"Trilipix",{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2309},{"trials":2291,"activeCount":101},[],{"trials":2293,"activeCount":101},[],{"trials":2295,"activeCount":101},[],{"trials":2297,"activeCount":101},[],{"trials":2299,"activeCount":101},[2300],{"nctId":2301,"briefTitle":2302,"status":193,"phases":2303,"primaryCompletion":2304,"completion":2304,"start":2305,"enrollment":407,"conditions":2306,"interventions":2308},"NCT01025492","Study of Trilipix Effects on Lipids and Arteries",[92],"2011-03","2009-11",[2307],"Dyslipidemia",[2288],{"trials":2310,"activeCount":101},[],{"intervention":2312,"totalTrials":97,"cells":2313},"Standard Antibiotic Treatment",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2322,"NA":2334},{"trials":2315,"activeCount":101},[],{"trials":2317,"activeCount":101},[],{"trials":2319,"activeCount":101},[],{"trials":2321,"activeCount":101},[],{"trials":2323,"activeCount":101},[2324],{"nctId":2325,"briefTitle":2326,"status":205,"phases":2327,"primaryCompletion":195,"completion":195,"start":2328,"enrollment":101,"conditions":2329,"interventions":2333},"NCT03168178","Intrapartum Fever: Antibiotics Versus no Treatment",[92],"2017-06-08",[2330,2331,2332],"Chorioamnionitis","Intrapartum Fever","Intra-amniotic Infection",[2312],{"trials":2335,"activeCount":101},[],{"intervention":2337,"totalTrials":97,"cells":2338},"Receipt of enoxaparin",{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2345,"PHASE4":2347,"NA":2362},{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":101},[],{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[2349],{"nctId":2350,"briefTitle":2351,"status":205,"phases":2352,"primaryCompletion":2353,"completion":2354,"start":2355,"enrollment":101,"conditions":2356,"interventions":2361},"NCT03988231","Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study",[92],"2022-06","2023-06","2021-07",[2357,2358,2359,2360],"Venous Thromboembolism","Bleeding as Surgical Complication (Treatment)","Deep Venous Thrombosis","Pulmonary Embolism",[2337],{"trials":2363,"activeCount":101},[],{"intervention":2365,"totalTrials":97,"cells":2366},"Testosterone",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2375,"NA":2386},{"trials":2368,"activeCount":101},[],{"trials":2370,"activeCount":101},[],{"trials":2372,"activeCount":101},[],{"trials":2374,"activeCount":101},[],{"trials":2376,"activeCount":101},[2377],{"nctId":2378,"briefTitle":2379,"status":219,"phases":2380,"primaryCompletion":2381,"completion":2381,"start":2382,"enrollment":282,"conditions":2383,"interventions":2385},"NCT02611154","Intranasal Delivery of Testosterone and Its Effect on Doping Markers",[92],"2016-01-19","2015-11-18",[2384],"Abuse of Anabolic Steroids",[2365],{"trials":2387,"activeCount":101},[],{"intervention":2389,"totalTrials":97,"cells":2390},"Myfortic",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2399,"NA":2411},{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[],{"trials":2396,"activeCount":101},[],{"trials":2398,"activeCount":101},[],{"trials":2400,"activeCount":101},[2401],{"nctId":2402,"briefTitle":2403,"status":219,"phases":2404,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":2407,"conditions":2408,"interventions":2410},"NCT00585468","Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State",[92],"2011-07","2007-12",21,[2409],"Kidney Transplantation",[2389],{"trials":2412,"activeCount":101},[],{"intervention":2414,"totalTrials":97,"cells":2415},"Sertraline",{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2424,"NA":2435},{"trials":2417,"activeCount":101},[],{"trials":2419,"activeCount":101},[],{"trials":2421,"activeCount":101},[],{"trials":2423,"activeCount":101},[],{"trials":2425,"activeCount":101},[2426],{"nctId":2427,"briefTitle":2428,"status":193,"phases":2429,"primaryCompletion":2430,"completion":2430,"start":2431,"enrollment":282,"conditions":2432,"interventions":2434},"NCT02520726","PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims",[92],"2016-09","2013-09",[2433],"Post-traumatic Stress Disorder",[2414],{"trials":2436,"activeCount":101},[],{"intervention":2438,"totalTrials":97,"cells":2439},"Enoxaparin 0.5 mg\u002Fkg once daily",{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2448,"NA":2461},{"trials":2441,"activeCount":101},[],{"trials":2443,"activeCount":101},[],{"trials":2445,"activeCount":101},[],{"trials":2447,"activeCount":101},[],{"trials":2449,"activeCount":101},[2450],{"nctId":2451,"briefTitle":2452,"status":219,"phases":2453,"primaryCompletion":2454,"completion":2454,"start":2455,"enrollment":2456,"conditions":2457,"interventions":2460},"NCT00585182","Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT",[92],"2008-04","2007-01",28,[32,2458,2459],"Venous Thrombosis","Anticoagulants",[2438],{"trials":2462,"activeCount":101},[],{"intervention":2464,"totalTrials":97,"cells":2465},"Lovaza",{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2472,"PHASE4":2474,"NA":2486},{"trials":2467,"activeCount":101},[],{"trials":2469,"activeCount":101},[],{"trials":2471,"activeCount":101},[],{"trials":2473,"activeCount":101},[],{"trials":2475,"activeCount":101},[2476],{"nctId":2477,"briefTitle":2478,"status":205,"phases":2479,"primaryCompletion":2480,"completion":2481,"start":2482,"enrollment":101,"conditions":2483,"interventions":2485},"NCT01180764","Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia",[92],"2012-08","2012-10","2010-08",[2484],"Hypertriglyceridemia",[2464],{"trials":2487,"activeCount":101},[],{"intervention":2489,"totalTrials":97,"cells":2490},"Standard of Care Oral antipsychotics",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2513},{"trials":2492,"activeCount":101},[],{"trials":2494,"activeCount":101},[],{"trials":2496,"activeCount":101},[],{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[2501],{"nctId":2502,"briefTitle":2503,"status":219,"phases":2504,"primaryCompletion":2505,"completion":2506,"start":2507,"enrollment":2508,"conditions":2509,"interventions":2511},"NCT02237417","Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism",[92],"2018-11-30","2020-07-30","2014-09-01",47,[2510],"Schizophrenia",[2489,2512],"IM aripiprazole once monthly",{"trials":2514,"activeCount":101},[],{"intervention":2512,"totalTrials":97,"cells":2516},{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2523,"PHASE4":2525,"NA":2531},{"trials":2518,"activeCount":101},[],{"trials":2520,"activeCount":101},[],{"trials":2522,"activeCount":101},[],{"trials":2524,"activeCount":101},[],{"trials":2526,"activeCount":101},[2527],{"nctId":2502,"briefTitle":2503,"status":219,"phases":2528,"primaryCompletion":2505,"completion":2506,"start":2507,"enrollment":2508,"conditions":2529,"interventions":2530},[92],[2510],[2489,2512],{"trials":2532,"activeCount":101},[],{"intervention":2534,"totalTrials":97,"cells":2535},"Natesto Nasal Product",{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2542,"PHASE4":2544,"NA":2557},{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[],{"trials":2541,"activeCount":101},[],{"trials":2543,"activeCount":101},[],{"trials":2545,"activeCount":101},[2546],{"nctId":2547,"briefTitle":2548,"status":205,"phases":2549,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":101,"conditions":2553,"interventions":2556},"NCT05484167","Natesto Testosterone Nasal Gel for Hypogonadal Men",[92],"2024-01-01","2025-04-01","2023-01-01",[2554,2555],"Erectile Dysfunction","Sexual Dysfunction",[2534],{"trials":2558,"activeCount":101},[],{"intervention":2560,"totalTrials":97,"cells":2561},"Creatine",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2580},{"trials":2563,"activeCount":101},[],{"trials":2565,"activeCount":101},[],{"trials":2567,"activeCount":101},[],{"trials":2569,"activeCount":101},[],{"trials":2571,"activeCount":101},[2572],{"nctId":2573,"briefTitle":2574,"status":205,"phases":2575,"primaryCompletion":2576,"completion":2576,"start":2577,"enrollment":101,"conditions":2578,"interventions":2579},"NCT01175616","Creatine Augmentation in Veterans With SSRI-Resistant Major Depression",[92],"2014-04","2012-09",[1023],[2560],{"trials":2581,"activeCount":101},[],{"intervention":2066,"totalTrials":97,"cells":2583},{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2598},{"trials":2585,"activeCount":101},[],{"trials":2587,"activeCount":101},[],{"trials":2589,"activeCount":101},[],{"trials":2591,"activeCount":101},[],{"trials":2593,"activeCount":101},[2594],{"nctId":2059,"briefTitle":2060,"status":219,"phases":2595,"primaryCompletion":2062,"completion":2062,"start":314,"enrollment":1962,"conditions":2596,"interventions":2597},[92],[2064],[2001,2066,1757,2067,2068],{"trials":2599,"activeCount":101},[],{"intervention":2067,"totalTrials":97,"cells":2601},{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2608,"PHASE4":2610,"NA":2616},{"trials":2603,"activeCount":101},[],{"trials":2605,"activeCount":101},[],{"trials":2607,"activeCount":101},[],{"trials":2609,"activeCount":101},[],{"trials":2611,"activeCount":101},[2612],{"nctId":2059,"briefTitle":2060,"status":219,"phases":2613,"primaryCompletion":2062,"completion":2062,"start":314,"enrollment":1962,"conditions":2614,"interventions":2615},[92],[2064],[2001,2066,1757,2067,2068],{"trials":2617,"activeCount":101},[],{"intervention":2068,"totalTrials":97,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2634},{"trials":2621,"activeCount":101},[],{"trials":2623,"activeCount":101},[],{"trials":2625,"activeCount":101},[],{"trials":2627,"activeCount":101},[],{"trials":2629,"activeCount":101},[2630],{"nctId":2059,"briefTitle":2060,"status":219,"phases":2631,"primaryCompletion":2062,"completion":2062,"start":314,"enrollment":1962,"conditions":2632,"interventions":2633},[92],[2064],[2001,2066,1757,2067,2068],{"trials":2635,"activeCount":101},[],{"intervention":2637,"totalTrials":97,"cells":2638},"Dabigatran etexilate",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2647,"NA":2658},{"trials":2640,"activeCount":101},[],{"trials":2642,"activeCount":101},[],{"trials":2644,"activeCount":101},[],{"trials":2646,"activeCount":101},[],{"trials":2648,"activeCount":101},[2649],{"nctId":2650,"briefTitle":2651,"status":193,"phases":2652,"primaryCompletion":2653,"completion":2653,"start":2654,"enrollment":35,"conditions":2655,"interventions":2657},"NCT01546883","Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation",[92],"2013-12","2012-02",[2656],"Atrial Fibrillation",[2637],{"trials":2659,"activeCount":101},[],{"intervention":2661,"totalTrials":97,"cells":2662},"Dexamethasone Sodium Phosphate 10 MG\u002FML",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2682},{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":101},[],{"trials":2668,"activeCount":101},[],{"trials":2670,"activeCount":101},[],{"trials":2672,"activeCount":101},[2673],{"nctId":2674,"briefTitle":2675,"status":219,"phases":2676,"primaryCompletion":2677,"completion":2262,"start":2678,"enrollment":1224,"conditions":2679,"interventions":2680},"NCT03382821","Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach",[92],"2020-04-15","2017-09-15",[2214],[2661,2138,2681],"Triamcinolone Acetonide 40mg\u002FmL",{"trials":2683,"activeCount":101},[],{"intervention":2681,"totalTrials":97,"cells":2685},{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2692,"PHASE4":2694,"NA":2700},{"trials":2687,"activeCount":101},[],{"trials":2689,"activeCount":101},[],{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[],{"trials":2695,"activeCount":101},[2696],{"nctId":2674,"briefTitle":2675,"status":219,"phases":2697,"primaryCompletion":2677,"completion":2262,"start":2678,"enrollment":1224,"conditions":2698,"interventions":2699},[92],[2214],[2661,2138,2681],{"trials":2701,"activeCount":101},[],{"intervention":2703,"totalTrials":97,"cells":2704},"Etonogestrel contraceptive implant",{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2727},{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"trials":2710,"activeCount":101},[],{"trials":2712,"activeCount":101},[],{"trials":2714,"activeCount":101},[2715],{"nctId":2716,"briefTitle":2717,"status":219,"phases":2718,"primaryCompletion":2719,"completion":2720,"start":2721,"enrollment":2722,"conditions":2723,"interventions":2726},"NCT00847587","Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant",[92],"2009-12","2010-05","2009-01",69,[2724,2725],"Complications; Contraceptive","Female Lactation",[2703,2703],{"trials":2728,"activeCount":101},[],{"intervention":2730,"totalTrials":97,"cells":2731},"OnabotulinumtoxinA Injectable Product",{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2738,"PHASE4":2740,"NA":2757},{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"trials":2739,"activeCount":101},[],{"trials":2741,"activeCount":101},[2742],{"nctId":2743,"briefTitle":2744,"status":219,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2748,"conditions":2749,"interventions":2754},"NCT03048383","Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis",[92],"2015-03","2012-07",71,[2750,2751,2752,2753],"Facial Nerve Injuries","Facial Paresis Associated With Facial Nerve Dysfunction","Facial Asymmetry","Synkinesis",[2730,2755,2756],"AbobotulinumtoxinA Injectable Product","Incobotulinumtoxin A Injectable Product",{"trials":2758,"activeCount":101},[],{"intervention":2755,"totalTrials":97,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2775},{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"trials":2766,"activeCount":101},[],{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":101},[2771],{"nctId":2743,"briefTitle":2744,"status":219,"phases":2772,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2748,"conditions":2773,"interventions":2774},[92],[2750,2751,2752,2753],[2730,2755,2756],{"trials":2776,"activeCount":101},[],{"intervention":2756,"totalTrials":97,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2787,"NA":2793},{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[],{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[2789],{"nctId":2743,"briefTitle":2744,"status":219,"phases":2790,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2748,"conditions":2791,"interventions":2792},[92],[2750,2751,2752,2753],[2730,2755,2756],{"trials":2794,"activeCount":101},[],{"intervention":2796,"totalTrials":97,"cells":2797},"Low Dose Acetazolamide",{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2819},{"trials":2799,"activeCount":101},[],{"trials":2801,"activeCount":101},[],{"trials":2803,"activeCount":101},[],{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[2808],{"nctId":2809,"briefTitle":2810,"status":219,"phases":2811,"primaryCompletion":2812,"completion":2812,"start":2813,"enrollment":2814,"conditions":2815,"interventions":2817},"NCT01993667","Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing",[92],"2016-11","2012-03",130,[2816],"Prophylaxis of Acute Mountain Sickness",[2796,2818],"Normal Dose Acetazolamide",{"trials":2820,"activeCount":101},[],{"intervention":2818,"totalTrials":97,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2829,"PHASE4":2831,"NA":2837},{"trials":2824,"activeCount":101},[],{"trials":2826,"activeCount":101},[],{"trials":2828,"activeCount":101},[],{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[2833],{"nctId":2809,"briefTitle":2810,"status":219,"phases":2834,"primaryCompletion":2812,"completion":2812,"start":2813,"enrollment":2814,"conditions":2835,"interventions":2836},[92],[2816],[2796,2818],{"trials":2838,"activeCount":101},[],{"intervention":2840,"totalTrials":97,"cells":2841},"Optison echocardiography contrast agent",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2860},{"trials":2843,"activeCount":101},[],{"trials":2845,"activeCount":101},[],{"trials":2847,"activeCount":101},[],{"trials":2849,"activeCount":101},[],{"trials":2851,"activeCount":101},[2852],{"nctId":2853,"briefTitle":2854,"status":219,"phases":2855,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":1962,"conditions":2858,"interventions":2859},"NCT01721447","Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage",[92],"2018-05","2013-06",[2656],[2840],{"trials":2861,"activeCount":101},[],{"intervention":2863,"totalTrials":97,"cells":2864},"Intravenous acetaminophen",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2871,"PHASE4":2873,"NA":2888},{"trials":2866,"activeCount":101},[],{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[],{"trials":2872,"activeCount":101},[],{"trials":2874,"activeCount":101},[2875],{"nctId":2876,"briefTitle":2877,"status":219,"phases":2878,"primaryCompletion":2812,"completion":2812,"start":2879,"enrollment":2880,"conditions":2881,"interventions":2887},"NCT01948505","Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit",[92],"2013-08",210,[2882,2883,2884,2885,2886],"Post-operative Craniotomy Patients","Carotid Endarterectomy and Carotid Artery Stenosis Patients","Post-op Spine Patients Admitted to the NCCU","Endovascular Patients Undergoing Intracranial Intervention","Traumatic Brain Injuries NPO for at Least 12 Hours",[2863],{"trials":2889,"activeCount":101},[],{"intervention":2891,"totalTrials":97,"cells":2892},"Loteprednol Etabonate 0.5% Oph Gel",{"EARLY_PHASE1":2893,"PHASE1":2895,"PHASE2":2897,"PHASE3":2899,"PHASE4":2901,"NA":2915},{"trials":2894,"activeCount":101},[],{"trials":2896,"activeCount":101},[],{"trials":2898,"activeCount":101},[],{"trials":2900,"activeCount":101},[],{"trials":2902,"activeCount":101},[2903],{"nctId":2904,"briefTitle":2905,"status":219,"phases":2906,"primaryCompletion":2907,"completion":2907,"start":2908,"enrollment":2909,"conditions":2910,"interventions":2913},"NCT03123614","Loteprednol vs. Prednisolone and Fluorometholone",[92],"2018-07","2014-09-19",131,[2911,2912],"Intraocular Pressure","Corneal Opacity",[2891,2914],"Prednisolone Acetate 1% Oph Susp",{"trials":2916,"activeCount":101},[],{"intervention":2914,"totalTrials":97,"cells":2918},{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2925,"PHASE4":2927,"NA":2933},{"trials":2920,"activeCount":101},[],{"trials":2922,"activeCount":101},[],{"trials":2924,"activeCount":101},[],{"trials":2926,"activeCount":101},[],{"trials":2928,"activeCount":101},[2929],{"nctId":2904,"briefTitle":2905,"status":219,"phases":2930,"primaryCompletion":2907,"completion":2907,"start":2908,"enrollment":2909,"conditions":2931,"interventions":2932},[92],[2911,2912],[2891,2914],{"trials":2934,"activeCount":101},[],{"intervention":2936,"totalTrials":97,"cells":2937},"Low back intradiscal injection of platelet rich plasma",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2946,"NA":2957},{"trials":2939,"activeCount":101},[],{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"trials":2945,"activeCount":101},[],{"trials":2947,"activeCount":101},[2948],{"nctId":2949,"briefTitle":2950,"status":193,"phases":2951,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":273,"conditions":2954,"interventions":2956},"NCT04544709","Intradiscal Platelet Rich Plasma",[92],"2022-07-29","2019-02-14",[2955,26,24],"Discogenic Pain",[2936],{"trials":2958,"activeCount":101},[],{"intervention":2960,"totalTrials":378,"cells":2961},"Cholecalciferol",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2978,"PHASE4":2998,"NA":3000},{"trials":2963,"activeCount":101},[],{"trials":2965,"activeCount":101},[],{"trials":2967,"activeCount":101},[2968],{"nctId":2969,"briefTitle":2970,"status":193,"phases":2971,"primaryCompletion":2972,"completion":2972,"start":2973,"enrollment":2974,"conditions":2975,"interventions":2977},"NCT01968590","Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)",[90],"2022-01-01","2017-08-16",26,[2976],"Neurofibromatosis Type 1 (NF1)",[2960],{"trials":2979,"activeCount":101},[2980],{"nctId":2981,"briefTitle":2982,"status":219,"phases":2983,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":2986,"conditions":2987,"interventions":2997},"NCT02881957","Hypovitaminosis D in Neurocritical Patients",[90,91],"2018-10-10","2016-10-10",274,[2988,2989,2990,2991,2992,2993,34,2994,2995,2996],"Craniocerebral Trauma","Intracranial Aneurysm","Brain Neoplasms","Spinal Cord Injuries","Seizures","Meningitis","Intracranial Hemorrhages","Critical Illness","Vitamin d Deficiency",[2960],{"trials":2999,"activeCount":101},[],{"trials":3001,"activeCount":101},[],{"intervention":3003,"totalTrials":378,"cells":3004},"Diprivan",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3018,"PHASE3":3020,"PHASE4":3032,"NA":3034},{"trials":3006,"activeCount":101},[],{"trials":3008,"activeCount":101},[3009],{"nctId":3010,"briefTitle":3011,"status":219,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":3015,"conditions":3016,"interventions":3017},"NCT02935647","Burst Suppression Anesthesia for Treatment of Severe Depression",[89],"2018-09","2016-10-01",11,[1023],[3003],{"trials":3019,"activeCount":101},[],{"trials":3021,"activeCount":101},[3022],{"nctId":3023,"briefTitle":3024,"status":205,"phases":3025,"primaryCompletion":3026,"completion":3027,"start":3028,"enrollment":101,"conditions":3029,"interventions":3031},"NCT03923361","Neural and Antidepressant Effects of Propofol (Phase 2)",[90,91],"2024-03","2024-07","2019-04-16",[3030],"Treatment Resistant Depression",[3003],{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"intervention":3037,"totalTrials":97,"cells":3038},"Achipex",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3045,"PHASE4":3057,"NA":3059},{"trials":3040,"activeCount":101},[],{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[3047],{"nctId":3048,"briefTitle":3049,"status":219,"phases":3050,"completion":3051,"start":3052,"enrollment":3053,"conditions":3054,"interventions":3056},"NCT00204672","The Role of GER in Exercise Triggered Asthma",[90,91],"2005-09","2000-10",36,[3055],"Asthma",[3037],{"trials":3058,"activeCount":101},[],{"trials":3060,"activeCount":101},[],{"intervention":3062,"totalTrials":97,"cells":3063},"methylphenidate",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3081,"NA":3083},{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[3072],{"nctId":3073,"briefTitle":3074,"status":219,"phases":3075,"primaryCompletion":3076,"completion":3076,"start":3077,"enrollment":614,"conditions":3078,"interventions":3080},"NCT00693212","Further Studies of Attention Deficit Disorder - Residual Type (RT)",[91],"1994-11","1986-02",[3079],"Attention Deficit Hyperactivity Disorder",[3062,3062],{"trials":3082,"activeCount":101},[],{"trials":3084,"activeCount":101},[],{"intervention":3086,"totalTrials":97,"cells":3087},"Mesalamine",{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3105,"NA":3107},{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"trials":3095,"activeCount":101},[3096],{"nctId":3097,"briefTitle":3098,"status":219,"phases":3099,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":1270,"conditions":3102,"interventions":3104},"NCT01412372","The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study",[91],"2019-04-22","2010-06",[3103],"Irritable Bowel Syndrome",[3086],{"trials":3106,"activeCount":101},[],{"trials":3108,"activeCount":101},[],{"intervention":3110,"totalTrials":97,"cells":3111},"Anastrozole",{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3118,"PHASE4":3129,"NA":3131},{"trials":3113,"activeCount":101},[],{"trials":3115,"activeCount":101},[],{"trials":3117,"activeCount":101},[],{"trials":3119,"activeCount":101},[3120],{"nctId":3121,"briefTitle":3122,"status":193,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":22,"conditions":3126,"interventions":3128},"NCT00440180","Aromatase Inhibitors in the Treatment of Male Infertility",[91],"2014-06","2007-03",[32,3127],"Oligospermia",[3110],{"trials":3130,"activeCount":101},[],{"trials":3132,"activeCount":101},[],{"intervention":3134,"totalTrials":97,"cells":3135},"Zolpidem",{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3153,"NA":3155},{"trials":3137,"activeCount":101},[],{"trials":3139,"activeCount":101},[],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":101},[3144],{"nctId":3145,"briefTitle":3146,"status":219,"phases":3147,"primaryCompletion":2812,"completion":2812,"start":3148,"enrollment":338,"conditions":3149,"interventions":3152},"NCT01804036","Two Contrasting Interventions for Sleep Management",[90,91],"2013-03",[3150,3151],"Primary Insomnia","Secondary Insomnia",[3134],{"trials":3154,"activeCount":101},[],{"trials":3156,"activeCount":101},[],{"intervention":1965,"totalTrials":97,"cells":3158},{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3165,"PHASE4":3175,"NA":3177},{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[],{"trials":3164,"activeCount":101},[],{"trials":3166,"activeCount":101},[3167],{"nctId":3168,"briefTitle":3169,"status":205,"phases":3170,"primaryCompletion":3171,"completion":3171,"start":3172,"enrollment":101,"conditions":3173,"interventions":3174},"NCT03068247","Neurobiology of Treatment Responses in MDD",[91],"2023-05","2021-11",[1023],[1965],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[],{"intervention":3180,"totalTrials":97,"cells":3181},"Enalapril",{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3188,"PHASE4":3201,"NA":3203},{"trials":3183,"activeCount":101},[],{"trials":3185,"activeCount":101},[],{"trials":3187,"activeCount":101},[],{"trials":3189,"activeCount":101},[3190],{"nctId":3191,"briefTitle":3192,"status":193,"phases":3193,"primaryCompletion":3194,"completion":3195,"start":2237,"enrollment":282,"conditions":3196,"interventions":3200},"NCT00113698","Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation",[91],"2005-11","2006-01",[3197,3198,3199],"Heart Defects, Congenital","Heart Septal Defects, Ventricular","Heart Failure, Congestive",[3180],{"trials":3202,"activeCount":101},[],{"trials":3204,"activeCount":101},[],{"intervention":3206,"totalTrials":97,"cells":3207},"dronedarone",{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3223,"NA":3225},{"trials":3209,"activeCount":101},[],{"trials":3211,"activeCount":101},[],{"trials":3213,"activeCount":101},[],{"trials":3215,"activeCount":101},[3216],{"nctId":3217,"briefTitle":3218,"status":219,"phases":3219,"primaryCompletion":2095,"completion":2095,"start":3220,"enrollment":640,"conditions":3221,"interventions":3222},"NCT01182376","SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI",[91],"2010-11",[2656],[3206],{"trials":3224,"activeCount":101},[],{"trials":3226,"activeCount":101},[],{"intervention":3228,"totalTrials":97,"cells":3229},"Ketamine Hydrochloride",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3245,"NA":3247},{"trials":3231,"activeCount":101},[],{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[],{"trials":3237,"activeCount":101},[3238],{"nctId":3239,"briefTitle":3240,"status":205,"phases":3241,"primaryCompletion":314,"completion":314,"start":3242,"enrollment":101,"conditions":3243,"interventions":3244},"NCT03051945","Endogenous Opioid Modulation by Ketamine",[91],"2019-08",[1023],[3228],{"trials":3246,"activeCount":101},[],{"trials":3248,"activeCount":101},[],{"intervention":3250,"totalTrials":97,"cells":3251},"exisulind",{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3258,"PHASE4":3269,"NA":3271},{"trials":3253,"activeCount":101},[],{"trials":3255,"activeCount":101},[],{"trials":3257,"activeCount":101},[],{"trials":3259,"activeCount":101},[3260],{"nctId":3261,"briefTitle":3262,"status":205,"phases":3263,"primaryCompletion":3264,"completion":3264,"start":3264,"enrollment":101,"conditions":3265,"interventions":3268},"NCT00026468","Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis",[90,91],"1999-07",[3266,3267],"Colorectal Cancer","Small Intestine Cancer",[3250],{"trials":3270,"activeCount":101},[],{"trials":3272,"activeCount":101},[],{"intervention":3274,"totalTrials":97,"cells":3275},"etanercept",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3292,"NA":3294},{"trials":3277,"activeCount":101},[],{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[],{"trials":3283,"activeCount":101},[3284],{"nctId":3285,"briefTitle":3286,"status":205,"phases":3287,"primaryCompletion":2747,"completion":2481,"start":3288,"enrollment":101,"conditions":3289,"interventions":3291},"NCT01030120","Etanercept for the Treatment of Chronic Urticaria",[90,91],"2010-12",[3290],"Chronic Idiopathic Urticaria",[3274],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[],{"intervention":3297,"totalTrials":97,"cells":3298},"imipramine",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3305,"PHASE4":3326,"NA":3328},{"trials":3300,"activeCount":101},[],{"trials":3302,"activeCount":101},[],{"trials":3304,"activeCount":101},[],{"trials":3306,"activeCount":101},[3307],{"nctId":3308,"briefTitle":3309,"status":219,"phases":3310,"completion":3311,"start":3312,"conditions":3313,"interventions":3321},"NCT00000518","Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)",[91],"1992-12","1985-07",[3314,3315,3316,3317,3318,3319,3320],"Arrhythmia","Cardiovascular Diseases","Death, Sudden, Cardiac","Heart Diseases","Tachycardia, Ventricular","Ventricular Arrhythmia","Ventricular Fibrillation",[3297,3322,3323,3324,3325],"mexiletine","procainamide","quinidine","sotalol",{"trials":3327,"activeCount":101},[],{"trials":3329,"activeCount":101},[],{"intervention":3322,"totalTrials":97,"cells":3331},{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3338,"PHASE4":3344,"NA":3346},{"trials":3333,"activeCount":101},[],{"trials":3335,"activeCount":101},[],{"trials":3337,"activeCount":101},[],{"trials":3339,"activeCount":101},[3340],{"nctId":3308,"briefTitle":3309,"status":219,"phases":3341,"completion":3311,"start":3312,"conditions":3342,"interventions":3343},[91],[3314,3315,3316,3317,3318,3319,3320],[3297,3322,3323,3324,3325],{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":101},[],{"intervention":3323,"totalTrials":97,"cells":3349},{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3356,"PHASE4":3362,"NA":3364},{"trials":3351,"activeCount":101},[],{"trials":3353,"activeCount":101},[],{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[3358],{"nctId":3308,"briefTitle":3309,"status":219,"phases":3359,"completion":3311,"start":3312,"conditions":3360,"interventions":3361},[91],[3314,3315,3316,3317,3318,3319,3320],[3297,3322,3323,3324,3325],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"intervention":3324,"totalTrials":97,"cells":3367},{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3374,"PHASE4":3380,"NA":3382},{"trials":3369,"activeCount":101},[],{"trials":3371,"activeCount":101},[],{"trials":3373,"activeCount":101},[],{"trials":3375,"activeCount":101},[3376],{"nctId":3308,"briefTitle":3309,"status":219,"phases":3377,"completion":3311,"start":3312,"conditions":3378,"interventions":3379},[91],[3314,3315,3316,3317,3318,3319,3320],[3297,3322,3323,3324,3325],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"intervention":3385,"totalTrials":97,"cells":3386},"OROS methylphenidate",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3393,"PHASE4":3404,"NA":3406},{"trials":3388,"activeCount":101},[],{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":101},[],{"trials":3394,"activeCount":101},[3395],{"nctId":3396,"briefTitle":3397,"status":219,"phases":3398,"primaryCompletion":3399,"completion":3400,"start":3401,"enrollment":2508,"conditions":3402,"interventions":3403},"NCT02215538","OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD",[90,91],"2006-02","2006-06","2004-11",[3079],[3385],{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"intervention":3409,"totalTrials":97,"cells":3410},"lansoprazole",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3417,"PHASE4":3427,"NA":3429},{"trials":3412,"activeCount":101},[],{"trials":3414,"activeCount":101},[],{"trials":3416,"activeCount":101},[],{"trials":3418,"activeCount":101},[3419],{"nctId":3420,"briefTitle":3421,"status":193,"phases":3422,"primaryCompletion":2096,"completion":2096,"start":3423,"enrollment":27,"conditions":3424,"interventions":3426},"NCT00361972","Elucidation of Acid-Induced Pulmonary Inflammation",[90,91],"2006-08",[3425,3055],"Gastroesophageal Reflux",[3409],{"trials":3428,"activeCount":101},[],{"trials":3430,"activeCount":101},[],{"intervention":3432,"totalTrials":97,"cells":3433},"Propofol",{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3438,"PHASE3":3440,"PHASE4":3452,"NA":3454},{"trials":3435,"activeCount":101},[],{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[3442],{"nctId":3443,"briefTitle":3444,"status":3445,"phases":3446,"primaryCompletion":3447,"completion":3027,"start":3448,"enrollment":3449,"conditions":3450,"interventions":3451},"NCT03684447","Neural and Antidepressant Effects of Propofol","UNKNOWN",[90,91],"2022-12-31","2019-04-21",48,[3030],[3432,3432],{"trials":3453,"activeCount":101},[],{"trials":3455,"activeCount":101},[],{"intervention":3457,"totalTrials":97,"cells":3458},"Aciphex",{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3465,"PHASE4":3476,"NA":3478},{"trials":3460,"activeCount":101},[],{"trials":3462,"activeCount":101},[],{"trials":3464,"activeCount":101},[],{"trials":3466,"activeCount":101},[3467],{"nctId":3468,"briefTitle":3469,"status":219,"phases":3470,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":407,"conditions":3473,"interventions":3475},"NCT00204698","Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment",[90,91],"2006-05","2003-08",[3474],"Laryngopharyngeal Reflux",[3457],{"trials":3477,"activeCount":101},[],{"trials":3479,"activeCount":101},[],{"intervention":3481,"totalTrials":97,"cells":3482},"VSL#3",{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3489,"PHASE4":3499,"NA":3501},{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":101},[],{"trials":3488,"activeCount":101},[],{"trials":3490,"activeCount":101},[3491],{"nctId":3492,"briefTitle":3493,"status":193,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":2431,"enrollment":472,"conditions":3496,"interventions":3498},"NCT02011542","Probiotic (VSL #3) for Gulf War Illness",[90,91],"2016-07",[3497],"Gulf War Illness",[3481],{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":101},[],{"intervention":3504,"totalTrials":97,"cells":3505},"Methylphenidate Transdermal System",{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3510,"PHASE3":3512,"PHASE4":3522,"NA":3524},{"trials":3507,"activeCount":101},[],{"trials":3509,"activeCount":101},[],{"trials":3511,"activeCount":101},[],{"trials":3513,"activeCount":101},[3514],{"nctId":3515,"briefTitle":3516,"status":219,"phases":3517,"primaryCompletion":2096,"completion":2096,"start":3518,"enrollment":3519,"conditions":3520,"interventions":3521},"NCT00506285","Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD",[91],"2007-06",92,[3079],[3504],{"trials":3523,"activeCount":101},[],{"trials":3525,"activeCount":101},[],{"intervention":3527,"totalTrials":97,"cells":3528},"Autonomic testing on and off levodopa",{"EARLY_PHASE1":3529,"PHASE1":3531,"PHASE2":3533,"PHASE3":3535,"PHASE4":3547,"NA":3549},{"trials":3530,"activeCount":101},[],{"trials":3532,"activeCount":101},[],{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[3537],{"nctId":3538,"briefTitle":3539,"status":219,"phases":3540,"primaryCompletion":3541,"completion":3541,"start":3542,"enrollment":9,"conditions":3543,"interventions":3546},"NCT05487300","Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease",[90,91],"2023-05-01","2022-05-11",[3544,3545],"Parkinson Disease","Orthostatic Hypotension",[3527],{"trials":3548,"activeCount":101},[],{"trials":3550,"activeCount":101},[],{"intervention":3552,"totalTrials":97,"cells":3553},"Methadon",{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3569,"NA":3571},{"trials":3555,"activeCount":101},[],{"trials":3557,"activeCount":101},[],{"trials":3559,"activeCount":101},[],{"trials":3561,"activeCount":101},[3562],{"nctId":3563,"briefTitle":3564,"status":205,"phases":3565,"primaryCompletion":3566,"completion":3566,"start":3566,"enrollment":101,"conditions":3567,"interventions":3568},"NCT07092475","The Impact of Intraoperative Methadone on Postoperative Opioid Use",[91],"2025-11",[21,2064],[3552],{"trials":3570,"activeCount":101},[],{"trials":3572,"activeCount":101},[],{"intervention":227,"totalTrials":282,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3591,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[3579,3587],{"nctId":3580,"briefTitle":3581,"status":219,"phases":3582,"primaryCompletion":3583,"completion":3583,"start":3584,"enrollment":2974,"conditions":3585,"interventions":3586},"NCT00708448","Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB\u002FIV or Recurrent Lung Cancer Patients",[89],"2010-08-12","2008-03-28",[15,363],[227,201],{"nctId":217,"briefTitle":218,"status":219,"phases":3588,"primaryCompletion":221,"completion":222,"start":223,"enrollment":35,"conditions":3589,"interventions":3590},[89],[225],[46,227,228,66],{"trials":3592,"activeCount":101},[3593,3603,3611],{"nctId":3594,"briefTitle":3595,"status":219,"phases":3596,"primaryCompletion":3124,"completion":3597,"start":3598,"enrollment":3519,"conditions":3599,"interventions":3601},"NCT01187901","A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients",[90],"2014-07","2010-04",[3600],"Adenomatous Polyposis Coli",[227,3602],"Sulindac",{"nctId":3604,"briefTitle":3605,"status":219,"phases":3606,"primaryCompletion":2813,"completion":2813,"start":3607,"enrollment":9,"conditions":3608,"interventions":3610},"NCT00585533","A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer",[90],"2004-06",[3609],"Lung Cancer",[227],{"nctId":3612,"briefTitle":3613,"status":205,"phases":3614,"primaryCompletion":3615,"completion":3615,"start":3616,"enrollment":101,"conditions":3617,"interventions":3620},"NCT01728181","A Phase I\u002FII Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation",[89,90],"2016-03","2013-11",[225,3618,3619],"Stage IV Disease","EGFR Unknown or Wild-type",[3621,227],"Tivozanib",{"trials":3623,"activeCount":101},[],{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[],{"intervention":3629,"totalTrials":282,"cells":3630},"[18F]fluoro-2-deoxy-D-glucose",{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3675,"PHASE3":3686,"PHASE4":3688,"NA":3690},{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":101},[3635,3646,3658,3666],{"nctId":3636,"briefTitle":3637,"status":193,"phases":3638,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":378,"conditions":3641,"interventions":3643},"NCT01246869","Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water",[89],"2014-05-03","2013-03-27",[3642],"Brain Cancer",[3629,3644,3645],"1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole","[15O]water",{"nctId":3647,"briefTitle":3648,"status":219,"phases":3649,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3015,"conditions":3652,"interventions":3654},"NCT00813566","Multi-Tracer PET Assessment of Primary Brain Tumors",[89],"2015-02-03","2010-11-12",[3653,15],"Brain Tumors",[3629,3655,3656,3657],"3'-deoxy-3'-[18F]fluorothymidine","[15O]-H2O","[11C]Acetate",{"nctId":3659,"briefTitle":3660,"status":219,"phases":3661,"primaryCompletion":3662,"completion":3662,"start":3663,"enrollment":878,"conditions":3664,"interventions":3665},"NCT00708045","A Multi-modality Imaging Assessment of Chemobrain",[89],"2015-02-05","2007-05-09",[15],[3629],{"nctId":3667,"briefTitle":3668,"status":193,"phases":3669,"primaryCompletion":3670,"completion":3670,"start":3671,"enrollment":3672,"conditions":3673,"interventions":3674},"NCT00707213","FDG-Positron Emission Tomography (PET)\u002FCT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients",[89],"2010-08-11","2007-08-21",19,[15],[3629],{"trials":3676,"activeCount":101},[3677],{"nctId":3678,"briefTitle":3679,"status":193,"phases":3680,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":30,"conditions":3683,"interventions":3684},"NCT02317783","Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment",[90],"2019-09-24","2018-01-31",[21],[3685,3629],"[18F]Flutemetamol",{"trials":3687,"activeCount":101},[],{"trials":3689,"activeCount":101},[],{"trials":3691,"activeCount":101},[],{"intervention":3693,"totalTrials":397,"cells":3694},"Hydroxychloroquine",{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3727,"PHASE3":3751,"PHASE4":3753,"NA":3755},{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[3699,3710],{"nctId":3700,"briefTitle":3701,"status":219,"phases":3702,"primaryCompletion":3703,"completion":3704,"start":3705,"enrollment":1646,"conditions":3706,"interventions":3708},"NCT04145297","Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas",[89],"2022-06-10","2022-08-18","2020-03-17",[3707],"Gastrointestinal Neoplasms",[3709,3693],"Ulixertinib",{"nctId":3711,"briefTitle":3712,"status":193,"phases":3713,"primaryCompletion":3714,"completion":3715,"start":3716,"enrollment":250,"conditions":3717,"interventions":3725},"NCT03825289","Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer",[89],"2025-01-15","2025-08-03","2019-01-30",[3718,3719,3720,3721,3722,3723,3724],"Metastatic Pancreatic Carcinoma","Stage II Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer","Unresectable Pancreatic Carcinoma",[3693,3726],"Trametinib",{"trials":3728,"activeCount":101},[3729,3738],{"nctId":3730,"briefTitle":3731,"status":205,"phases":3732,"primaryCompletion":3733,"completion":2355,"start":3495,"enrollment":101,"conditions":3734,"interventions":3737},"NCT02379650","Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss",[90],"2019-07",[3735,3736],"Recurrent Pregnancy Loss","Miscarriage",[3693],{"nctId":3739,"briefTitle":3740,"status":219,"phases":3741,"primaryCompletion":3742,"completion":3743,"start":3744,"enrollment":3745,"conditions":3746,"interventions":3750},"NCT04342169","University of Utah COVID-19 Hydrochloroquine Trial",[90],"2021-10-30","2021-11-15","2020-04-04",368,[3747,3748,3749],"Coronavirus Infection","Coronavirus","Infectious Disease",[3693],{"trials":3752,"activeCount":101},[],{"trials":3754,"activeCount":101},[],{"trials":3756,"activeCount":101},[],{"intervention":201,"totalTrials":397,"cells":3758},{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3771,"PHASE3":3793,"PHASE4":3795,"NA":3797},{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[3763,3767],{"nctId":3580,"briefTitle":3581,"status":219,"phases":3764,"primaryCompletion":3583,"completion":3583,"start":3584,"enrollment":2974,"conditions":3765,"interventions":3766},[89],[15,363],[227,201],{"nctId":191,"briefTitle":192,"status":193,"phases":3768,"primaryCompletion":195,"completion":196,"start":197,"enrollment":97,"conditions":3769,"interventions":3770},[89],[199],[66,201],{"trials":3772,"activeCount":101},[3773,3784],{"nctId":3774,"briefTitle":3775,"status":219,"phases":3776,"primaryCompletion":3777,"completion":3778,"start":3779,"enrollment":554,"conditions":3780,"interventions":3782},"NCT01580969","Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma",[89,90],"2018-01-12","2018-05-15","2012-07-06",[3781],"Recurrent Glioma",[201,3783],"Minocycline",{"nctId":3785,"briefTitle":3786,"status":219,"phases":3787,"primaryCompletion":3788,"completion":3788,"start":2720,"enrollment":2508,"conditions":3789,"interventions":3790},"NCT01047293","RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma",[89,90],"2015-08",[3266],[3791,3792,201],"RAD001","FOLFOX",{"trials":3794,"activeCount":101},[],{"trials":3796,"activeCount":101},[],{"trials":3798,"activeCount":101},[],{"intervention":3800,"totalTrials":273,"cells":3801},"Prednisone",{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3816,"PHASE3":3845,"PHASE4":3847,"NA":3849},{"trials":3803,"activeCount":101},[],{"trials":3805,"activeCount":101},[3806],{"nctId":3807,"briefTitle":3808,"status":205,"phases":3809,"primaryCompletion":3810,"completion":3810,"start":3811,"enrollment":101,"conditions":3812,"interventions":3813},"NCT02815059","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",[89],"2018-01-09","2016-09-28",[1432],[3814,3815,3800],"Ibrutinib","Dasatinib",{"trials":3817,"activeCount":101},[3818,3834],{"nctId":3819,"briefTitle":3820,"status":193,"phases":3821,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":97,"conditions":3824,"interventions":3830},"NCT03827473","Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer",[90],"2019-07-31","2019-02-08",[3825,3826,3827,3828,3829],"Castration-Sensitive Prostate Carcinoma","Metastatic Prostatic Adenocarcinoma","Stage IV Prostate Cancer","Stage IVA Prostate Cancer","Stage IVB Prostate Cancer",[3831,3832,3833,3800],"Abiraterone Acetate","Antiandrogen Therapy","Docetaxel",{"nctId":3835,"briefTitle":3836,"status":219,"phases":3837,"completion":3838,"start":3839,"conditions":3840,"interventions":3842},"NCT00000524","Myocarditis Treatment Trial",[90],"1994-03","1986-07",[3315,3317,3841],"Myocarditis",[3843,3844],"cyclosporine","prednisone",{"trials":3846,"activeCount":101},[],{"trials":3848,"activeCount":101},[],{"trials":3850,"activeCount":101},[],{"intervention":3852,"totalTrials":273,"cells":3853},"Valproic Acid",{"EARLY_PHASE1":3854,"PHASE1":3856,"PHASE2":3874,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3855,"activeCount":101},[],{"trials":3857,"activeCount":101},[3858,3867],{"nctId":3859,"briefTitle":3860,"status":219,"phases":3861,"completion":3399,"start":3862,"enrollment":3863,"conditions":3864,"interventions":3866},"NCT00374075","Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy",[89],"2003-09",42,[3865],"Spinal Muscular Atrophy",[3852],{"nctId":3868,"briefTitle":3869,"status":193,"phases":3870,"primaryCompletion":3871,"completion":3871,"start":2720,"enrollment":16,"conditions":3872,"interventions":3873},"NCT01007695","Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot",[89],"2015-05",[15],[3852],{"trials":3875,"activeCount":101},[3876],{"nctId":3877,"briefTitle":3878,"status":219,"phases":3879,"primaryCompletion":2719,"completion":3220,"start":3880,"enrollment":640,"conditions":3881,"interventions":3882},"NCT00481013","Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy",[90],"2007-07",[3865],[3852],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[],{"trials":3888,"activeCount":101},[],{"intervention":1410,"totalTrials":273,"cells":3890},{"EARLY_PHASE1":3891,"PHASE1":3893,"PHASE2":3908,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3892,"activeCount":101},[],{"trials":3894,"activeCount":101},[3895],{"nctId":3896,"briefTitle":3897,"status":193,"phases":3898,"primaryCompletion":2261,"completion":3899,"start":3900,"enrollment":282,"conditions":3901,"interventions":3906},"NCT03407976","Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies",[89],"2020-07-02","2018-06-19",[3902,3903,3904,3905],"Advanced Malignancies","Urothelial Carcinoma","MSI-H or dMMR Solid Tumors","Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[3907,1410],"Apatinib",{"trials":3909,"activeCount":101},[3910,3920],{"nctId":3911,"briefTitle":3912,"status":193,"phases":3913,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":3917,"conditions":3918,"interventions":3919},"NCT03190213","Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma",[90],"2018-12-13","2019-03-11","2017-12-04",6,[790],[1410],{"nctId":1401,"briefTitle":1402,"status":219,"phases":3921,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":1407,"conditions":3922,"interventions":3923},[90],[375,259],[1371,1410],{"trials":3925,"activeCount":101},[],{"trials":3927,"activeCount":101},[],{"trials":3929,"activeCount":101},[],{"intervention":3931,"totalTrials":378,"cells":3932},"Busulfan",{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3934,"activeCount":101},[],{"trials":3936,"activeCount":101},[],{"trials":3938,"activeCount":101},[3939,3960],{"nctId":3940,"briefTitle":3941,"status":193,"phases":3942,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":3917,"conditions":3946,"interventions":3957},"NCT03303950","Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis",[90],"2019-05-14","2020-02-19","2018-03-30",[3947,3948,3949,3950,3951,3952,3953,3954,3955,3956],"Anemia","ASXL1 Gene Mutation","EZH2 Gene Mutation","IDH1 Gene Mutation","IDH2 Gene Mutation","Plasma Cell Myeloma","Primary Myelofibrosis","Recurrent Plasma Cell Myeloma","Secondary Myelofibrosis","Thrombocytopenia",[3931,3958,3959],"Cyclophosphamide","Fludarabine",{"nctId":3961,"briefTitle":3962,"status":219,"phases":3963,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":2508,"conditions":3966,"interventions":3972},"NCT00795132","Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies",[90],"2009-07","2004-04",[3967,3968,3969,3970,3971],"Acute Leukaemia","Chronic Disease","Leukemia","Myelodysplasia","Lymphoma",[3931,3973,3959,3974,3975],"Anti-Thymocyte Globulin","Cyclosporine","Mycophenolate mofetil",{"trials":3977,"activeCount":101},[],{"trials":3979,"activeCount":101},[],{"trials":3981,"activeCount":101},[],{"intervention":3958,"totalTrials":378,"cells":3983},{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3999,"PHASE3":4005,"PHASE4":4007,"NA":4009},{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[3988],{"nctId":3989,"briefTitle":3990,"status":193,"phases":3991,"primaryCompletion":3992,"completion":3992,"start":2009,"enrollment":1313,"conditions":3993,"interventions":3995},"NCT01090128","Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer",[89],"2017-03-24",[3994],"Stages II-III Breast Cancer",[3996,3997,3998],"Nanoparticle Albumin Bound Paclitaxel","doxorubicin","cyclophosphamide",{"trials":4000,"activeCount":101},[4001],{"nctId":3940,"briefTitle":3941,"status":193,"phases":4002,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":3917,"conditions":4003,"interventions":4004},[90],[3947,3948,3949,3950,3951,3952,3953,3954,3955,3956],[3931,3958,3959],{"trials":4006,"activeCount":101},[],{"trials":4008,"activeCount":101},[],{"trials":4010,"activeCount":101},[],{"intervention":3959,"totalTrials":378,"cells":4012},{"EARLY_PHASE1":4013,"PHASE1":4015,"PHASE2":4017,"PHASE3":4027,"PHASE4":4029,"NA":4031},{"trials":4014,"activeCount":101},[],{"trials":4016,"activeCount":101},[],{"trials":4018,"activeCount":101},[4019,4023],{"nctId":3940,"briefTitle":3941,"status":193,"phases":4020,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":3917,"conditions":4021,"interventions":4022},[90],[3947,3948,3949,3950,3951,3952,3953,3954,3955,3956],[3931,3958,3959],{"nctId":3961,"briefTitle":3962,"status":219,"phases":4024,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":2508,"conditions":4025,"interventions":4026},[90],[3967,3968,3969,3970,3971],[3931,3973,3959,3974,3975],{"trials":4028,"activeCount":101},[],{"trials":4030,"activeCount":101},[],{"trials":4032,"activeCount":101},[],{"intervention":4034,"totalTrials":378,"cells":4035},"Aspirin 81 mg",{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4062,"PHASE4":4064,"NA":4066},{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[4042,4053],{"nctId":4043,"briefTitle":4044,"status":219,"phases":4045,"primaryCompletion":4046,"completion":4046,"start":4047,"enrollment":4048,"conditions":4049,"interventions":4051},"NCT04066725","Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma",[90],"2021-03-19","2019-07-25",95,[4050],"Melanoma (Skin)",[4034,4052],"Aspirin 325mg",{"nctId":4054,"briefTitle":4055,"status":219,"phases":4056,"primaryCompletion":4057,"completion":4057,"start":4058,"enrollment":4059,"conditions":4060,"interventions":4061},"NCT04062032","Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma",[90],"2019-02-27","2016-09-27",41,[4050],[4034,4052],{"trials":4063,"activeCount":101},[],{"trials":4065,"activeCount":101},[],{"trials":4067,"activeCount":101},[],{"intervention":4052,"totalTrials":378,"cells":4069},{"EARLY_PHASE1":4070,"PHASE1":4072,"PHASE2":4074,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4071,"activeCount":101},[],{"trials":4073,"activeCount":101},[],{"trials":4075,"activeCount":101},[4076,4080],{"nctId":4043,"briefTitle":4044,"status":219,"phases":4077,"primaryCompletion":4046,"completion":4046,"start":4047,"enrollment":4048,"conditions":4078,"interventions":4079},[90],[4050],[4034,4052],{"nctId":4054,"briefTitle":4055,"status":219,"phases":4081,"primaryCompletion":4057,"completion":4057,"start":4058,"enrollment":4059,"conditions":4082,"interventions":4083},[90],[4050],[4034,4052],{"trials":4085,"activeCount":101},[],{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"intervention":4091,"totalTrials":378,"cells":4092},"Human Amniotic Fluid",{"EARLY_PHASE1":4093,"PHASE1":4104,"PHASE2":4106,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4094,"activeCount":101},[4095],{"nctId":4096,"briefTitle":4097,"status":219,"phases":4098,"primaryCompletion":4099,"completion":4099,"start":4100,"enrollment":1430,"conditions":4101,"interventions":4103},"NCT04319731","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure",[88],"2020-06-09","2020-03-20",[4102],"SARS CoV-2 Infection",[4091],{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[4108],{"nctId":4109,"briefTitle":4110,"status":219,"phases":4111,"primaryCompletion":4112,"completion":4113,"start":4114,"enrollment":2508,"conditions":4115,"interventions":4117},"NCT04497389","Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients",[89,90],"2022-08-02","2023-02-15","2020-10-28",[4116],"SARS CoV-2",[4091],{"trials":4119,"activeCount":101},[],{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[],{"intervention":4125,"totalTrials":378,"cells":4126},"Valproic Acid and Levocarnitine",{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4128,"activeCount":101},[],{"trials":4130,"activeCount":101},[],{"trials":4132,"activeCount":101},[4133,4142],{"nctId":4134,"briefTitle":4135,"status":219,"phases":4136,"primaryCompletion":4137,"completion":4138,"start":2454,"enrollment":9,"conditions":4139,"interventions":4141},"NCT00661453","CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I",[89,90],"2012-05","2012-06",[4140],"Spinal Muscular Atrophy Type I",[4125],{"nctId":4143,"briefTitle":4144,"status":219,"phases":4145,"primaryCompletion":4146,"completion":4146,"start":3051,"enrollment":4147,"conditions":4148,"interventions":4149},"NCT00227266","Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy",[90],"2007-11",94,[3865],[4125],{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":101},[],{"trials":4155,"activeCount":101},[],{"intervention":3843,"totalTrials":378,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4172,"PHASE4":4174,"NA":4176},{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[4164,4168],{"nctId":3835,"briefTitle":3836,"status":219,"phases":4165,"completion":3838,"start":3839,"conditions":4166,"interventions":4167},[90],[3315,3317,3841],[3843,3844],{"nctId":3961,"briefTitle":3962,"status":219,"phases":4169,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":2508,"conditions":4170,"interventions":4171},[90],[3967,3968,3969,3970,3971],[3931,3973,3959,3974,3975],{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":101},[],{"trials":4177,"activeCount":101},[],{"intervention":4179,"totalTrials":378,"cells":4180},"Amniotic Fluid",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4182,"activeCount":101},[],{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[4187,4196],{"nctId":4188,"briefTitle":4189,"status":219,"phases":4190,"primaryCompletion":4191,"completion":4191,"start":4192,"enrollment":304,"conditions":4193,"interventions":4195},"NCT04886960","pAF for the Treatment of Osteoarthritis",[89,90],"2025-01-31","2021-07-08",[4194],"Osteo Arthritis Knee",[4179],{"nctId":4197,"briefTitle":4198,"status":219,"phases":4199,"primaryCompletion":4200,"completion":4200,"start":4201,"enrollment":1270,"conditions":4202,"interventions":4204},"NCT04281004","Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)",[89,90],"2023-01-16","2020-07-10",[4203],"Photorefractive Keratectomy",[4179],{"trials":4206,"activeCount":101},[],{"trials":4208,"activeCount":101},[],{"trials":4210,"activeCount":101},[],{"intervention":4212,"totalTrials":378,"cells":4213},"[18F]Fluoroestradiol (FES) PET\u002FCT",{"EARLY_PHASE1":4214,"PHASE1":4226,"PHASE2":4228,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4215,"activeCount":101},[4216],{"nctId":4217,"briefTitle":4218,"status":193,"phases":4219,"primaryCompletion":4220,"completion":4221,"start":4222,"enrollment":378,"conditions":4223,"interventions":4225},"NCT04727632","[18F]Fluoroestradiol-PET\u002FCT Companion Imaging Study to the FORESEE Trial",[88],"2023-09-14","2024-07-30","2021-03-31",[4224],"Estrogen Receptor Positive Breast Cancer",[4212],{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[4230],{"nctId":4231,"briefTitle":4232,"status":193,"phases":4233,"primaryCompletion":4234,"completion":4234,"start":4235,"enrollment":4236,"conditions":4237,"interventions":4239},"NCT04252859","[18F]Fluoroestradiol-PET\u002FCT Imaging of Invasive Lobular Carcinoma",[90],"2024-12-07","2020-12-11",44,[4238],"Invasive Lobular Breast Carcinoma",[4212],{"trials":4241,"activeCount":101},[],{"trials":4243,"activeCount":101},[],{"trials":4245,"activeCount":101},[],{"intervention":4247,"totalTrials":378,"cells":4248},"Abreva",{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4253,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[4255,4266],{"nctId":4256,"briefTitle":4257,"status":219,"phases":4258,"primaryCompletion":4259,"completion":4260,"start":4261,"enrollment":1430,"conditions":4262,"interventions":4264},"NCT04893577","EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions",[90],"2024-08-31","2025-08-01","2022-01-20",[4263],"Herpes Simplex Oral",[4265,4247],"EDTA",{"nctId":4267,"briefTitle":4268,"status":219,"phases":4269,"primaryCompletion":4270,"completion":4270,"start":4271,"enrollment":9,"conditions":4272,"interventions":4273},"NCT06558838","Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions",[90],"2025-11-30","2024-08-19",[4263],[4274,4247],"acyclovir-penciclovir cream",{"trials":4276,"activeCount":101},[],{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"intervention":4282,"totalTrials":378,"cells":4283},"Cisplatin",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4294,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4285,"activeCount":101},[],{"trials":4287,"activeCount":101},[4288],{"nctId":4289,"briefTitle":4290,"status":205,"phases":4291,"primaryCompletion":3598,"completion":3598,"start":3964,"enrollment":101,"conditions":4292,"interventions":4293},"NCT00942838","Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity",[89],[1352],[4282],{"trials":4295,"activeCount":101},[4296],{"nctId":4297,"briefTitle":4298,"status":193,"phases":4299,"primaryCompletion":4300,"completion":4300,"start":3051,"enrollment":3917,"conditions":4301,"interventions":4302},"NCT00707161","Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma",[90],"2010-02",[15,240],[4282],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"intervention":4310,"totalTrials":378,"cells":4311},"regorafenib",{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4335,"PHASE4":4337,"NA":4339},{"trials":4313,"activeCount":101},[],{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[4318,4326],{"nctId":4319,"briefTitle":4320,"status":193,"phases":4321,"primaryCompletion":2430,"completion":2430,"start":4322,"enrollment":282,"conditions":4323,"interventions":4325},"NCT02241720","Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers",[90],"2014-05",[4324],"Upper GI Cancer",[4310],{"nctId":4327,"briefTitle":4328,"status":193,"phases":4329,"primaryCompletion":3495,"completion":325,"start":2746,"enrollment":97,"conditions":4330,"interventions":4334},"NCT02278783","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[90],[4331,4332,4333],"Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer",[4310],{"trials":4336,"activeCount":101},[],{"trials":4338,"activeCount":101},[],{"trials":4340,"activeCount":101},[],{"intervention":4342,"totalTrials":378,"cells":4343},"Radium Ra 223 Dichloride",{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4345,"activeCount":101},[],{"trials":4347,"activeCount":101},[],{"trials":4349,"activeCount":101},[4350,4362],{"nctId":4351,"briefTitle":4352,"status":219,"phases":4353,"primaryCompletion":4354,"completion":4355,"start":4356,"enrollment":4357,"conditions":4358,"interventions":4360},"NCT02199197","Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer",[90],"2018-04-19","2019-10-03","2014-06-25",49,[4359],"Prostate Cancer",[4342,4361],"Enzalutamide",{"nctId":4363,"briefTitle":4364,"status":219,"phases":4365,"primaryCompletion":4366,"completion":4367,"start":4368,"enrollment":22,"conditions":4369,"interventions":4371},"NCT03304418","Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone",[90],"2022-09-30","2023-08-31","2018-02-27",[4370],"Prostate Cancer Metastatic to Bone",[4342],{"trials":4373,"activeCount":101},[],{"trials":4375,"activeCount":101},[],{"trials":4377,"activeCount":101},[],{"intervention":4379,"totalTrials":378,"cells":4380},"Fluorescein",{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4382,"activeCount":101},[],{"trials":4384,"activeCount":101},[],{"trials":4386,"activeCount":101},[4387,4394],{"nctId":4388,"briefTitle":4389,"status":205,"phases":4390,"primaryCompletion":2857,"completion":2857,"start":4391,"enrollment":101,"conditions":4392,"interventions":4393},"NCT01614184","Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer",[89,90],"2008-05",[21],[4379],{"nctId":4395,"briefTitle":4396,"status":219,"phases":4397,"primaryCompletion":3495,"completion":3495,"start":4398,"enrollment":4399,"conditions":4400,"interventions":4401},"NCT00847522","Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma",[89,90],"2009-02",90,[15],[4379],{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[],{"intervention":4409,"totalTrials":378,"cells":4410},"Everolimus",{"EARLY_PHASE1":4411,"PHASE1":4413,"PHASE2":4415,"PHASE3":4435,"PHASE4":4437,"NA":4439},{"trials":4412,"activeCount":101},[],{"trials":4414,"activeCount":101},[],{"trials":4416,"activeCount":101},[4417,4425],{"nctId":4418,"briefTitle":4419,"status":193,"phases":4420,"primaryCompletion":2304,"completion":2304,"start":4421,"enrollment":273,"conditions":4422,"interventions":4424},"NCT00811590","Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome",[90],"2008-11",[4423],"Peutz-Jeghers Syndrome",[4409],{"nctId":4426,"briefTitle":4427,"status":193,"phases":4428,"primaryCompletion":2480,"completion":2480,"start":4429,"enrollment":3672,"conditions":4430,"interventions":4433},"NCT01149434","Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers",[89,90],"2010-09",[15,4431,4331,4432],"Neuroendocrine","Colon Cancer",[4434,4409],"JI-101",{"trials":4436,"activeCount":101},[],{"trials":4438,"activeCount":101},[],{"trials":4440,"activeCount":101},[],{"intervention":4442,"totalTrials":97,"cells":4443},"Magnesium Sulfate, Heptahydrate",{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4461,"PHASE4":4463,"NA":4465},{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":101},[4450],{"nctId":4451,"briefTitle":4452,"status":219,"phases":4453,"primaryCompletion":4454,"completion":4455,"start":4456,"enrollment":4457,"conditions":4458,"interventions":4459},"NCT05166811","Timely Intravenous Magnesium for Asthma in Children",[90],"2023-05-31","2023-07-31","2022-09-12",52,[3055],[4442,4460],"0.9% saline",{"trials":4462,"activeCount":101},[],{"trials":4464,"activeCount":101},[],{"trials":4466,"activeCount":101},[],{"intervention":4460,"totalTrials":97,"cells":4468},{"EARLY_PHASE1":4469,"PHASE1":4471,"PHASE2":4473,"PHASE3":4479,"PHASE4":4481,"NA":4483},{"trials":4470,"activeCount":101},[],{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":101},[4475],{"nctId":4451,"briefTitle":4452,"status":219,"phases":4476,"primaryCompletion":4454,"completion":4455,"start":4456,"enrollment":4457,"conditions":4477,"interventions":4478},[90],[3055],[4442,4460],{"trials":4480,"activeCount":101},[],{"trials":4482,"activeCount":101},[],{"trials":4484,"activeCount":101},[],{"intervention":3831,"totalTrials":97,"cells":4486},{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4497,"PHASE4":4499,"NA":4501},{"trials":4488,"activeCount":101},[],{"trials":4490,"activeCount":101},[],{"trials":4492,"activeCount":101},[4493],{"nctId":3819,"briefTitle":3820,"status":193,"phases":4494,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":97,"conditions":4495,"interventions":4496},[90],[3825,3826,3827,3828,3829],[3831,3832,3833,3800],{"trials":4498,"activeCount":101},[],{"trials":4500,"activeCount":101},[],{"trials":4502,"activeCount":101},[],{"intervention":3832,"totalTrials":97,"cells":4504},{"EARLY_PHASE1":4505,"PHASE1":4507,"PHASE2":4509,"PHASE3":4515,"PHASE4":4517,"NA":4519},{"trials":4506,"activeCount":101},[],{"trials":4508,"activeCount":101},[],{"trials":4510,"activeCount":101},[4511],{"nctId":3819,"briefTitle":3820,"status":193,"phases":4512,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":97,"conditions":4513,"interventions":4514},[90],[3825,3826,3827,3828,3829],[3831,3832,3833,3800],{"trials":4516,"activeCount":101},[],{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":101},[],{"intervention":3833,"totalTrials":97,"cells":4522},{"EARLY_PHASE1":4523,"PHASE1":4525,"PHASE2":4527,"PHASE3":4533,"PHASE4":4535,"NA":4537},{"trials":4524,"activeCount":101},[],{"trials":4526,"activeCount":101},[],{"trials":4528,"activeCount":101},[4529],{"nctId":3819,"briefTitle":3820,"status":193,"phases":4530,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":97,"conditions":4531,"interventions":4532},[90],[3825,3826,3827,3828,3829],[3831,3832,3833,3800],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"intervention":4540,"totalTrials":97,"cells":4541},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4559,"PHASE4":4561,"NA":4563},{"trials":4543,"activeCount":101},[],{"trials":4545,"activeCount":101},[],{"trials":4547,"activeCount":101},[4548],{"nctId":4549,"briefTitle":4550,"status":219,"phases":4551,"primaryCompletion":4552,"completion":4553,"start":4554,"enrollment":293,"conditions":4555,"interventions":4557},"NCT04772222","Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)",[90],"2025-01-17","2025-12-31","2022-06-20",[4556,18],"Hypoxic-Ischemic Encephalopathy",[4540,4558],"Morphine Sulfate",{"trials":4560,"activeCount":101},[],{"trials":4562,"activeCount":101},[],{"trials":4564,"activeCount":101},[],{"intervention":4558,"totalTrials":97,"cells":4566},{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4571,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4568,"activeCount":101},[],{"trials":4570,"activeCount":101},[],{"trials":4572,"activeCount":101},[4573],{"nctId":4549,"briefTitle":4550,"status":219,"phases":4574,"primaryCompletion":4552,"completion":4553,"start":4554,"enrollment":293,"conditions":4575,"interventions":4576},[90],[4556,18],[4540,4558],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":101},[],{"trials":4582,"activeCount":101},[],{"intervention":4584,"totalTrials":97,"cells":4585},"Oxytocin",{"EARLY_PHASE1":4586,"PHASE1":4588,"PHASE2":4590,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4587,"activeCount":101},[],{"trials":4589,"activeCount":101},[],{"trials":4591,"activeCount":101},[4592],{"nctId":4593,"briefTitle":4594,"status":3445,"phases":4595,"primaryCompletion":2353,"completion":4596,"start":2812,"enrollment":4597,"conditions":4598,"interventions":4601},"NCT02652195","Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II",[90],"2024-06",88,[4599,4600],"Healthy Controls","Alcohol Use Disorder",[4584],{"trials":4603,"activeCount":101},[],{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":101},[],{"intervention":4609,"totalTrials":97,"cells":4610},"Hydroxyurea",{"EARLY_PHASE1":4611,"PHASE1":4613,"PHASE2":4615,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4612,"activeCount":101},[],{"trials":4614,"activeCount":101},[],{"trials":4616,"activeCount":101},[4617],{"nctId":4618,"briefTitle":4619,"status":219,"phases":4620,"primaryCompletion":4621,"completion":4621,"start":2406,"enrollment":171,"conditions":4622,"interventions":4624},"NCT00706810","Combination of Hydroxyurea and Verapamil for Refractory Meningiomas",[90],"2015-09",[15,3642,4623],"Meningioma",[4609,4625],"Verapamil",{"trials":4627,"activeCount":101},[],{"trials":4629,"activeCount":101},[],{"trials":4631,"activeCount":101},[],{"intervention":4625,"totalTrials":97,"cells":4633},{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4635,"activeCount":101},[],{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[4640],{"nctId":4618,"briefTitle":4619,"status":219,"phases":4641,"primaryCompletion":4621,"completion":4621,"start":2406,"enrollment":171,"conditions":4642,"interventions":4643},[90],[15,3642,4623],[4609,4625],{"trials":4645,"activeCount":101},[],{"trials":4647,"activeCount":101},[],{"trials":4649,"activeCount":101},[],{"intervention":4651,"totalTrials":97,"cells":4652},"omalizumab",{"EARLY_PHASE1":4653,"PHASE1":4655,"PHASE2":4657,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4654,"activeCount":101},[],{"trials":4656,"activeCount":101},[],{"trials":4658,"activeCount":101},[4659],{"nctId":4660,"briefTitle":4661,"status":219,"phases":4662,"primaryCompletion":4663,"completion":4663,"start":3194,"enrollment":361,"conditions":4664,"interventions":4666},"NCT00123630","A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab",[90],"2010-01",[4665],"Esophagitis",[4651],{"trials":4668,"activeCount":101},[],{"trials":4670,"activeCount":101},[],{"trials":4672,"activeCount":101},[],{"intervention":4674,"totalTrials":97,"cells":4675},"18F-Flutemetamol",{"EARLY_PHASE1":4676,"PHASE1":4678,"PHASE2":4680,"PHASE3":4692,"PHASE4":4694,"NA":4696},{"trials":4677,"activeCount":101},[],{"trials":4679,"activeCount":101},[],{"trials":4681,"activeCount":101},[4682],{"nctId":4683,"briefTitle":4684,"status":219,"phases":4685,"primaryCompletion":4686,"completion":4687,"start":4688,"enrollment":1313,"conditions":4689,"interventions":4691},"NCT01202994","Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET",[90],"2016-05","2020-10-14","2011-05",[4690],"Alzheimer's Disease",[4674],{"trials":4693,"activeCount":101},[],{"trials":4695,"activeCount":101},[],{"trials":4697,"activeCount":101},[],{"intervention":4699,"totalTrials":97,"cells":4700},"Darbepoetin alfa",{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4705,"PHASE3":4714,"PHASE4":4716,"NA":4718},{"trials":4702,"activeCount":101},[],{"trials":4704,"activeCount":101},[],{"trials":4706,"activeCount":101},[4707],{"nctId":4708,"briefTitle":4709,"status":219,"phases":4710,"primaryCompletion":1903,"completion":1903,"start":2577,"enrollment":361,"conditions":4711,"interventions":4713},"NCT01471015","Darbe Administration in Newborns Undergoing Cooling for Encephalopathy",[89,90],[4712],"Hypoxic Ischemic Encephalopathy",[4699,4699],{"trials":4715,"activeCount":101},[],{"trials":4717,"activeCount":101},[],{"trials":4719,"activeCount":101},[],{"intervention":242,"totalTrials":97,"cells":4721},{"EARLY_PHASE1":4722,"PHASE1":4724,"PHASE2":4726,"PHASE3":4732,"PHASE4":4734,"NA":4736},{"trials":4723,"activeCount":101},[],{"trials":4725,"activeCount":101},[],{"trials":4727,"activeCount":101},[4728],{"nctId":232,"briefTitle":233,"status":193,"phases":4729,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":4730,"interventions":4731},[90],[240],[66,242],{"trials":4733,"activeCount":101},[],{"trials":4735,"activeCount":101},[],{"trials":4737,"activeCount":101},[],{"intervention":4739,"totalTrials":97,"cells":4740},"Lidocaine HCl Gel 2%",{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"trials":4746,"activeCount":101},[4747],{"nctId":4748,"briefTitle":4749,"status":205,"phases":4750,"primaryCompletion":4751,"completion":4751,"start":4752,"enrollment":101,"conditions":4753,"interventions":4755},"NCT03560349","RCT of SPG Blocks for Post-dural Headache",[90],"2019-01-01","2018-07-01",[4754],"Post-Dural Puncture Headache",[4739],{"trials":4757,"activeCount":101},[],{"trials":4759,"activeCount":101},[],{"trials":4761,"activeCount":101},[],{"intervention":3602,"totalTrials":97,"cells":4763},{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4768,"PHASE3":4774,"PHASE4":4776,"NA":4778},{"trials":4765,"activeCount":101},[],{"trials":4767,"activeCount":101},[],{"trials":4769,"activeCount":101},[4770],{"nctId":3594,"briefTitle":3595,"status":219,"phases":4771,"primaryCompletion":3124,"completion":3597,"start":3598,"enrollment":3519,"conditions":4772,"interventions":4773},[90],[3600],[227,3602],{"trials":4775,"activeCount":101},[],{"trials":4777,"activeCount":101},[],{"trials":4779,"activeCount":101},[],{"intervention":4781,"totalTrials":97,"cells":4782},"Anakinra",{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4787,"PHASE3":4797,"PHASE4":4799,"NA":4801},{"trials":4784,"activeCount":101},[],{"trials":4786,"activeCount":101},[],{"trials":4788,"activeCount":101},[4789],{"nctId":4790,"briefTitle":4791,"status":219,"phases":4792,"primaryCompletion":4793,"completion":4793,"start":4794,"enrollment":1430,"conditions":4795,"interventions":4796},"NCT02547766","Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices",[89,90],"2016-12","2015-04",[2240],[4781],{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":101},[],{"trials":4802,"activeCount":101},[],{"intervention":4804,"totalTrials":97,"cells":4805},"glycopyrronium cloths",{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4810,"PHASE3":4823,"PHASE4":4825,"NA":4827},{"trials":4807,"activeCount":101},[],{"trials":4809,"activeCount":101},[],{"trials":4811,"activeCount":101},[4812],{"nctId":4813,"briefTitle":4814,"status":219,"phases":4815,"primaryCompletion":4816,"completion":4817,"start":4818,"enrollment":2025,"conditions":4819,"interventions":4822},"NCT04924036","Qbrexza Cloths for Hyperhidrosis of Amputation Sites",[90],"2023-12-02","2023-12-03","2021-09-27",[4820,4821],"Amputation","Hyperhidrosis",[4804],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"trials":4828,"activeCount":101},[],{"intervention":2089,"totalTrials":97,"cells":4830},{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4841,"PHASE4":4843,"NA":4845},{"trials":4832,"activeCount":101},[],{"trials":4834,"activeCount":101},[],{"trials":4836,"activeCount":101},[4837],{"nctId":2081,"briefTitle":2082,"status":219,"phases":4838,"primaryCompletion":2084,"completion":2085,"start":2086,"enrollment":384,"conditions":4839,"interventions":4840},[90],[1023],[2089,2090],{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":101},[],{"trials":4846,"activeCount":101},[],{"intervention":4848,"totalTrials":97,"cells":4849},"Amrubicin",{"EARLY_PHASE1":4850,"PHASE1":4852,"PHASE2":4854,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4851,"activeCount":101},[],{"trials":4853,"activeCount":101},[],{"trials":4855,"activeCount":101},[4856],{"nctId":4857,"briefTitle":4858,"status":219,"phases":4859,"primaryCompletion":4860,"completion":4860,"start":4861,"enrollment":407,"conditions":4862,"interventions":4864},"NCT01259375","Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma",[90],"2016-02","2011-09",[4863],"Soft Tissue Sarcoma",[4848],{"trials":4866,"activeCount":101},[],{"trials":4868,"activeCount":101},[],{"trials":4870,"activeCount":101},[],{"intervention":4872,"totalTrials":97,"cells":4873},"Itacitinib",{"EARLY_PHASE1":4874,"PHASE1":4876,"PHASE2":4878,"PHASE3":4889,"PHASE4":4891,"NA":4893},{"trials":4875,"activeCount":101},[],{"trials":4877,"activeCount":101},[],{"trials":4879,"activeCount":101},[4880],{"nctId":4881,"briefTitle":4882,"status":193,"phases":4883,"primaryCompletion":639,"completion":4884,"start":4885,"enrollment":273,"conditions":4886,"interventions":4888},"NCT04446182","Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD",[90],"2023-01-30","2021-01-29",[4887],"Chronic Graft-versus-host-disease",[4872],{"trials":4890,"activeCount":101},[],{"trials":4892,"activeCount":101},[],{"trials":4894,"activeCount":101},[],{"intervention":4896,"totalTrials":97,"cells":4897},"Amniotic Fluid Eye Drops",{"EARLY_PHASE1":4898,"PHASE1":4900,"PHASE2":4902,"PHASE3":4914,"PHASE4":4916,"NA":4918},{"trials":4899,"activeCount":101},[],{"trials":4901,"activeCount":101},[],{"trials":4903,"activeCount":101},[4904],{"nctId":4905,"briefTitle":4906,"status":219,"phases":4907,"primaryCompletion":4908,"completion":4909,"start":4910,"enrollment":30,"conditions":4911,"interventions":4913},"NCT03298815","Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)",[89,90],"2022-12-16","2023-02-24","2019-12-20",[4912],"Ocular Graft Versus Host Disease",[4896],{"trials":4915,"activeCount":101},[],{"trials":4917,"activeCount":101},[],{"trials":4919,"activeCount":101},[],{"intervention":4921,"totalTrials":97,"cells":4922},"levosimendan",{"EARLY_PHASE1":4923,"PHASE1":4925,"PHASE2":4927,"PHASE3":4937,"PHASE4":4939,"NA":4941},{"trials":4924,"activeCount":101},[],{"trials":4926,"activeCount":101},[],{"trials":4928,"activeCount":101},[4929],{"nctId":4930,"briefTitle":4931,"status":219,"phases":4932,"primaryCompletion":4933,"completion":4933,"start":4934,"enrollment":1430,"conditions":4935,"interventions":4936},"NCT00585104","Myocardial Hemodynamic Effects of Levosimendan",[90],"2008-12","2006-09",[2240],[4921],{"trials":4938,"activeCount":101},[],{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[],{"intervention":4944,"totalTrials":97,"cells":4945},"Amitriptyline",{"EARLY_PHASE1":4946,"PHASE1":4948,"PHASE2":4950,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4947,"activeCount":101},[],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[4952],{"nctId":4953,"briefTitle":4954,"status":193,"phases":4955,"primaryCompletion":4956,"completion":4956,"start":4957,"enrollment":378,"conditions":4958,"interventions":4961},"NCT03591458","Amitriptyline in Treating Hypoglycemia",[90],"2019-06-03","2018-08-01",[4959,4960],"Type1 Diabetes Mellitus","Hypoglycemia Unawareness",[4944],{"trials":4963,"activeCount":101},[],{"trials":4965,"activeCount":101},[],{"trials":4967,"activeCount":101},[],{"intervention":4969,"totalTrials":97,"cells":4970},"SOM230B",{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4975,"PHASE3":4983,"PHASE4":4985,"NA":4987},{"trials":4972,"activeCount":101},[],{"trials":4974,"activeCount":101},[],{"trials":4976,"activeCount":101},[4977],{"nctId":4978,"briefTitle":4979,"status":193,"phases":4980,"primaryCompletion":3148,"completion":3148,"start":4421,"enrollment":378,"conditions":4981,"interventions":4982},"NCT00813592","Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma",[90],[15],[4969],{"trials":4984,"activeCount":101},[],{"trials":4986,"activeCount":101},[],{"trials":4988,"activeCount":101},[],{"intervention":4990,"totalTrials":97,"cells":4991},"RP-3500",{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":5008,"PHASE4":5010,"NA":5012},{"trials":4993,"activeCount":101},[],{"trials":4995,"activeCount":101},[],{"trials":4997,"activeCount":101},[4998],{"nctId":4999,"briefTitle":5000,"status":193,"phases":5001,"primaryCompletion":5002,"completion":5003,"start":5004,"enrollment":282,"conditions":5005,"interventions":5006},"NCT05405309","RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed\u002FRefractory Chronic Lymphocytic Leukemia",[89,90],"2023-10-24","2025-01-10","2022-09-23",[716],[4990,5007],"Olaparib",{"trials":5009,"activeCount":101},[],{"trials":5011,"activeCount":101},[],{"trials":5013,"activeCount":101},[],{"intervention":5007,"totalTrials":97,"cells":5015},{"EARLY_PHASE1":5016,"PHASE1":5018,"PHASE2":5020,"PHASE3":5026,"PHASE4":5028,"NA":5030},{"trials":5017,"activeCount":101},[],{"trials":5019,"activeCount":101},[],{"trials":5021,"activeCount":101},[5022],{"nctId":4999,"briefTitle":5000,"status":193,"phases":5023,"primaryCompletion":5002,"completion":5003,"start":5004,"enrollment":282,"conditions":5024,"interventions":5025},[89,90],[716],[4990,5007],{"trials":5027,"activeCount":101},[],{"trials":5029,"activeCount":101},[],{"trials":5031,"activeCount":101},[],{"intervention":4265,"totalTrials":97,"cells":5033},{"EARLY_PHASE1":5034,"PHASE1":5036,"PHASE2":5038,"PHASE3":5044,"PHASE4":5046,"NA":5048},{"trials":5035,"activeCount":101},[],{"trials":5037,"activeCount":101},[],{"trials":5039,"activeCount":101},[5040],{"nctId":4256,"briefTitle":4257,"status":219,"phases":5041,"primaryCompletion":4259,"completion":4260,"start":4261,"enrollment":1430,"conditions":5042,"interventions":5043},[90],[4263],[4265,4247],{"trials":5045,"activeCount":101},[],{"trials":5047,"activeCount":101},[],{"trials":5049,"activeCount":101},[],{"intervention":5051,"totalTrials":97,"cells":5052},"Rucaparib",{"EARLY_PHASE1":5053,"PHASE1":5055,"PHASE2":5057,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5054,"activeCount":101},[],{"trials":5056,"activeCount":101},[],{"trials":5058,"activeCount":101},[5059],{"nctId":5060,"briefTitle":5061,"status":193,"phases":5062,"primaryCompletion":5063,"completion":5063,"start":5064,"enrollment":238,"conditions":5065,"interventions":5066},"NCT03533946","Rucaparib in Nonmetastatic prOstAte With BRCAness",[90],"2023-01-12","2019-05-20",[4359],[5051],{"trials":5068,"activeCount":101},[],{"trials":5070,"activeCount":101},[],{"trials":5072,"activeCount":101},[],{"intervention":5074,"totalTrials":97,"cells":5075},"32ppm Silver Particle",{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5080,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[5082],{"nctId":5083,"briefTitle":5084,"status":219,"phases":5085,"primaryCompletion":5086,"completion":5086,"start":2405,"enrollment":1393,"conditions":5087,"interventions":5089},"NCT01405794","In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm",[89,90],"2011-11",[5088],"Healthy",[5074],{"trials":5091,"activeCount":101},[],{"trials":5093,"activeCount":101},[],{"trials":5095,"activeCount":101},[],{"intervention":5097,"totalTrials":97,"cells":5098},"Eltrombopag",{"EARLY_PHASE1":5099,"PHASE1":5101,"PHASE2":5103,"PHASE3":5116,"PHASE4":5118,"NA":5120},{"trials":5100,"activeCount":101},[],{"trials":5102,"activeCount":101},[],{"trials":5104,"activeCount":101},[5105],{"nctId":5106,"briefTitle":5107,"status":219,"phases":5108,"primaryCompletion":5109,"completion":5109,"start":5110,"enrollment":2025,"conditions":5111,"interventions":5115},"NCT01703169","Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia",[90],"2016-06","2012-11",[5112,5113,5114],"Severe Aplastic Anemia","Very Severe Aplastic Anemia","Moderate Aplastic Anemia",[5097],{"trials":5117,"activeCount":101},[],{"trials":5119,"activeCount":101},[],{"trials":5121,"activeCount":101},[],{"intervention":5123,"totalTrials":97,"cells":5124},"RAPAMYCIN",{"EARLY_PHASE1":5125,"PHASE1":5127,"PHASE2":5129,"PHASE3":5140,"PHASE4":5142,"NA":5144},{"trials":5126,"activeCount":101},[],{"trials":5128,"activeCount":101},[],{"trials":5130,"activeCount":101},[5131],{"nctId":5132,"briefTitle":5133,"status":219,"phases":5134,"primaryCompletion":5135,"completion":5135,"start":5136,"enrollment":5137,"conditions":5138,"interventions":5139},"NCT00795886","Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)",[90],"2010-03","2005-08",63,[1432],[5123],{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":101},[],{"trials":5145,"activeCount":101},[],{"intervention":5147,"totalTrials":97,"cells":5148},"Sodium phenylbutyrate",{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5161,"PHASE4":5163,"NA":5165},{"trials":5150,"activeCount":101},[],{"trials":5152,"activeCount":101},[],{"trials":5154,"activeCount":101},[5155],{"nctId":5156,"briefTitle":5157,"status":219,"phases":5158,"primaryCompletion":2653,"completion":2653,"start":3880,"enrollment":554,"conditions":5159,"interventions":5160},"NCT00528268","Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy",[89,90],[3865],[5147],{"trials":5162,"activeCount":101},[],{"trials":5164,"activeCount":101},[],{"trials":5166,"activeCount":101},[],{"intervention":5168,"totalTrials":97,"cells":5169},"Tamoxifen",{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5183,"PHASE4":5185,"NA":5187},{"trials":5171,"activeCount":101},[],{"trials":5173,"activeCount":101},[],{"trials":5175,"activeCount":101},[5176],{"nctId":5177,"briefTitle":5178,"status":219,"phases":5179,"primaryCompletion":2812,"completion":2812,"start":2480,"enrollment":4457,"conditions":5180,"interventions":5182},"NCT01614210","Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance",[90],[5181],"Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer",[5168],{"trials":5184,"activeCount":101},[],{"trials":5186,"activeCount":101},[],{"trials":5188,"activeCount":101},[],{"intervention":3783,"totalTrials":97,"cells":5190},{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5195,"PHASE3":5201,"PHASE4":5203,"NA":5205},{"trials":5192,"activeCount":101},[],{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[5197],{"nctId":3774,"briefTitle":3775,"status":219,"phases":5198,"primaryCompletion":3777,"completion":3778,"start":3779,"enrollment":554,"conditions":5199,"interventions":5200},[89,90],[3781],[201,3783],{"trials":5202,"activeCount":101},[],{"trials":5204,"activeCount":101},[],{"trials":5206,"activeCount":101},[],{"intervention":5208,"totalTrials":97,"cells":5209},"Velcade",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5211,"activeCount":101},[],{"trials":5213,"activeCount":101},[],{"trials":5215,"activeCount":101},[5216],{"nctId":5217,"briefTitle":5218,"status":193,"phases":5219,"primaryCompletion":4794,"completion":5220,"start":5221,"enrollment":171,"conditions":5222,"interventions":5223},"NCT01720043","Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients",[90],"2017-07","2013-07",[565],[5208],{"trials":5225,"activeCount":101},[],{"trials":5227,"activeCount":101},[],{"trials":5229,"activeCount":101},[],{"intervention":4361,"totalTrials":97,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5242,"PHASE4":5244,"NA":5246},{"trials":5233,"activeCount":101},[],{"trials":5235,"activeCount":101},[],{"trials":5237,"activeCount":101},[5238],{"nctId":4351,"briefTitle":4352,"status":219,"phases":5239,"primaryCompletion":4354,"completion":4355,"start":4356,"enrollment":4357,"conditions":5240,"interventions":5241},[90],[4359],[4342,4361],{"trials":5243,"activeCount":101},[],{"trials":5245,"activeCount":101},[],{"trials":5247,"activeCount":101},[],{"intervention":5249,"totalTrials":97,"cells":5250},"Regadenoson MRI",{"EARLY_PHASE1":5251,"PHASE1":5253,"PHASE2":5255,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5252,"activeCount":101},[],{"trials":5254,"activeCount":101},[],{"trials":5256,"activeCount":101},[5257],{"nctId":5258,"briefTitle":5259,"status":219,"phases":5260,"primaryCompletion":5261,"completion":5261,"start":5262,"enrollment":361,"conditions":5263,"interventions":5265},"NCT01710254","Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients",[90],"2016-10","2013-01",[2656,5264],"Coronary Artery Disease",[5249,5266],"Gadobenate dimeglumine",{"trials":5268,"activeCount":101},[],{"trials":5270,"activeCount":101},[],{"trials":5272,"activeCount":101},[],{"intervention":5266,"totalTrials":97,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5285,"PHASE4":5287,"NA":5289},{"trials":5276,"activeCount":101},[],{"trials":5278,"activeCount":101},[],{"trials":5280,"activeCount":101},[5281],{"nctId":5258,"briefTitle":5259,"status":219,"phases":5282,"primaryCompletion":5261,"completion":5261,"start":5262,"enrollment":361,"conditions":5283,"interventions":5284},[90],[2656,5264],[5249,5266],{"trials":5286,"activeCount":101},[],{"trials":5288,"activeCount":101},[],{"trials":5290,"activeCount":101},[],{"intervention":3973,"totalTrials":97,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5303,"PHASE4":5305,"NA":5307},{"trials":5294,"activeCount":101},[],{"trials":5296,"activeCount":101},[],{"trials":5298,"activeCount":101},[5299],{"nctId":3961,"briefTitle":3962,"status":219,"phases":5300,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":2508,"conditions":5301,"interventions":5302},[90],[3967,3968,3969,3970,3971],[3931,3973,3959,3974,3975],{"trials":5304,"activeCount":101},[],{"trials":5306,"activeCount":101},[],{"trials":5308,"activeCount":101},[],{"intervention":3975,"totalTrials":97,"cells":5310},{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5321,"PHASE4":5323,"NA":5325},{"trials":5312,"activeCount":101},[],{"trials":5314,"activeCount":101},[],{"trials":5316,"activeCount":101},[5317],{"nctId":3961,"briefTitle":3962,"status":219,"phases":5318,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":2508,"conditions":5319,"interventions":5320},[90],[3967,3968,3969,3970,3971],[3931,3973,3959,3974,3975],{"trials":5322,"activeCount":101},[],{"trials":5324,"activeCount":101},[],{"trials":5326,"activeCount":101},[],{"intervention":5328,"totalTrials":97,"cells":5329},"Fluorouracil",{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5344,"PHASE4":5346,"NA":5348},{"trials":5331,"activeCount":101},[],{"trials":5333,"activeCount":101},[],{"trials":5335,"activeCount":101},[5336],{"nctId":5337,"briefTitle":5338,"status":193,"phases":5339,"primaryCompletion":2813,"completion":2813,"start":5340,"enrollment":97,"conditions":5341,"interventions":5342},"NCT00983541","Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy\u002FStereotactic Radiation Boost in Locally Advanced Intra\u002FExtrahepatic Cholangiocarcinoma",[90],"2009-09",[15],[5328,5343],"Gemcitabine",{"trials":5345,"activeCount":101},[],{"trials":5347,"activeCount":101},[],{"trials":5349,"activeCount":101},[],{"intervention":5343,"totalTrials":97,"cells":5351},{"EARLY_PHASE1":5352,"PHASE1":5354,"PHASE2":5356,"PHASE3":5362,"PHASE4":5364,"NA":5366},{"trials":5353,"activeCount":101},[],{"trials":5355,"activeCount":101},[],{"trials":5357,"activeCount":101},[5358],{"nctId":5337,"briefTitle":5338,"status":193,"phases":5359,"primaryCompletion":2813,"completion":2813,"start":5340,"enrollment":97,"conditions":5360,"interventions":5361},[90],[15],[5328,5343],{"trials":5363,"activeCount":101},[],{"trials":5365,"activeCount":101},[],{"trials":5367,"activeCount":101},[],{"intervention":5369,"totalTrials":97,"cells":5370},"growth hormone",{"EARLY_PHASE1":5371,"PHASE1":5373,"PHASE2":5375,"PHASE3":5386,"PHASE4":5388,"NA":5390},{"trials":5372,"activeCount":101},[],{"trials":5374,"activeCount":101},[],{"trials":5376,"activeCount":101},[5377],{"nctId":5378,"briefTitle":5379,"status":219,"phases":5380,"primaryCompletion":5381,"start":5382,"enrollment":9,"conditions":5383,"interventions":5385},"NCT00016445","Phase II Study of Growth Hormone in Children With Cystic Fibrosis",[90],"2007-08","2001-02",[5384],"Cystic Fibrosis",[5369],{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"intervention":5393,"totalTrials":97,"cells":5394},"10ppm Oral Silver Particle",{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5399,"PHASE3":5408,"PHASE4":5410,"NA":5412},{"trials":5396,"activeCount":101},[],{"trials":5398,"activeCount":101},[],{"trials":5400,"activeCount":101},[5401],{"nctId":5402,"briefTitle":5403,"status":219,"phases":5404,"primaryCompletion":2405,"completion":2405,"start":3288,"enrollment":3053,"conditions":5405,"interventions":5406},"NCT01243320","In Vivo Assessment of Silver Biomaterial Nano-Toxicity",[89,90],[5088],[5393,5407],"32ppm Oral Silver Particle",{"trials":5409,"activeCount":101},[],{"trials":5411,"activeCount":101},[],{"trials":5413,"activeCount":101},[],{"intervention":5407,"totalTrials":97,"cells":5415},{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5420,"PHASE3":5426,"PHASE4":5428,"NA":5430},{"trials":5417,"activeCount":101},[],{"trials":5419,"activeCount":101},[],{"trials":5421,"activeCount":101},[5422],{"nctId":5402,"briefTitle":5403,"status":219,"phases":5423,"primaryCompletion":2405,"completion":2405,"start":3288,"enrollment":3053,"conditions":5424,"interventions":5425},[89,90],[5088],[5393,5407],{"trials":5427,"activeCount":101},[],{"trials":5429,"activeCount":101},[],{"trials":5431,"activeCount":101},[],{"intervention":5433,"totalTrials":97,"cells":5434},"Liquid Lidocaine",{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5439,"PHASE3":5451,"PHASE4":5453,"NA":5455},{"trials":5436,"activeCount":101},[],{"trials":5438,"activeCount":101},[],{"trials":5440,"activeCount":101},[5441],{"nctId":5442,"briefTitle":5443,"status":205,"phases":5444,"primaryCompletion":5445,"completion":5446,"start":5447,"enrollment":101,"conditions":5448,"interventions":5450},"NCT05365880","Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache",[90],"2025-03-22","2025-06-01","2022-03-23",[5449,34,1905],"Headache",[5433],{"trials":5452,"activeCount":101},[],{"trials":5454,"activeCount":101},[],{"trials":5456,"activeCount":101},[],{"intervention":5458,"totalTrials":97,"cells":5459},"5-Azacitidine",{"EARLY_PHASE1":5460,"PHASE1":5462,"PHASE2":5464,"PHASE3":5474,"PHASE4":5476,"NA":5478},{"trials":5461,"activeCount":101},[],{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[5466],{"nctId":5467,"briefTitle":5468,"status":219,"phases":5469,"primaryCompletion":561,"completion":561,"start":5470,"enrollment":3015,"conditions":5471,"interventions":5473},"NCT01350947","A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia",[90],"2011-04",[5472],"Chronic Myelomonocytic Leukemia",[5458],{"trials":5475,"activeCount":101},[],{"trials":5477,"activeCount":101},[],{"trials":5479,"activeCount":101},[],{"intervention":5481,"totalTrials":97,"cells":5482},"Azacitidine",{"EARLY_PHASE1":5483,"PHASE1":5485,"PHASE2":5487,"PHASE3":5499,"PHASE4":5501,"NA":5503},{"trials":5484,"activeCount":101},[],{"trials":5486,"activeCount":101},[],{"trials":5488,"activeCount":101},[5489],{"nctId":5490,"briefTitle":5491,"status":219,"phases":5492,"primaryCompletion":5493,"completion":5493,"start":2009,"enrollment":361,"conditions":5494,"interventions":5497},"NCT00748553","A Phase I\u002FII Clinical Trial of Vidaza With Abraxane in Patients With Advanced\u002FMetastatic Solid Tumors and Breast Cancer",[89,90],"2015-10",[5495,5496],"Advanced or Metastatic Solid Tumors","Advanced or Metastatic Breast Cancer",[5481,5498],"Nab-paclitaxel",{"trials":5500,"activeCount":101},[],{"trials":5502,"activeCount":101},[],{"trials":5504,"activeCount":101},[],{"intervention":5498,"totalTrials":97,"cells":5506},{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5511,"PHASE3":5517,"PHASE4":5519,"NA":5521},{"trials":5508,"activeCount":101},[],{"trials":5510,"activeCount":101},[],{"trials":5512,"activeCount":101},[5513],{"nctId":5490,"briefTitle":5491,"status":219,"phases":5514,"primaryCompletion":5493,"completion":5493,"start":2009,"enrollment":361,"conditions":5515,"interventions":5516},[89,90],[5495,5496],[5481,5498],{"trials":5518,"activeCount":101},[],{"trials":5520,"activeCount":101},[],{"trials":5522,"activeCount":101},[],{"intervention":5524,"totalTrials":97,"cells":5525},"Cetuximab",{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5530,"PHASE3":5540,"PHASE4":5542,"NA":5544},{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":101},[],{"trials":5531,"activeCount":101},[5532],{"nctId":5533,"briefTitle":5534,"status":193,"phases":5535,"primaryCompletion":1429,"completion":5536,"start":5537,"enrollment":238,"conditions":5538,"interventions":5539},"NCT04853043","Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer",[90],"2024-05-03","2021-11-03",[3266],[5524],{"trials":5541,"activeCount":101},[],{"trials":5543,"activeCount":101},[],{"trials":5545,"activeCount":101},[],{"intervention":5547,"totalTrials":97,"cells":5548},"Fixed dose",{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5553,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5550,"activeCount":101},[],{"trials":5552,"activeCount":101},[],{"trials":5554,"activeCount":101},[5555],{"nctId":5556,"briefTitle":5557,"status":219,"phases":5558,"primaryCompletion":5559,"completion":5560,"start":5561,"enrollment":5562,"conditions":5563,"interventions":5566},"NCT03212365","Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery",[90],"2019-06-02","2019-10-01","2017-07-03",295,[2357,2359,5564,5565],"Pulmonary Embolus","Reconstructive Surgery",[5547,5567],"Variable dose",{"trials":5569,"activeCount":101},[],{"trials":5571,"activeCount":101},[],{"trials":5573,"activeCount":101},[],{"intervention":5567,"totalTrials":97,"cells":5575},{"EARLY_PHASE1":5576,"PHASE1":5578,"PHASE2":5580,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5577,"activeCount":101},[],{"trials":5579,"activeCount":101},[],{"trials":5581,"activeCount":101},[5582],{"nctId":5556,"briefTitle":5557,"status":219,"phases":5583,"primaryCompletion":5559,"completion":5560,"start":5561,"enrollment":5562,"conditions":5584,"interventions":5585},[90],[2357,2359,5564,5565],[5547,5567],{"trials":5587,"activeCount":101},[],{"trials":5589,"activeCount":101},[],{"trials":5591,"activeCount":101},[],{"intervention":5593,"totalTrials":97,"cells":5594},"Amniotic Fluid Allograft",{"EARLY_PHASE1":5595,"PHASE1":5597,"PHASE2":5599,"PHASE3":5611,"PHASE4":5613,"NA":5615},{"trials":5596,"activeCount":101},[],{"trials":5598,"activeCount":101},[],{"trials":5600,"activeCount":101},[5601],{"nctId":5602,"briefTitle":5603,"status":219,"phases":5604,"primaryCompletion":5605,"completion":5605,"start":5606,"enrollment":1270,"conditions":5607,"interventions":5609},"NCT04537026","Sterile Amniotic Fluid Filtrate Epidural Injection.",[89,90],"2025-07-01","2021-06-16",[5608],"Lumbar Spinal Stenosis",[5593,5610],"Dexamethasone sodium phosphate",{"trials":5612,"activeCount":101},[],{"trials":5614,"activeCount":101},[],{"trials":5616,"activeCount":101},[],{"intervention":5610,"totalTrials":97,"cells":5618},{"EARLY_PHASE1":5619,"PHASE1":5621,"PHASE2":5623,"PHASE3":5629,"PHASE4":5631,"NA":5633},{"trials":5620,"activeCount":101},[],{"trials":5622,"activeCount":101},[],{"trials":5624,"activeCount":101},[5625],{"nctId":5602,"briefTitle":5603,"status":219,"phases":5626,"primaryCompletion":5605,"completion":5605,"start":5606,"enrollment":1270,"conditions":5627,"interventions":5628},[89,90],[5608],[5593,5610],{"trials":5630,"activeCount":101},[],{"trials":5632,"activeCount":101},[],{"trials":5634,"activeCount":101},[],{"intervention":5636,"totalTrials":97,"cells":5637},"Selinexor",{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":101},[5644],{"nctId":5645,"briefTitle":5646,"status":193,"phases":5647,"primaryCompletion":5648,"completion":5649,"start":5650,"enrollment":27,"conditions":5651,"interventions":5654},"NCT03627403","Selinexor in Myelofibrosis Refractory or Intolerant to JAK1\u002F2 Inhibitors",[90],"2023-08-16","2025-03-05","2019-05-10",[3953,5652,5653],"Post-essential Thrombocythemia Myelofibrosis","Post-polycythemia Vera Myelofibrosis",[5636],{"trials":5656,"activeCount":101},[],{"trials":5658,"activeCount":101},[],{"trials":5660,"activeCount":101},[],{"intervention":5662,"totalTrials":97,"cells":5663},"Clofarabine",{"EARLY_PHASE1":5664,"PHASE1":5666,"PHASE2":5668,"PHASE3":5678,"PHASE4":5680,"NA":5682},{"trials":5665,"activeCount":101},[],{"trials":5667,"activeCount":101},[],{"trials":5669,"activeCount":101},[5670],{"nctId":5671,"briefTitle":5672,"status":193,"phases":5673,"primaryCompletion":5674,"completion":5674,"start":5675,"enrollment":3015,"conditions":5676,"interventions":5677},"NCT00708721","Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia",[89,90],"2014-11","2008-03",[15,5472],[5662],{"trials":5679,"activeCount":101},[],{"trials":5681,"activeCount":101},[],{"trials":5683,"activeCount":101},[],{"intervention":5685,"totalTrials":97,"cells":5686},"MVA-BN-Brachyury",{"EARLY_PHASE1":5687,"PHASE1":5689,"PHASE2":5691,"PHASE3":5702,"PHASE4":5704,"NA":5706},{"trials":5688,"activeCount":101},[],{"trials":5690,"activeCount":101},[],{"trials":5692,"activeCount":101},[5693],{"nctId":5694,"briefTitle":5695,"status":205,"phases":5696,"primaryCompletion":5697,"completion":5697,"start":5698,"enrollment":101,"conditions":5699,"interventions":5701},"NCT04020094","Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer",[90],"2021-04-09","2019-11-20",[5700],"Prostate Adenocarcinoma",[5685],{"trials":5703,"activeCount":101},[],{"trials":5705,"activeCount":101},[],{"trials":5707,"activeCount":101},[],{"intervention":5709,"totalTrials":97,"cells":5710},"Bevacizumab and Erlotinib",{"EARLY_PHASE1":5711,"PHASE1":5713,"PHASE2":5715,"PHASE3":5724,"PHASE4":5726,"NA":5728},{"trials":5712,"activeCount":101},[],{"trials":5714,"activeCount":101},[],{"trials":5716,"activeCount":101},[5717],{"nctId":5718,"briefTitle":5719,"status":219,"phases":5720,"primaryCompletion":5721,"completion":5721,"start":5381,"enrollment":293,"conditions":5722,"interventions":5723},"NCT00585377","Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB\u002FIV or Recurrent, Non-squamous Cell Lung Cancer",[90],"2013-05",[15],[5709],{"trials":5725,"activeCount":101},[],{"trials":5727,"activeCount":101},[],{"trials":5729,"activeCount":101},[],{"intervention":5731,"totalTrials":97,"cells":5732},"N-acetylcysteine",{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5737,"PHASE3":5746,"PHASE4":5748,"NA":5750},{"trials":5734,"activeCount":101},[],{"trials":5736,"activeCount":101},[],{"trials":5738,"activeCount":101},[5739],{"nctId":5740,"briefTitle":5741,"status":219,"phases":5742,"primaryCompletion":4860,"completion":4860,"start":2577,"enrollment":1962,"conditions":5743,"interventions":5745},"NCT01612221","Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress\u002FDamage in Vivo",[90],[5744],"Patients at Risk for Melanoma",[5731],{"trials":5747,"activeCount":101},[],{"trials":5749,"activeCount":101},[],{"trials":5751,"activeCount":101},[],{"intervention":5753,"totalTrials":97,"cells":5754},"Fluciclitite , PET imaging, and Bevacizumab",{"EARLY_PHASE1":5755,"PHASE1":5757,"PHASE2":5759,"PHASE3":5770,"PHASE4":5772,"NA":5774},{"trials":5756,"activeCount":101},[],{"trials":5758,"activeCount":101},[],{"trials":5760,"activeCount":101},[5761],{"nctId":5762,"briefTitle":5763,"status":205,"phases":5764,"primaryCompletion":5765,"completion":5765,"start":5766,"enrollment":101,"conditions":5767,"interventions":5769},"NCT01788280","Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab",[90],"2022-01","2018-01",[5768],"Glioblastoma Multiforme (GBM)",[5753],{"trials":5771,"activeCount":101},[],{"trials":5773,"activeCount":101},[],{"trials":5775,"activeCount":101},[],{"intervention":3791,"totalTrials":97,"cells":5777},{"EARLY_PHASE1":5778,"PHASE1":5780,"PHASE2":5782,"PHASE3":5788,"PHASE4":5790,"NA":5792},{"trials":5779,"activeCount":101},[],{"trials":5781,"activeCount":101},[],{"trials":5783,"activeCount":101},[5784],{"nctId":3785,"briefTitle":3786,"status":219,"phases":5785,"primaryCompletion":3788,"completion":3788,"start":2720,"enrollment":2508,"conditions":5786,"interventions":5787},[89,90],[3266],[3791,3792,201],{"trials":5789,"activeCount":101},[],{"trials":5791,"activeCount":101},[],{"trials":5793,"activeCount":101},[],{"intervention":3792,"totalTrials":97,"cells":5795},{"EARLY_PHASE1":5796,"PHASE1":5798,"PHASE2":5800,"PHASE3":5806,"PHASE4":5808,"NA":5810},{"trials":5797,"activeCount":101},[],{"trials":5799,"activeCount":101},[],{"trials":5801,"activeCount":101},[5802],{"nctId":3785,"briefTitle":3786,"status":219,"phases":5803,"primaryCompletion":3788,"completion":3788,"start":2720,"enrollment":2508,"conditions":5804,"interventions":5805},[89,90],[3266],[3791,3792,201],{"trials":5807,"activeCount":101},[],{"trials":5809,"activeCount":101},[],{"trials":5811,"activeCount":101},[],{"intervention":4434,"totalTrials":97,"cells":5813},{"EARLY_PHASE1":5814,"PHASE1":5816,"PHASE2":5818,"PHASE3":5824,"PHASE4":5826,"NA":5828},{"trials":5815,"activeCount":101},[],{"trials":5817,"activeCount":101},[],{"trials":5819,"activeCount":101},[5820],{"nctId":4426,"briefTitle":4427,"status":193,"phases":5821,"primaryCompletion":2480,"completion":2480,"start":4429,"enrollment":3672,"conditions":5822,"interventions":5823},[89,90],[15,4431,4331,4432],[4434,4409],{"trials":5825,"activeCount":101},[],{"trials":5827,"activeCount":101},[],{"trials":5829,"activeCount":101},[],{"intervention":5831,"totalTrials":97,"cells":5832},"Non-narcotic pain control",{"EARLY_PHASE1":5833,"PHASE1":5835,"PHASE2":5837,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5834,"activeCount":101},[],{"trials":5836,"activeCount":101},[],{"trials":5838,"activeCount":101},[5839],{"nctId":5840,"briefTitle":5841,"status":205,"phases":5842,"primaryCompletion":5843,"completion":5843,"start":5844,"enrollment":101,"conditions":5845,"interventions":5847},"NCT03528343","Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy",[89,90],"2017-12-01","2017-09-05",[5846,1754],"Appendicitis",[5831],{"trials":5849,"activeCount":101},[],{"trials":5851,"activeCount":101},[],{"trials":5853,"activeCount":101},[],{"intervention":4274,"totalTrials":97,"cells":5855},{"EARLY_PHASE1":5856,"PHASE1":5858,"PHASE2":5860,"PHASE3":5866,"PHASE4":5868,"NA":5870},{"trials":5857,"activeCount":101},[],{"trials":5859,"activeCount":101},[],{"trials":5861,"activeCount":101},[5862],{"nctId":4267,"briefTitle":4268,"status":219,"phases":5863,"primaryCompletion":4270,"completion":4270,"start":4271,"enrollment":9,"conditions":5864,"interventions":5865},[90],[4263],[4274,4247],{"trials":5867,"activeCount":101},[],{"trials":5869,"activeCount":101},[],{"trials":5871,"activeCount":101},[],{"intervention":5873,"totalTrials":97,"cells":5874},"Fixed Dose Enoxaparin",{"EARLY_PHASE1":5875,"PHASE1":5877,"PHASE2":5879,"PHASE3":5891,"PHASE4":5893,"NA":5895},{"trials":5876,"activeCount":101},[],{"trials":5878,"activeCount":101},[],{"trials":5880,"activeCount":101},[5881],{"nctId":5882,"briefTitle":5883,"status":219,"phases":5884,"primaryCompletion":5885,"completion":5886,"start":2678,"enrollment":2909,"conditions":5887,"interventions":5889},"NCT03251963","Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients",[90],"2019-03-27","2019-07-27",[2357,2359,5888],"Surgery",[5873,5890],"Variable Dose Enoxaparin",{"trials":5892,"activeCount":101},[],{"trials":5894,"activeCount":101},[],{"trials":5896,"activeCount":101},[],{"intervention":5890,"totalTrials":97,"cells":5898},{"EARLY_PHASE1":5899,"PHASE1":5901,"PHASE2":5903,"PHASE3":5909,"PHASE4":5911,"NA":5913},{"trials":5900,"activeCount":101},[],{"trials":5902,"activeCount":101},[],{"trials":5904,"activeCount":101},[5905],{"nctId":5882,"briefTitle":5883,"status":219,"phases":5906,"primaryCompletion":5885,"completion":5886,"start":2678,"enrollment":2909,"conditions":5907,"interventions":5908},[90],[2357,2359,5888],[5873,5890],{"trials":5910,"activeCount":101},[],{"trials":5912,"activeCount":101},[],{"trials":5914,"activeCount":101},[],{"intervention":5916,"totalTrials":97,"cells":5917},"Sodium Oxybate",{"EARLY_PHASE1":5918,"PHASE1":5920,"PHASE2":5922,"PHASE3":5933,"PHASE4":5935,"NA":5937},{"trials":5919,"activeCount":101},[],{"trials":5921,"activeCount":101},[],{"trials":5923,"activeCount":101},[5924],{"nctId":5925,"briefTitle":5926,"status":219,"phases":5927,"primaryCompletion":5928,"completion":4861,"start":5929,"enrollment":3917,"conditions":5930,"interventions":5932},"NCT00931164","Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)",[89,90],"2011-01","2009-08",[5931],"Alternating Hemiplegia of Childhood",[5916],{"trials":5934,"activeCount":101},[],{"trials":5936,"activeCount":101},[],{"trials":5938,"activeCount":101},[],{"intervention":5940,"totalTrials":97,"cells":5941},"BKM120",{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5946,"PHASE3":5955,"PHASE4":5957,"NA":5959},{"trials":5943,"activeCount":101},[],{"trials":5945,"activeCount":101},[],{"trials":5947,"activeCount":101},[5948],{"nctId":5949,"briefTitle":5950,"status":205,"phases":5951,"primaryCompletion":3597,"completion":3597,"start":4322,"enrollment":101,"conditions":5952,"interventions":5954},"NCT01550380","BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers",[90],[5953],"Endometrial Cancer",[5940],{"trials":5956,"activeCount":101},[],{"trials":5958,"activeCount":101},[],{"trials":5960,"activeCount":101},[],{"intervention":5962,"totalTrials":97,"cells":5963},"Pimecrolimus 1% cream",{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5977,"PHASE4":5979,"NA":5981},{"trials":5965,"activeCount":101},[],{"trials":5967,"activeCount":101},[],{"trials":5969,"activeCount":101},[5970],{"nctId":5971,"briefTitle":5972,"status":219,"phases":5973,"primaryCompletion":4398,"completion":4398,"start":5136,"enrollment":2407,"conditions":5974,"interventions":5976},"NCT00297037","Pimecrolimus Cream for Oral Lichen Planus",[90],[5975],"Oral Lichen Planus",[5962],{"trials":5978,"activeCount":101},[],{"trials":5980,"activeCount":101},[],{"trials":5982,"activeCount":101},[],{"intervention":5984,"totalTrials":97,"cells":5985},"Peginterferon-alpha 2b (PegIFNa2b);",{"EARLY_PHASE1":5986,"PHASE1":5988,"PHASE2":5990,"PHASE3":6002,"PHASE4":6004,"NA":6006},{"trials":5987,"activeCount":101},[],{"trials":5989,"activeCount":101},[],{"trials":5991,"activeCount":101},[5992],{"nctId":5993,"briefTitle":5994,"status":193,"phases":5995,"primaryCompletion":3964,"completion":3964,"start":3880,"enrollment":171,"conditions":5996,"interventions":6000},"NCT00585221","Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients",[90],[5997,5998,5999],"Gastrointestinal Stromal Tumors","Cancer Brain","Solid Tumors",[5984,6001],"Imatinib",{"trials":6003,"activeCount":101},[],{"trials":6005,"activeCount":101},[],{"trials":6007,"activeCount":101},[],{"intervention":6001,"totalTrials":97,"cells":6009},{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6014,"PHASE3":6020,"PHASE4":6022,"NA":6024},{"trials":6011,"activeCount":101},[],{"trials":6013,"activeCount":101},[],{"trials":6015,"activeCount":101},[6016],{"nctId":5993,"briefTitle":5994,"status":193,"phases":6017,"primaryCompletion":3964,"completion":3964,"start":3880,"enrollment":171,"conditions":6018,"interventions":6019},[90],[5997,5998,5999],[5984,6001],{"trials":6021,"activeCount":101},[],{"trials":6023,"activeCount":101},[],{"trials":6025,"activeCount":101},[],{"intervention":6027,"totalTrials":97,"cells":6028},"Midazolam",{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6033,"PHASE3":6043,"PHASE4":6045,"NA":6047},{"trials":6030,"activeCount":101},[],{"trials":6032,"activeCount":101},[],{"trials":6034,"activeCount":101},[6035],{"nctId":6036,"briefTitle":6037,"status":219,"phases":6038,"primaryCompletion":4933,"completion":4933,"start":3400,"enrollment":6039,"conditions":6040,"interventions":6041},"NCT00326612","Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures",[90],358,[2992],[6027,6042],"Diazepam",{"trials":6044,"activeCount":101},[],{"trials":6046,"activeCount":101},[],{"trials":6048,"activeCount":101},[],{"intervention":6042,"totalTrials":97,"cells":6050},{"EARLY_PHASE1":6051,"PHASE1":6053,"PHASE2":6055,"PHASE3":6061,"PHASE4":6063,"NA":6065},{"trials":6052,"activeCount":101},[],{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[6057],{"nctId":6036,"briefTitle":6037,"status":219,"phases":6058,"primaryCompletion":4933,"completion":4933,"start":3400,"enrollment":6039,"conditions":6059,"interventions":6060},[90],[2992],[6027,6042],{"trials":6062,"activeCount":101},[],{"trials":6064,"activeCount":101},[],{"trials":6066,"activeCount":101},[],{"intervention":3621,"totalTrials":97,"cells":6068},{"EARLY_PHASE1":6069,"PHASE1":6071,"PHASE2":6073,"PHASE3":6079,"PHASE4":6081,"NA":6083},{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[6075],{"nctId":3612,"briefTitle":3613,"status":205,"phases":6076,"primaryCompletion":3615,"completion":3615,"start":3616,"enrollment":101,"conditions":6077,"interventions":6078},[89,90],[225,3618,3619],[3621,227],{"trials":6080,"activeCount":101},[],{"trials":6082,"activeCount":101},[],{"trials":6084,"activeCount":101},[],{"intervention":6086,"totalTrials":97,"cells":6087},"disulfiram and chelated zinc",{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6102,"PHASE4":6104,"NA":6106},{"trials":6089,"activeCount":101},[],{"trials":6091,"activeCount":101},[],{"trials":6093,"activeCount":101},[6094],{"nctId":6095,"briefTitle":6096,"status":219,"phases":6097,"primaryCompletion":6098,"completion":6099,"start":5135,"enrollment":1393,"conditions":6100,"interventions":6101},"NCT02101008","Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy",[90],"2013-02","2013-11-27",[240],[6086],{"trials":6103,"activeCount":101},[],{"trials":6105,"activeCount":101},[],{"trials":6107,"activeCount":101},[],{"intervention":6109,"totalTrials":97,"cells":6110},"Q-Urol",{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6126,"PHASE4":6128,"NA":6130},{"trials":6112,"activeCount":101},[],{"trials":6114,"activeCount":101},[],{"trials":6116,"activeCount":101},[6117],{"nctId":6118,"briefTitle":6119,"status":193,"phases":6120,"primaryCompletion":6121,"completion":6122,"start":6123,"enrollment":1430,"conditions":6124,"interventions":6125},"NCT04252625","Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis",[90],"2023-12-27","2024-01-25","2022-11-14",[5700],[6109],{"trials":6127,"activeCount":101},[],{"trials":6129,"activeCount":101},[],{"trials":6131,"activeCount":101},[],{"intervention":6133,"totalTrials":97,"cells":6134},"triamcinolone",{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6151,"PHASE4":6153,"NA":6155},{"trials":6136,"activeCount":101},[],{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[6141],{"nctId":6142,"briefTitle":6143,"status":205,"phases":6144,"primaryCompletion":6145,"completion":6145,"start":2305,"enrollment":101,"conditions":6146,"interventions":6149},"NCT00846625","Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids",[90],"2011-08",[6147,6148],"Macular Edema","Uveitis",[6133,6150],"ranibizumab",{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[],{"trials":6156,"activeCount":101},[],{"intervention":6150,"totalTrials":97,"cells":6158},{"EARLY_PHASE1":6159,"PHASE1":6161,"PHASE2":6163,"PHASE3":6169,"PHASE4":6171,"NA":6173},{"trials":6160,"activeCount":101},[],{"trials":6162,"activeCount":101},[],{"trials":6164,"activeCount":101},[6165],{"nctId":6142,"briefTitle":6143,"status":205,"phases":6166,"primaryCompletion":6145,"completion":6145,"start":2305,"enrollment":101,"conditions":6167,"interventions":6168},[90],[6147,6148],[6133,6150],{"trials":6170,"activeCount":101},[],{"trials":6172,"activeCount":101},[],{"trials":6174,"activeCount":101},[],{"intervention":6176,"totalTrials":97,"cells":6177},"Processed Amniotic Fluid",{"EARLY_PHASE1":6178,"PHASE1":6180,"PHASE2":6182,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6179,"activeCount":101},[],{"trials":6181,"activeCount":101},[],{"trials":6183,"activeCount":101},[6184],{"nctId":6185,"briefTitle":6186,"status":193,"phases":6187,"primaryCompletion":6188,"completion":6188,"start":6189,"enrollment":97,"conditions":6190,"interventions":6192},"NCT04438174","Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds",[89,90],"2023-03","2022-08",[6191],"Wounds and Injuries",[6176],{"trials":6194,"activeCount":101},[],{"trials":6196,"activeCount":101},[],{"trials":6198,"activeCount":101},[],{"intervention":6200,"totalTrials":97,"cells":6201},"Fluciclovine F18",{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6218,"PHASE4":6220,"NA":6222},{"trials":6203,"activeCount":101},[],{"trials":6205,"activeCount":101},[],{"trials":6207,"activeCount":101},[6208],{"nctId":6209,"briefTitle":6210,"status":219,"phases":6211,"primaryCompletion":6212,"completion":6212,"start":6213,"enrollment":27,"conditions":6214,"interventions":6217},"NCT03707184","Fluciclovine F18 PET\u002FCT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone",[90],"2022-02-03","2018-10-02",[6215,6216,3827],"Metastatic Prostate Carcinoma","Prostate Carcinoma Metastatic in the Bone",[6200],{"trials":6219,"activeCount":101},[],{"trials":6221,"activeCount":101},[],{"trials":6223,"activeCount":101},[],{"intervention":6225,"totalTrials":97,"cells":6226},"sufentanil",{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6240,"PHASE4":6242,"NA":6244},{"trials":6228,"activeCount":101},[],{"trials":6230,"activeCount":101},[],{"trials":6232,"activeCount":101},[6233],{"nctId":6234,"briefTitle":6235,"status":193,"phases":6236,"primaryCompletion":2304,"completion":2304,"start":2305,"enrollment":1646,"conditions":6237,"interventions":6239},"NCT01012999","A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain",[89,90],[18,6238],"Opiate",[6225],{"trials":6241,"activeCount":101},[],{"trials":6243,"activeCount":101},[],{"trials":6245,"activeCount":101},[],{"intervention":6247,"totalTrials":97,"cells":6248},"[18F]FLT",{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6253,"PHASE3":6266,"PHASE4":6268,"NA":6270},{"trials":6250,"activeCount":101},[],{"trials":6252,"activeCount":101},[],{"trials":6254,"activeCount":101},[6255],{"nctId":6256,"briefTitle":6257,"status":193,"phases":6258,"primaryCompletion":6259,"completion":6260,"start":6261,"enrollment":1430,"conditions":6262,"interventions":6264},"NCT03276676","[18F]Fluciclovine and [18F]FLT PET\u002FCT Assessment of Primary High-Grade Brain Tumors",[89,90],"2021-04-12","2023-08-18","2018-09-24",[6263],"Brain Tumor",[6247,6265],"[18F]Fluciclovine",{"trials":6267,"activeCount":101},[],{"trials":6269,"activeCount":101},[],{"trials":6271,"activeCount":101},[],{"intervention":6265,"totalTrials":97,"cells":6273},{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6278,"PHASE3":6284,"PHASE4":6286,"NA":6288},{"trials":6275,"activeCount":101},[],{"trials":6277,"activeCount":101},[],{"trials":6279,"activeCount":101},[6280],{"nctId":6256,"briefTitle":6257,"status":193,"phases":6281,"primaryCompletion":6259,"completion":6260,"start":6261,"enrollment":1430,"conditions":6282,"interventions":6283},[89,90],[6263],[6247,6265],{"trials":6285,"activeCount":101},[],{"trials":6287,"activeCount":101},[],{"trials":6289,"activeCount":101},[],{"intervention":6291,"totalTrials":97,"cells":6292},"Pazopanib",{"EARLY_PHASE1":6293,"PHASE1":6295,"PHASE2":6297,"PHASE3":6308,"PHASE4":6310,"NA":6312},{"trials":6294,"activeCount":101},[],{"trials":6296,"activeCount":101},[],{"trials":6298,"activeCount":101},[6299],{"nctId":6300,"briefTitle":6301,"status":219,"phases":6302,"primaryCompletion":6303,"completion":6304,"start":2879,"enrollment":361,"conditions":6305,"interventions":6307},"NCT01832259","A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection",[90],"2017-02-07","2018-08-09",[6306],"Adenocarcinoma of the Prostate",[6291],{"trials":6309,"activeCount":101},[],{"trials":6311,"activeCount":101},[],{"trials":6313,"activeCount":101},[],{"intervention":6315,"totalTrials":97,"cells":6316},"esomeprazole",{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6321,"PHASE3":6332,"PHASE4":6334,"NA":6336},{"trials":6318,"activeCount":101},[],{"trials":6320,"activeCount":101},[],{"trials":6322,"activeCount":101},[6323],{"nctId":6324,"briefTitle":6325,"status":219,"phases":6326,"primaryCompletion":6327,"completion":6327,"start":6328,"enrollment":361,"conditions":6329,"interventions":6330},"NCT00123656","Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis",[90],"2006-12","2004-08",[4665],[6315,6331],"fluticasone",{"trials":6333,"activeCount":101},[],{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"intervention":6331,"totalTrials":97,"cells":6339},{"EARLY_PHASE1":6340,"PHASE1":6342,"PHASE2":6344,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6341,"activeCount":101},[],{"trials":6343,"activeCount":101},[],{"trials":6345,"activeCount":101},[6346],{"nctId":6324,"briefTitle":6325,"status":219,"phases":6347,"primaryCompletion":6327,"completion":6327,"start":6328,"enrollment":361,"conditions":6348,"interventions":6349},[90],[4665],[6315,6331],{"trials":6351,"activeCount":101},[],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[],{"intervention":6357,"totalTrials":97,"cells":6358},"valacyclovir+clobetasol gel",{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6363,"PHASE3":6375,"PHASE4":6377,"NA":6379},{"trials":6360,"activeCount":101},[],{"trials":6362,"activeCount":101},[],{"trials":6364,"activeCount":101},[6365],{"nctId":6366,"briefTitle":6367,"status":219,"phases":6368,"primaryCompletion":3125,"completion":6369,"start":6370,"enrollment":6371,"conditions":6372,"interventions":6374},"NCT00297011","Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis",[90],"2008-01","2004-09",300,[6373],"Herpes Labialis",[6357],{"trials":6376,"activeCount":101},[],{"trials":6378,"activeCount":101},[],{"trials":6380,"activeCount":101},[],{"intervention":6382,"totalTrials":97,"cells":6383},"Sapropterin",{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6388,"PHASE3":6397,"PHASE4":6399,"NA":6401},{"trials":6385,"activeCount":101},[],{"trials":6387,"activeCount":101},[],{"trials":6389,"activeCount":101},[6390],{"nctId":6391,"briefTitle":6392,"status":219,"phases":6393,"primaryCompletion":2879,"completion":2879,"start":6145,"enrollment":1393,"conditions":6394,"interventions":6396},"NCT01425528","Study of Kuvan Treatment in Adults With GTPCH Deficiency",[89,90],[6395],"GTP Cyclohydrolase Deficiency",[6382],{"trials":6398,"activeCount":101},[],{"trials":6400,"activeCount":101},[],{"trials":6402,"activeCount":101},[],{"intervention":6404,"totalTrials":273,"cells":6405},"Cannabidiol",{"EARLY_PHASE1":6406,"PHASE1":6427,"PHASE2":6438,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6407,"activeCount":101},[6408,6416],{"nctId":6409,"briefTitle":6410,"status":219,"phases":6411,"primaryCompletion":6412,"completion":6412,"start":6413,"enrollment":407,"conditions":6414,"interventions":6415},"NCT04044729","Mechanisms of CBD for Chronic Pain",[88],"2024-12-01","2020-03-16",[24],[6404],{"nctId":6417,"briefTitle":6418,"status":219,"phases":6419,"primaryCompletion":6412,"completion":6412,"start":6420,"enrollment":6421,"conditions":6422,"interventions":6424},"NCT03215940","Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)",[88],"2018-02-01",53,[6423],"Chronic Pain, Widespread",[6425,6404,6426],"Delta-9-Tetrahydrocannabinol","Placebos",{"trials":6428,"activeCount":101},[6429],{"nctId":6430,"briefTitle":6431,"status":219,"phases":6432,"primaryCompletion":6433,"completion":6433,"start":6434,"enrollment":2974,"conditions":6435,"interventions":6437},"NCT02286986","Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy",[89],"2019-06-13","2014-09-18",[6436],"Epilepsy",[6404],{"trials":6439,"activeCount":101},[],{"trials":6441,"activeCount":101},[],{"trials":6443,"activeCount":101},[],{"trials":6445,"activeCount":101},[],{"intervention":6447,"totalTrials":378,"cells":6448},"Disulfiram",{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6470,"PHASE3":6472,"PHASE4":6474,"NA":6476},{"trials":6450,"activeCount":101},[],{"trials":6452,"activeCount":101},[6453,6463],{"nctId":6454,"briefTitle":6455,"status":193,"phases":6456,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":378,"conditions":6460,"interventions":6461},"NCT04521335","Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma",[89],"2021-12-09","2022-02-06","2021-05-21",[565],[6447,6462],"Copper Gluconate",{"nctId":6464,"briefTitle":6465,"status":219,"phases":6466,"primaryCompletion":3148,"completion":3148,"start":6467,"enrollment":2407,"conditions":6468,"interventions":6469},"NCT00742911","Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver",[89],"2008-07",[15],[6447,6462],{"trials":6471,"activeCount":101},[],{"trials":6473,"activeCount":101},[],{"trials":6475,"activeCount":101},[],{"trials":6477,"activeCount":101},[],{"intervention":6462,"totalTrials":378,"cells":6479},{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6492,"PHASE3":6494,"PHASE4":6496,"NA":6498},{"trials":6481,"activeCount":101},[],{"trials":6483,"activeCount":101},[6484,6488],{"nctId":6454,"briefTitle":6455,"status":193,"phases":6485,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":378,"conditions":6486,"interventions":6487},[89],[565],[6447,6462],{"nctId":6464,"briefTitle":6465,"status":219,"phases":6489,"primaryCompletion":3148,"completion":3148,"start":6467,"enrollment":2407,"conditions":6490,"interventions":6491},[89],[15],[6447,6462],{"trials":6493,"activeCount":101},[],{"trials":6495,"activeCount":101},[],{"trials":6497,"activeCount":101},[],{"trials":6499,"activeCount":101},[],{"intervention":6501,"totalTrials":378,"cells":6502},"Psilocybin",{"EARLY_PHASE1":6503,"PHASE1":6513,"PHASE2":6525,"PHASE3":6527,"PHASE4":6529,"NA":6531},{"trials":6504,"activeCount":101},[6505],{"nctId":6506,"briefTitle":6507,"status":219,"phases":6508,"primaryCompletion":6509,"completion":4908,"start":6510,"enrollment":1393,"conditions":6511,"interventions":6512},"NCT04522804","Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer",[88],"2022-06-11","2021-10-04",[15],[6501],{"trials":6514,"activeCount":101},[6515],{"nctId":6516,"briefTitle":6517,"status":219,"phases":6518,"primaryCompletion":6519,"completion":6519,"start":6520,"enrollment":407,"conditions":6521,"interventions":6524},"NCT05557643","PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout",[89],"2024-09-20","2023-01-02",[6522,6523],"Depression","Burnout, Professional",[6501],{"trials":6526,"activeCount":101},[],{"trials":6528,"activeCount":101},[],{"trials":6530,"activeCount":101},[],{"trials":6532,"activeCount":101},[],{"intervention":6534,"totalTrials":378,"cells":6535},"Oxaliplatin",{"EARLY_PHASE1":6536,"PHASE1":6538,"PHASE2":6559,"PHASE3":6561,"PHASE4":6563,"NA":6565},{"trials":6537,"activeCount":101},[],{"trials":6539,"activeCount":101},[6540,6548],{"nctId":6541,"briefTitle":6542,"status":219,"phases":6543,"primaryCompletion":6145,"completion":6145,"start":3051,"enrollment":2025,"conditions":6544,"interventions":6546},"NCT00707278","Radiation Therapy and Capecitabine\u002FOxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma",[89],[15,6545],"Pancreas",[6547,6534],"Capecitabine",{"nctId":6549,"briefTitle":6550,"status":193,"phases":6551,"primaryCompletion":6552,"completion":6552,"start":6553,"enrollment":97,"conditions":6554,"interventions":6557},"NCT04158349","Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer",[89],"2021-05-14","2021-03-22",[3266,6555,6556],"Appendiceal Cancer","Peritoneal Carcinoma",[6534,6558],"mFOLFIRI",{"trials":6560,"activeCount":101},[],{"trials":6562,"activeCount":101},[],{"trials":6564,"activeCount":101},[],{"trials":6566,"activeCount":101},[],{"intervention":6568,"totalTrials":97,"cells":6569},"Oxandrin",{"EARLY_PHASE1":6570,"PHASE1":6572,"PHASE2":6582,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6571,"activeCount":101},[],{"trials":6573,"activeCount":101},[6574],{"nctId":6575,"briefTitle":6576,"status":219,"phases":6577,"primaryCompletion":6578,"completion":6578,"start":256,"enrollment":3917,"conditions":6579,"interventions":6581},"NCT03218631","Oxandrolone in Healthy Adults: A Relative Bioavailability Study",[89],"2017-11-30",[6580],"Bioavailability",[6568],{"trials":6583,"activeCount":101},[],{"trials":6585,"activeCount":101},[],{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[],{"intervention":6591,"totalTrials":97,"cells":6592},"Botulinum Toxin Type A",{"EARLY_PHASE1":6593,"PHASE1":6595,"PHASE2":6606,"PHASE3":6608,"PHASE4":6610,"NA":6612},{"trials":6594,"activeCount":101},[],{"trials":6596,"activeCount":101},[6597],{"nctId":6598,"briefTitle":6599,"status":219,"phases":6600,"primaryCompletion":6601,"completion":6602,"start":6603,"enrollment":250,"conditions":6604,"interventions":6605},"NCT03236012","Hyperhidrosis in Patients With Amputations-Botox",[89],"2022-01-15","2022-02-14","2019-01-08",[4821],[6591],{"trials":6607,"activeCount":101},[],{"trials":6609,"activeCount":101},[],{"trials":6611,"activeCount":101},[],{"trials":6613,"activeCount":101},[],{"intervention":450,"totalTrials":97,"cells":6615},{"EARLY_PHASE1":6616,"PHASE1":6618,"PHASE2":6624,"PHASE3":6626,"PHASE4":6628,"NA":6630},{"trials":6617,"activeCount":101},[],{"trials":6619,"activeCount":101},[6620],{"nctId":440,"briefTitle":441,"status":442,"phases":6621,"primaryCompletion":444,"completion":445,"start":446,"enrollment":407,"conditions":6622,"interventions":6623},[89],[448],[450,451,433,452],{"trials":6625,"activeCount":101},[],{"trials":6627,"activeCount":101},[],{"trials":6629,"activeCount":101},[],{"trials":6631,"activeCount":101},[],{"intervention":451,"totalTrials":97,"cells":6633},{"EARLY_PHASE1":6634,"PHASE1":6636,"PHASE2":6642,"PHASE3":6644,"PHASE4":6646,"NA":6648},{"trials":6635,"activeCount":101},[],{"trials":6637,"activeCount":101},[6638],{"nctId":440,"briefTitle":441,"status":442,"phases":6639,"primaryCompletion":444,"completion":445,"start":446,"enrollment":407,"conditions":6640,"interventions":6641},[89],[448],[450,451,433,452],{"trials":6643,"activeCount":101},[],{"trials":6645,"activeCount":101},[],{"trials":6647,"activeCount":101},[],{"trials":6649,"activeCount":101},[],{"intervention":452,"totalTrials":97,"cells":6651},{"EARLY_PHASE1":6652,"PHASE1":6654,"PHASE2":6660,"PHASE3":6662,"PHASE4":6664,"NA":6666},{"trials":6653,"activeCount":101},[],{"trials":6655,"activeCount":101},[6656],{"nctId":440,"briefTitle":441,"status":442,"phases":6657,"primaryCompletion":444,"completion":445,"start":446,"enrollment":407,"conditions":6658,"interventions":6659},[89],[448],[450,451,433,452],{"trials":6661,"activeCount":101},[],{"trials":6663,"activeCount":101},[],{"trials":6665,"activeCount":101},[],{"trials":6667,"activeCount":101},[],{"intervention":6669,"totalTrials":97,"cells":6670},"Recombinant Activated Factor VII",{"EARLY_PHASE1":6671,"PHASE1":6673,"PHASE2":6684,"PHASE3":6686,"PHASE4":6688,"NA":6690},{"trials":6672,"activeCount":101},[],{"trials":6674,"activeCount":101},[6675],{"nctId":6676,"briefTitle":6677,"status":193,"phases":6678,"primaryCompletion":3598,"completion":3598,"start":2454,"enrollment":378,"conditions":6679,"interventions":6681},"NCT00770718","Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage",[89],[6680],"Intracranial Hemorrhage",[6669,6682,6683],"Prothrombin Complex Concentrate","Fresh Frozen Plasma",{"trials":6685,"activeCount":101},[],{"trials":6687,"activeCount":101},[],{"trials":6689,"activeCount":101},[],{"trials":6691,"activeCount":101},[],{"intervention":6682,"totalTrials":97,"cells":6693},{"EARLY_PHASE1":6694,"PHASE1":6696,"PHASE2":6702,"PHASE3":6704,"PHASE4":6706,"NA":6708},{"trials":6695,"activeCount":101},[],{"trials":6697,"activeCount":101},[6698],{"nctId":6676,"briefTitle":6677,"status":193,"phases":6699,"primaryCompletion":3598,"completion":3598,"start":2454,"enrollment":378,"conditions":6700,"interventions":6701},[89],[6680],[6669,6682,6683],{"trials":6703,"activeCount":101},[],{"trials":6705,"activeCount":101},[],{"trials":6707,"activeCount":101},[],{"trials":6709,"activeCount":101},[],{"intervention":6711,"totalTrials":97,"cells":6712},"Propranolol 1",{"EARLY_PHASE1":6713,"PHASE1":6715,"PHASE2":6726,"PHASE3":6728,"PHASE4":6730,"NA":6732},{"trials":6714,"activeCount":101},[],{"trials":6716,"activeCount":101},[6717],{"nctId":6718,"briefTitle":6719,"status":193,"phases":6720,"primaryCompletion":6721,"completion":2907,"start":325,"enrollment":30,"conditions":6722,"interventions":6724},"NCT03029845","Propranolol for Treating Fibromyalgia Pain",[89],"2018-04",[6723],"Fibromyalgia Pain",[6711,6725],"Propranolol 2",{"trials":6727,"activeCount":101},[],{"trials":6729,"activeCount":101},[],{"trials":6731,"activeCount":101},[],{"trials":6733,"activeCount":101},[],{"intervention":6725,"totalTrials":97,"cells":6735},{"EARLY_PHASE1":6736,"PHASE1":6738,"PHASE2":6744,"PHASE3":6746,"PHASE4":6748,"NA":6750},{"trials":6737,"activeCount":101},[],{"trials":6739,"activeCount":101},[6740],{"nctId":6718,"briefTitle":6719,"status":193,"phases":6741,"primaryCompletion":6721,"completion":2907,"start":325,"enrollment":30,"conditions":6742,"interventions":6743},[89],[6723],[6711,6725],{"trials":6745,"activeCount":101},[],{"trials":6747,"activeCount":101},[],{"trials":6749,"activeCount":101},[],{"trials":6751,"activeCount":101},[],{"intervention":6753,"totalTrials":97,"cells":6754},"Tadalafil Citrate",{"EARLY_PHASE1":6755,"PHASE1":6757,"PHASE2":6768,"PHASE3":6770,"PHASE4":6772,"NA":6774},{"trials":6756,"activeCount":101},[],{"trials":6758,"activeCount":101},[6759],{"nctId":6760,"briefTitle":6761,"status":219,"phases":6762,"primaryCompletion":6763,"completion":6763,"start":4861,"enrollment":22,"conditions":6764,"interventions":6766},"NCT01291069","Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients",[89],"2014-02",[6765],"Single Ventricle",[6753,6767],"Sugar pill",{"trials":6769,"activeCount":101},[],{"trials":6771,"activeCount":101},[],{"trials":6773,"activeCount":101},[],{"trials":6775,"activeCount":101},[],{"intervention":6767,"totalTrials":97,"cells":6777},{"EARLY_PHASE1":6778,"PHASE1":6780,"PHASE2":6786,"PHASE3":6788,"PHASE4":6790,"NA":6792},{"trials":6779,"activeCount":101},[],{"trials":6781,"activeCount":101},[6782],{"nctId":6760,"briefTitle":6761,"status":219,"phases":6783,"primaryCompletion":6763,"completion":6763,"start":4861,"enrollment":22,"conditions":6784,"interventions":6785},[89],[6765],[6753,6767],{"trials":6787,"activeCount":101},[],{"trials":6789,"activeCount":101},[],{"trials":6791,"activeCount":101},[],{"trials":6793,"activeCount":101},[],{"intervention":6795,"totalTrials":97,"cells":6796},"Oxandrolone",{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6809,"PHASE3":6811,"PHASE4":6813,"NA":6815},{"trials":6798,"activeCount":101},[],{"trials":6800,"activeCount":101},[6801],{"nctId":6802,"briefTitle":6803,"status":219,"phases":6804,"primaryCompletion":4686,"completion":4686,"start":6805,"enrollment":22,"conditions":6806,"interventions":6808},"NCT01048632","Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants",[89],"2010-07",[6807],"Malnutrition",[6795],{"trials":6810,"activeCount":101},[],{"trials":6812,"activeCount":101},[],{"trials":6814,"activeCount":101},[],{"trials":6816,"activeCount":101},[],{"intervention":6818,"totalTrials":97,"cells":6819},"Gamunex-C",{"EARLY_PHASE1":6820,"PHASE1":6822,"PHASE2":6833,"PHASE3":6835,"PHASE4":6837,"NA":6839},{"trials":6821,"activeCount":101},[],{"trials":6823,"activeCount":101},[6824],{"nctId":6825,"briefTitle":6826,"status":205,"phases":6827,"primaryCompletion":3495,"completion":3495,"start":3597,"enrollment":101,"conditions":6828,"interventions":6832},"NCT02042027","Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions",[89],[6829,6830,6831],"Corneal Neovascularization","Corneal Graft Failure","Anterior Segment Inflammation",[6818],{"trials":6834,"activeCount":101},[],{"trials":6836,"activeCount":101},[],{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[],{"intervention":6842,"totalTrials":97,"cells":6843},"stem cell transplant",{"EARLY_PHASE1":6844,"PHASE1":6846,"PHASE2":6857,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6845,"activeCount":101},[],{"trials":6847,"activeCount":101},[6848],{"nctId":6849,"briefTitle":6850,"status":193,"phases":6851,"primaryCompletion":6852,"completion":6852,"start":6853,"enrollment":1430,"conditions":6854,"interventions":6856},"NCT01818479","Phase I\u002FII Study of Treg\u002FTcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies",[89],"2019-04-01","2013-07-12",[6855],"High Risk Hematologic Malignancies",[6842],{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[],{"trials":6864,"activeCount":101},[],{"intervention":6866,"totalTrials":97,"cells":6867},"MEK162 and mFOLFIRI",{"EARLY_PHASE1":6868,"PHASE1":6870,"PHASE2":6882,"PHASE3":6884,"PHASE4":6886,"NA":6888},{"trials":6869,"activeCount":101},[],{"trials":6871,"activeCount":101},[6872],{"nctId":6873,"briefTitle":6874,"status":219,"phases":6875,"primaryCompletion":6876,"completion":6877,"start":6878,"enrollment":250,"conditions":6879,"interventions":6881},"NCT02613650","A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers",[89],"2022-11-23","2022-12-21","2016-08-19",[6880],"Advanced KRAS Positive Metastatic Colorectal Cancer",[6866],{"trials":6883,"activeCount":101},[],{"trials":6885,"activeCount":101},[],{"trials":6887,"activeCount":101},[],{"trials":6889,"activeCount":101},[],{"intervention":3996,"totalTrials":97,"cells":6891},{"EARLY_PHASE1":6892,"PHASE1":6894,"PHASE2":6900,"PHASE3":6902,"PHASE4":6904,"NA":6906},{"trials":6893,"activeCount":101},[],{"trials":6895,"activeCount":101},[6896],{"nctId":3989,"briefTitle":3990,"status":193,"phases":6897,"primaryCompletion":3992,"completion":3992,"start":2009,"enrollment":1313,"conditions":6898,"interventions":6899},[89],[3994],[3996,3997,3998],{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[],{"trials":6905,"activeCount":101},[],{"trials":6907,"activeCount":101},[],{"intervention":3997,"totalTrials":97,"cells":6909},{"EARLY_PHASE1":6910,"PHASE1":6912,"PHASE2":6918,"PHASE3":6920,"PHASE4":6922,"NA":6924},{"trials":6911,"activeCount":101},[],{"trials":6913,"activeCount":101},[6914],{"nctId":3989,"briefTitle":3990,"status":193,"phases":6915,"primaryCompletion":3992,"completion":3992,"start":2009,"enrollment":1313,"conditions":6916,"interventions":6917},[89],[3994],[3996,3997,3998],{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[],{"trials":6923,"activeCount":101},[],{"trials":6925,"activeCount":101},[],{"intervention":6927,"totalTrials":97,"cells":6928},"Intratumoral Ipilimumab and Interleukin-2",{"EARLY_PHASE1":6929,"PHASE1":6931,"PHASE2":6940,"PHASE3":6942,"PHASE4":6944,"NA":6946},{"trials":6930,"activeCount":101},[],{"trials":6932,"activeCount":101},[6933],{"nctId":6934,"briefTitle":6935,"status":219,"phases":6936,"primaryCompletion":6937,"completion":6937,"start":2577,"enrollment":1393,"conditions":6938,"interventions":6939},"NCT01672450","A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma",[89],"2014-08",[240],[6927],{"trials":6941,"activeCount":101},[],{"trials":6943,"activeCount":101},[],{"trials":6945,"activeCount":101},[],{"trials":6947,"activeCount":101},[],{"intervention":6949,"totalTrials":97,"cells":6950},"Muscle Contraction with Metabolite Solution Administration",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6963,"PHASE3":6965,"PHASE4":6967,"NA":6969},{"trials":6952,"activeCount":101},[],{"trials":6954,"activeCount":101},[6955],{"nctId":6956,"briefTitle":6957,"status":219,"phases":6958,"primaryCompletion":237,"completion":237,"start":2431,"enrollment":6959,"conditions":6960,"interventions":6962},"NCT01919918","Muscle Afferent Feedback Effects in Patients With Heart Failure",[89],144,[6961],"Chronic Heart Failure",[6949],{"trials":6964,"activeCount":101},[],{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[],{"trials":6970,"activeCount":101},[],{"intervention":6972,"totalTrials":97,"cells":6973},"Dacogen™",{"EARLY_PHASE1":6974,"PHASE1":6976,"PHASE2":6985,"PHASE3":6987,"PHASE4":6989,"NA":6991},{"trials":6975,"activeCount":101},[],{"trials":6977,"activeCount":101},[6978],{"nctId":6979,"briefTitle":6980,"status":219,"phases":6981,"primaryCompletion":5262,"completion":5262,"start":2719,"enrollment":2407,"conditions":6982,"interventions":6983},"NCT00879385","KRAS Wild-type Metastatic Colorectal Cancer Trial",[89],[3266],[6972,6984],"Vectibix®",{"trials":6986,"activeCount":101},[],{"trials":6988,"activeCount":101},[],{"trials":6990,"activeCount":101},[],{"trials":6992,"activeCount":101},[],{"intervention":6984,"totalTrials":97,"cells":6994},{"EARLY_PHASE1":6995,"PHASE1":6997,"PHASE2":7003,"PHASE3":7005,"PHASE4":7007,"NA":7009},{"trials":6996,"activeCount":101},[],{"trials":6998,"activeCount":101},[6999],{"nctId":6979,"briefTitle":6980,"status":219,"phases":7000,"primaryCompletion":5262,"completion":5262,"start":2719,"enrollment":2407,"conditions":7001,"interventions":7002},[89],[3266],[6972,6984],{"trials":7004,"activeCount":101},[],{"trials":7006,"activeCount":101},[],{"trials":7008,"activeCount":101},[],{"trials":7010,"activeCount":101},[],{"intervention":7012,"totalTrials":97,"cells":7013},"Aluminum Chloride 20%",{"EARLY_PHASE1":7014,"PHASE1":7016,"PHASE2":7026,"PHASE3":7028,"PHASE4":7030,"NA":7032},{"trials":7015,"activeCount":101},[],{"trials":7017,"activeCount":101},[7018],{"nctId":7019,"briefTitle":7020,"status":219,"phases":7021,"primaryCompletion":6601,"completion":6602,"start":7022,"enrollment":4048,"conditions":7023,"interventions":7024},"NCT03416348","Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2",[89],"2018-05-08",[4821],[7012,7025],"Alcohol",{"trials":7027,"activeCount":101},[],{"trials":7029,"activeCount":101},[],{"trials":7031,"activeCount":101},[],{"trials":7033,"activeCount":101},[],{"intervention":7025,"totalTrials":97,"cells":7035},{"EARLY_PHASE1":7036,"PHASE1":7038,"PHASE2":7044,"PHASE3":7046,"PHASE4":7048,"NA":7050},{"trials":7037,"activeCount":101},[],{"trials":7039,"activeCount":101},[7040],{"nctId":7019,"briefTitle":7020,"status":219,"phases":7041,"primaryCompletion":6601,"completion":6602,"start":7022,"enrollment":4048,"conditions":7042,"interventions":7043},[89],[4821],[7012,7025],{"trials":7045,"activeCount":101},[],{"trials":7047,"activeCount":101},[],{"trials":7049,"activeCount":101},[],{"trials":7051,"activeCount":101},[],{"intervention":3644,"totalTrials":97,"cells":7053},{"EARLY_PHASE1":7054,"PHASE1":7056,"PHASE2":7062,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7055,"activeCount":101},[],{"trials":7057,"activeCount":101},[7058],{"nctId":3636,"briefTitle":3637,"status":193,"phases":7059,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":378,"conditions":7060,"interventions":7061},[89],[3642],[3629,3644,3645],{"trials":7063,"activeCount":101},[],{"trials":7065,"activeCount":101},[],{"trials":7067,"activeCount":101},[],{"trials":7069,"activeCount":101},[],{"intervention":3645,"totalTrials":97,"cells":7071},{"EARLY_PHASE1":7072,"PHASE1":7074,"PHASE2":7080,"PHASE3":7082,"PHASE4":7084,"NA":7086},{"trials":7073,"activeCount":101},[],{"trials":7075,"activeCount":101},[7076],{"nctId":3636,"briefTitle":3637,"status":193,"phases":7077,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":378,"conditions":7078,"interventions":7079},[89],[3642],[3629,3644,3645],{"trials":7081,"activeCount":101},[],{"trials":7083,"activeCount":101},[],{"trials":7085,"activeCount":101},[],{"trials":7087,"activeCount":101},[],{"intervention":7089,"totalTrials":97,"cells":7090},"Twice daily enoxaparin prophylaxis",{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7105,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7092,"activeCount":101},[],{"trials":7094,"activeCount":101},[7095],{"nctId":7096,"briefTitle":7097,"status":219,"phases":7098,"primaryCompletion":7099,"completion":7100,"start":3615,"enrollment":7101,"conditions":7102,"interventions":7103},"NCT02687204","Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients",[89],"2017-06-23","2017-12-06",118,[2357,2359,5564],[7089,7104],"Real time dose adjustment",{"trials":7106,"activeCount":101},[],{"trials":7108,"activeCount":101},[],{"trials":7110,"activeCount":101},[],{"trials":7112,"activeCount":101},[],{"intervention":7104,"totalTrials":97,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7123,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":101},[],{"trials":7118,"activeCount":101},[7119],{"nctId":7096,"briefTitle":7097,"status":219,"phases":7120,"primaryCompletion":7099,"completion":7100,"start":3615,"enrollment":7101,"conditions":7121,"interventions":7122},[89],[2357,2359,5564],[7089,7104],{"trials":7124,"activeCount":101},[],{"trials":7126,"activeCount":101},[],{"trials":7128,"activeCount":101},[],{"trials":7130,"activeCount":101},[],{"intervention":7132,"totalTrials":97,"cells":7133},"Empagliflozin",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7155,"PHASE3":7157,"PHASE4":7159,"NA":7161},{"trials":7135,"activeCount":101},[],{"trials":7137,"activeCount":101},[7138],{"nctId":7139,"briefTitle":7140,"status":219,"phases":7141,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":7144,"conditions":7145,"interventions":7154},"NCT05614115","Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD",[89],"2025-06-30","2023-03-21",62,[7146,7147,7148,7149,7150,7151,7152,7153],"End-stage Kidney Disease","Kidney Disease, Chronic","Dialysis","Diabetic","Non-diabetic","Kidney Dysfunction","Kidney Failure","Hemodialysis",[7132],{"trials":7156,"activeCount":101},[],{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[],{"trials":7162,"activeCount":101},[],{"intervention":7164,"totalTrials":97,"cells":7165},"regorafenib + panitumumab",{"EARLY_PHASE1":7166,"PHASE1":7168,"PHASE2":7177,"PHASE3":7179,"PHASE4":7181,"NA":7183},{"trials":7167,"activeCount":101},[],{"trials":7169,"activeCount":101},[7170],{"nctId":7171,"briefTitle":7172,"status":193,"phases":7173,"primaryCompletion":4686,"completion":4686,"start":3124,"enrollment":378,"conditions":7174,"interventions":7176},"NCT02199223","Regorafenib + Panitumumab for Colorectal Cancers",[89],[7175],"KRAS and NRAS Wild-type Colorectal Cancer",[7164],{"trials":7178,"activeCount":101},[],{"trials":7180,"activeCount":101},[],{"trials":7182,"activeCount":101},[],{"trials":7184,"activeCount":101},[],{"intervention":3814,"totalTrials":97,"cells":7186},{"EARLY_PHASE1":7187,"PHASE1":7189,"PHASE2":7195,"PHASE3":7197,"PHASE4":7199,"NA":7201},{"trials":7188,"activeCount":101},[],{"trials":7190,"activeCount":101},[7191],{"nctId":3807,"briefTitle":3808,"status":205,"phases":7192,"primaryCompletion":3810,"completion":3810,"start":3811,"enrollment":101,"conditions":7193,"interventions":7194},[89],[1432],[3814,3815,3800],{"trials":7196,"activeCount":101},[],{"trials":7198,"activeCount":101},[],{"trials":7200,"activeCount":101},[],{"trials":7202,"activeCount":101},[],{"intervention":3815,"totalTrials":97,"cells":7204},{"EARLY_PHASE1":7205,"PHASE1":7207,"PHASE2":7213,"PHASE3":7215,"PHASE4":7217,"NA":7219},{"trials":7206,"activeCount":101},[],{"trials":7208,"activeCount":101},[7209],{"nctId":3807,"briefTitle":3808,"status":205,"phases":7210,"primaryCompletion":3810,"completion":3810,"start":3811,"enrollment":101,"conditions":7211,"interventions":7212},[89],[1432],[3814,3815,3800],{"trials":7214,"activeCount":101},[],{"trials":7216,"activeCount":101},[],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[],{"intervention":3655,"totalTrials":97,"cells":7222},{"EARLY_PHASE1":7223,"PHASE1":7225,"PHASE2":7231,"PHASE3":7233,"PHASE4":7235,"NA":7237},{"trials":7224,"activeCount":101},[],{"trials":7226,"activeCount":101},[7227],{"nctId":3647,"briefTitle":3648,"status":219,"phases":7228,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3015,"conditions":7229,"interventions":7230},[89],[3653,15],[3629,3655,3656,3657],{"trials":7232,"activeCount":101},[],{"trials":7234,"activeCount":101},[],{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[],{"intervention":3656,"totalTrials":97,"cells":7240},{"EARLY_PHASE1":7241,"PHASE1":7243,"PHASE2":7249,"PHASE3":7251,"PHASE4":7253,"NA":7255},{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[7245],{"nctId":3647,"briefTitle":3648,"status":219,"phases":7246,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3015,"conditions":7247,"interventions":7248},[89],[3653,15],[3629,3655,3656,3657],{"trials":7250,"activeCount":101},[],{"trials":7252,"activeCount":101},[],{"trials":7254,"activeCount":101},[],{"trials":7256,"activeCount":101},[],{"intervention":3657,"totalTrials":97,"cells":7258},{"EARLY_PHASE1":7259,"PHASE1":7261,"PHASE2":7267,"PHASE3":7269,"PHASE4":7271,"NA":7273},{"trials":7260,"activeCount":101},[],{"trials":7262,"activeCount":101},[7263],{"nctId":3647,"briefTitle":3648,"status":219,"phases":7264,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3015,"conditions":7265,"interventions":7266},[89],[3653,15],[3629,3655,3656,3657],{"trials":7268,"activeCount":101},[],{"trials":7270,"activeCount":101},[],{"trials":7272,"activeCount":101},[],{"trials":7274,"activeCount":101},[],{"intervention":7276,"totalTrials":97,"cells":7277},"Minocycline with chemoradiation",{"EARLY_PHASE1":7278,"PHASE1":7280,"PHASE2":7292,"PHASE3":7294,"PHASE4":7296,"NA":7298},{"trials":7279,"activeCount":101},[],{"trials":7281,"activeCount":101},[7282],{"nctId":7283,"briefTitle":7284,"status":219,"phases":7285,"primaryCompletion":7286,"completion":7287,"start":7288,"enrollment":250,"conditions":7289,"interventions":7291},"NCT02272270","Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline\u002FTemozolomide (D-TERMINED)",[89],"2017-03-08","2018-02-18","2014-10-27",[7290],"Newly Diagnosed High Grade Glioma",[7276],{"trials":7293,"activeCount":101},[],{"trials":7295,"activeCount":101},[],{"trials":7297,"activeCount":101},[],{"trials":7299,"activeCount":101},[],{"intervention":3907,"totalTrials":97,"cells":7301},{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7310,"PHASE3":7312,"PHASE4":7314,"NA":7316},{"trials":7303,"activeCount":101},[],{"trials":7305,"activeCount":101},[7306],{"nctId":3896,"briefTitle":3897,"status":193,"phases":7307,"primaryCompletion":2261,"completion":3899,"start":3900,"enrollment":282,"conditions":7308,"interventions":7309},[89],[3902,3903,3904,3905],[3907,1410],{"trials":7311,"activeCount":101},[],{"trials":7313,"activeCount":101},[],{"trials":7315,"activeCount":101},[],{"trials":7317,"activeCount":101},[],{"intervention":3709,"totalTrials":97,"cells":7319},{"EARLY_PHASE1":7320,"PHASE1":7322,"PHASE2":7328,"PHASE3":7330,"PHASE4":7332,"NA":7334},{"trials":7321,"activeCount":101},[],{"trials":7323,"activeCount":101},[7324],{"nctId":3700,"briefTitle":3701,"status":219,"phases":7325,"primaryCompletion":3703,"completion":3704,"start":3705,"enrollment":1646,"conditions":7326,"interventions":7327},[89],[3707],[3709,3693],{"trials":7329,"activeCount":101},[],{"trials":7331,"activeCount":101},[],{"trials":7333,"activeCount":101},[],{"trials":7335,"activeCount":101},[],{"intervention":7337,"totalTrials":97,"cells":7338},"ipilimumab and dabrafenib",{"EARLY_PHASE1":7339,"PHASE1":7341,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7358},{"trials":7340,"activeCount":101},[],{"trials":7342,"activeCount":101},[7343],{"nctId":7344,"briefTitle":7345,"status":193,"phases":7346,"primaryCompletion":7347,"completion":7347,"start":7348,"enrollment":3917,"conditions":7349,"interventions":7351},"NCT02200562","Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III\u002FIV Melanoma",[89],"2017-01-20","2014-12",[7350],"Stage III or IV Melanoma",[7337],{"trials":7353,"activeCount":101},[],{"trials":7355,"activeCount":101},[],{"trials":7357,"activeCount":101},[],{"trials":7359,"activeCount":101},[],{"intervention":7361,"totalTrials":97,"cells":7362},"Sunitinib",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7375,"PHASE3":7377,"PHASE4":7379,"NA":7381},{"trials":7364,"activeCount":101},[],{"trials":7366,"activeCount":101},[7367],{"nctId":7368,"briefTitle":7369,"status":219,"phases":7370,"primaryCompletion":561,"completion":561,"start":7371,"enrollment":250,"conditions":7372,"interventions":7374},"NCT00694096","Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response",[89],"2007-09",[7373],"Renal Cell Cancer",[7361],{"trials":7376,"activeCount":101},[],{"trials":7378,"activeCount":101},[],{"trials":7380,"activeCount":101},[],{"trials":7382,"activeCount":101},[],{"intervention":7384,"totalTrials":97,"cells":7385},"Merestinib",{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7399,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7387,"activeCount":101},[],{"trials":7389,"activeCount":101},[7390],{"nctId":7391,"briefTitle":7392,"status":193,"phases":7393,"primaryCompletion":7394,"completion":7394,"start":7395,"enrollment":378,"conditions":7396,"interventions":7398},"NCT03292536","Merestinib on Bone Metastases in Subjects With Breast Cancer",[89],"2019-06-24","2018-01-11",[7397,21],"Bone Metastases",[7384],{"trials":7400,"activeCount":101},[],{"trials":7402,"activeCount":101},[],{"trials":7404,"activeCount":101},[],{"trials":7406,"activeCount":101},[],{"intervention":7408,"totalTrials":97,"cells":7409},"MK-3475",{"EARLY_PHASE1":7410,"PHASE1":7412,"PHASE2":7424,"PHASE3":7426,"PHASE4":7428,"NA":7430},{"trials":7411,"activeCount":101},[],{"trials":7413,"activeCount":101},[7414],{"nctId":7415,"briefTitle":7416,"status":193,"phases":7417,"primaryCompletion":7418,"completion":7419,"start":7420,"enrollment":185,"conditions":7421,"interventions":7423},"NCT02268825","Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers",[89],"2017-01-25","2017-06-26","2015-01-23",[7422],"Advanced GI Cancer",[7408],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"trials":7431,"activeCount":101},[],{"intervention":7433,"totalTrials":97,"cells":7434},"N803",{"EARLY_PHASE1":7435,"PHASE1":7437,"PHASE2":7447,"PHASE3":7449,"PHASE4":7451,"NA":7453},{"trials":7436,"activeCount":101},[],{"trials":7438,"activeCount":101},[7439],{"nctId":7440,"briefTitle":7441,"status":205,"phases":7442,"primaryCompletion":738,"completion":459,"start":7443,"enrollment":101,"conditions":7444,"interventions":7446},"NCT07049432","N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas",[89],"2026-02",[7445],"B-cell Non Hodgkin Lymphoma",[7433],{"trials":7448,"activeCount":101},[],{"trials":7450,"activeCount":101},[],{"trials":7452,"activeCount":101},[],{"trials":7454,"activeCount":101},[],{"intervention":7456,"totalTrials":97,"cells":7457},"Provex CV",{"EARLY_PHASE1":7458,"PHASE1":7460,"PHASE2":7470,"PHASE3":7472,"PHASE4":7474,"NA":7476},{"trials":7459,"activeCount":101},[],{"trials":7461,"activeCount":101},[7462],{"nctId":7463,"briefTitle":7464,"status":219,"phases":7465,"primaryCompletion":7466,"completion":7466,"start":5135,"enrollment":22,"conditions":7467,"interventions":7469},"NCT01106170","Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure",[89],"2011-10",[7468],"Blood Pressure",[7456],{"trials":7471,"activeCount":101},[],{"trials":7473,"activeCount":101},[],{"trials":7475,"activeCount":101},[],{"trials":7477,"activeCount":101},[],{"intervention":7479,"totalTrials":97,"cells":7480},"Nexium",{"EARLY_PHASE1":7481,"PHASE1":7483,"PHASE2":7493,"PHASE3":7495,"PHASE4":7497,"NA":7499},{"trials":7482,"activeCount":101},[],{"trials":7484,"activeCount":101},[7485],{"nctId":7486,"briefTitle":7487,"status":193,"phases":7488,"primaryCompletion":5340,"completion":5340,"start":7489,"enrollment":16,"conditions":7490,"interventions":7492},"NCT00444236","Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression",[89],"2007-04",[7491,3425],"Exercise Triggered Asthma",[7479],{"trials":7494,"activeCount":101},[],{"trials":7496,"activeCount":101},[],{"trials":7498,"activeCount":101},[],{"trials":7500,"activeCount":101},[],{"intervention":7502,"totalTrials":97,"cells":7503},"Vemurafenib",{"EARLY_PHASE1":7504,"PHASE1":7506,"PHASE2":7517,"PHASE3":7519,"PHASE4":7521,"NA":7523},{"trials":7505,"activeCount":101},[],{"trials":7507,"activeCount":101},[7508],{"nctId":7509,"briefTitle":7510,"status":205,"phases":7511,"primaryCompletion":6189,"completion":6189,"start":7512,"enrollment":101,"conditions":7513,"interventions":7516},"NCT01843738","Radiation Use During Vemurafenib Treatment",[89],"2017-06",[7514,7515],"BRAFV600 Mutation","Stage IV Melanoma",[7502],{"trials":7518,"activeCount":101},[],{"trials":7520,"activeCount":101},[],{"trials":7522,"activeCount":101},[],{"trials":7524,"activeCount":101},[],{"intervention":7526,"totalTrials":97,"cells":7527},"4-Methylpyrazole",{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7539,"PHASE3":7541,"PHASE4":7543,"NA":7545},{"trials":7529,"activeCount":101},[],{"trials":7531,"activeCount":101},[7532],{"nctId":7533,"briefTitle":7534,"status":219,"phases":7535,"primaryCompletion":3471,"completion":4934,"start":3194,"enrollment":1430,"conditions":7536,"interventions":7538},"NCT00346853","Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy",[89],[7537],"Macular Dystrophy, Corneal",[7526],{"trials":7540,"activeCount":101},[],{"trials":7542,"activeCount":101},[],{"trials":7544,"activeCount":101},[],{"trials":7546,"activeCount":101},[],{"intervention":6547,"totalTrials":97,"cells":7548},{"EARLY_PHASE1":7549,"PHASE1":7551,"PHASE2":7557,"PHASE3":7559,"PHASE4":7561,"NA":7563},{"trials":7550,"activeCount":101},[],{"trials":7552,"activeCount":101},[7553],{"nctId":6541,"briefTitle":6542,"status":219,"phases":7554,"primaryCompletion":6145,"completion":6145,"start":3051,"enrollment":2025,"conditions":7555,"interventions":7556},[89],[15,6545],[6547,6534],{"trials":7558,"activeCount":101},[],{"trials":7560,"activeCount":101},[],{"trials":7562,"activeCount":101},[],{"trials":7564,"activeCount":101},[],{"intervention":228,"totalTrials":97,"cells":7566},{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7575,"PHASE3":7577,"PHASE4":7579,"NA":7581},{"trials":7568,"activeCount":101},[],{"trials":7570,"activeCount":101},[7571],{"nctId":217,"briefTitle":218,"status":219,"phases":7572,"primaryCompletion":221,"completion":222,"start":223,"enrollment":35,"conditions":7573,"interventions":7574},[89],[225],[46,227,228,66],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"trials":7582,"activeCount":101},[],{"intervention":3726,"totalTrials":97,"cells":7584},{"EARLY_PHASE1":7585,"PHASE1":7587,"PHASE2":7593,"PHASE3":7595,"PHASE4":7597,"NA":7599},{"trials":7586,"activeCount":101},[],{"trials":7588,"activeCount":101},[7589],{"nctId":3711,"briefTitle":3712,"status":193,"phases":7590,"primaryCompletion":3714,"completion":3715,"start":3716,"enrollment":250,"conditions":7591,"interventions":7592},[89],[3718,3719,3720,3721,3722,3723,3724],[3693,3726],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[],{"trials":7598,"activeCount":101},[],{"trials":7600,"activeCount":101},[],{"intervention":7602,"totalTrials":97,"cells":7603},"Ergocalciferol",{"EARLY_PHASE1":7604,"PHASE1":7606,"PHASE2":7616,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7605,"activeCount":101},[],{"trials":7607,"activeCount":101},[7608],{"nctId":7609,"briefTitle":7610,"status":219,"phases":7611,"primaryCompletion":5928,"completion":5928,"start":7612,"enrollment":589,"conditions":7613,"interventions":7615},"NCT02011828","Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol",[89],"2009-05",[7614,317],"Inflammation",[7602],{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[],{"trials":7621,"activeCount":101},[],{"trials":7623,"activeCount":101},[],{"intervention":7625,"totalTrials":97,"cells":7626},"Methadone HCl Inject 10 mg\u002Fml",{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7640,"PHASE3":7642,"PHASE4":7644,"NA":7646},{"trials":7628,"activeCount":101},[],{"trials":7630,"activeCount":101},[7631],{"nctId":7632,"briefTitle":7633,"status":219,"phases":7634,"primaryCompletion":2577,"completion":7635,"start":7636,"enrollment":238,"conditions":7637,"interventions":7638},"NCT00715988","Methadone Pharmacokinetics and Cardiac Effects in Newborns",[89],"2017-02-10","2007-10",[18],[7625,7639],"Methadone",{"trials":7641,"activeCount":101},[],{"trials":7643,"activeCount":101},[],{"trials":7645,"activeCount":101},[],{"trials":7647,"activeCount":101},[],{"intervention":7639,"totalTrials":97,"cells":7649},{"EARLY_PHASE1":7650,"PHASE1":7652,"PHASE2":7658,"PHASE3":7660,"PHASE4":7662,"NA":7664},{"trials":7651,"activeCount":101},[],{"trials":7653,"activeCount":101},[7654],{"nctId":7632,"briefTitle":7633,"status":219,"phases":7655,"primaryCompletion":2577,"completion":7635,"start":7636,"enrollment":238,"conditions":7656,"interventions":7657},[89],[18],[7625,7639],{"trials":7659,"activeCount":101},[],{"trials":7661,"activeCount":101},[],{"trials":7663,"activeCount":101},[],{"trials":7665,"activeCount":101},[],{"intervention":7667,"totalTrials":97,"cells":7668},"Decitabine",{"EARLY_PHASE1":7669,"PHASE1":7671,"PHASE2":7682,"PHASE3":7684,"PHASE4":7686,"NA":7688},{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[7673],{"nctId":7674,"briefTitle":7675,"status":219,"phases":7676,"primaryCompletion":561,"completion":561,"start":7677,"enrollment":273,"conditions":7678,"interventions":7681},"NCT01149408","Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients",[89],"2011-02",[7679,7680],"Acute Myeloid Leukemia","AML",[7667],{"trials":7683,"activeCount":101},[],{"trials":7685,"activeCount":101},[],{"trials":7687,"activeCount":101},[],{"trials":7689,"activeCount":101},[],{"intervention":1397,"totalTrials":97,"cells":7691},{"EARLY_PHASE1":7692,"PHASE1":7694,"PHASE2":7700,"PHASE3":7702,"PHASE4":7704,"NA":7706},{"trials":7693,"activeCount":101},[],{"trials":7695,"activeCount":101},[7696],{"nctId":1387,"briefTitle":1388,"status":219,"phases":7697,"primaryCompletion":1390,"completion":1391,"start":1392,"enrollment":1393,"conditions":7698,"interventions":7699},[89],[1395],[1397,1371],{"trials":7701,"activeCount":101},[],{"trials":7703,"activeCount":101},[],{"trials":7705,"activeCount":101},[],{"trials":7707,"activeCount":101},[],{"intervention":6558,"totalTrials":97,"cells":7709},{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7718,"PHASE3":7720,"PHASE4":7722,"NA":7724},{"trials":7711,"activeCount":101},[],{"trials":7713,"activeCount":101},[7714],{"nctId":6549,"briefTitle":6550,"status":193,"phases":7715,"primaryCompletion":6552,"completion":6552,"start":6553,"enrollment":97,"conditions":7716,"interventions":7717},[89],[3266,6555,6556],[6534,6558],{"trials":7719,"activeCount":101},[],{"trials":7721,"activeCount":101},[],{"trials":7723,"activeCount":101},[],{"trials":7725,"activeCount":101},[],{"intervention":7727,"totalTrials":97,"cells":7728},"Lumason Contrast-Enhanced Ultrasound",{"EARLY_PHASE1":7729,"PHASE1":7731,"PHASE2":7741,"PHASE3":7743,"PHASE4":7745,"NA":7747},{"trials":7730,"activeCount":101},[],{"trials":7732,"activeCount":101},[7733],{"nctId":7734,"briefTitle":7735,"status":193,"phases":7736,"primaryCompletion":7737,"completion":7737,"start":7738,"enrollment":22,"conditions":7739,"interventions":7740},"NCT02911714","Contrast-Enhanced Ultrasound for Kidney Transplant",[89],"2022-06-30","2018-02-21",[2409],[7727],{"trials":7742,"activeCount":101},[],{"trials":7744,"activeCount":101},[],{"trials":7746,"activeCount":101},[],{"trials":7748,"activeCount":101},[],{"intervention":7750,"totalTrials":97,"cells":7751},"sildenafil citrate",{"EARLY_PHASE1":7752,"PHASE1":7754,"PHASE2":7762,"PHASE3":7764,"PHASE4":7766,"NA":7768},{"trials":7753,"activeCount":101},[],{"trials":7755,"activeCount":101},[7756],{"nctId":7757,"briefTitle":7758,"status":193,"phases":7759,"primaryCompletion":5261,"completion":5261,"start":2813,"enrollment":3015,"conditions":7760,"interventions":7761},"NCT02628847","Sildenafil and Stroke Recovery",[89],[34],[7750],{"trials":7763,"activeCount":101},[],{"trials":7765,"activeCount":101},[],{"trials":7767,"activeCount":101},[],{"trials":7769,"activeCount":101},[],{"intervention":7771,"totalTrials":378,"cells":7772},"Standard heparin dose",{"EARLY_PHASE1":7773,"PHASE1":7796,"PHASE2":7798,"PHASE3":7800,"PHASE4":7802,"NA":7804},{"trials":7774,"activeCount":101},[7775,7786],{"nctId":7776,"briefTitle":7777,"status":219,"phases":7778,"primaryCompletion":7779,"completion":7780,"start":7781,"enrollment":22,"conditions":7782,"interventions":7784},"NCT03516656","Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin",[88],"2019-06-30","2021-08-24","2018-03-23",[7783,2360,2357],"Deep Vein Thrombosis",[7771,7785],"Real time heparin dose adjustment",{"nctId":7787,"briefTitle":7788,"status":219,"phases":7789,"primaryCompletion":7790,"completion":7791,"start":7792,"enrollment":22,"conditions":7793,"interventions":7795},"NCT02970032","Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin",[88],"2017-09-10","2017-12-08","2016-11-10",[7794,2360,2357],"Deep-Venous Thrombosis",[7785,7771],{"trials":7797,"activeCount":101},[],{"trials":7799,"activeCount":101},[],{"trials":7801,"activeCount":101},[],{"trials":7803,"activeCount":101},[],{"trials":7805,"activeCount":101},[],{"intervention":7785,"totalTrials":378,"cells":7807},{"EARLY_PHASE1":7808,"PHASE1":7818,"PHASE2":7820,"PHASE3":7822,"PHASE4":7824,"NA":7826},{"trials":7809,"activeCount":101},[7810,7814],{"nctId":7776,"briefTitle":7777,"status":219,"phases":7811,"primaryCompletion":7779,"completion":7780,"start":7781,"enrollment":22,"conditions":7812,"interventions":7813},[88],[7783,2360,2357],[7771,7785],{"nctId":7787,"briefTitle":7788,"status":219,"phases":7815,"primaryCompletion":7790,"completion":7791,"start":7792,"enrollment":22,"conditions":7816,"interventions":7817},[88],[7794,2360,2357],[7785,7771],{"trials":7819,"activeCount":101},[],{"trials":7821,"activeCount":101},[],{"trials":7823,"activeCount":101},[],{"trials":7825,"activeCount":101},[],{"trials":7827,"activeCount":101},[],{"intervention":7829,"totalTrials":378,"cells":7830},"bupivacaine",{"EARLY_PHASE1":7831,"PHASE1":7851,"PHASE2":7853,"PHASE3":7855,"PHASE4":7857,"NA":7859},{"trials":7832,"activeCount":101},[7833,7840],{"nctId":7834,"briefTitle":7835,"status":219,"phases":7836,"primaryCompletion":7348,"completion":7348,"start":6098,"enrollment":282,"conditions":7837,"interventions":7839},"NCT02168959","Continuous Femoral Nerve Block With a Tibial Plateau Fracture",[88],[7838],"Tibial Plateau Fracture",[7829],{"nctId":7841,"briefTitle":7842,"status":193,"phases":7843,"primaryCompletion":7844,"completion":7844,"start":561,"enrollment":7845,"conditions":7846,"interventions":7847},"NCT02369523","Multimodal Pain Management Following Primary TKA",[88],"2017-04",84,[18],[7848,7849,7850],"Exparel","Ropivacaine cocktail","Bupivacaine",{"trials":7852,"activeCount":101},[],{"trials":7854,"activeCount":101},[],{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[],{"intervention":7862,"totalTrials":97,"cells":7863},"calcitriol",{"EARLY_PHASE1":7864,"PHASE1":7875,"PHASE2":7877,"PHASE3":7879,"PHASE4":7881,"NA":7883},{"trials":7865,"activeCount":101},[7866],{"nctId":7867,"briefTitle":7868,"status":193,"phases":7869,"primaryCompletion":2010,"completion":2010,"start":7870,"enrollment":1393,"conditions":7871,"interventions":7874},"NCT00585442","Effects of Vitamin D on Renin Expression in Hypertensive Patients",[88],"2007-05",[7872,7873],"Hypertension","Vitamin D Deficiency",[7862],{"trials":7876,"activeCount":101},[],{"trials":7878,"activeCount":101},[],{"trials":7880,"activeCount":101},[],{"trials":7882,"activeCount":101},[],{"trials":7884,"activeCount":101},[],{"intervention":7886,"totalTrials":97,"cells":7887},"Naproxen",{"EARLY_PHASE1":7888,"PHASE1":7900,"PHASE2":7902,"PHASE3":7904,"PHASE4":7906,"NA":7908},{"trials":7889,"activeCount":101},[7890],{"nctId":7891,"briefTitle":7892,"status":219,"phases":7893,"primaryCompletion":7894,"completion":7894,"start":7895,"enrollment":7896,"conditions":7897,"interventions":7899},"NCT01539447","Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy",[88],"2022-03-16","2012-01",108,[7898],"Heterotopic Ossification",[7886],{"trials":7901,"activeCount":101},[],{"trials":7903,"activeCount":101},[],{"trials":7905,"activeCount":101},[],{"trials":7907,"activeCount":101},[],{"trials":7909,"activeCount":101},[],{"intervention":7911,"totalTrials":97,"cells":7912},"oral ulipristal acetate",{"EARLY_PHASE1":7913,"PHASE1":7924,"PHASE2":7926,"PHASE3":7928,"PHASE4":7930,"NA":7932},{"trials":7914,"activeCount":101},[7915],{"nctId":7916,"briefTitle":7917,"status":219,"phases":7918,"primaryCompletion":7919,"completion":7920,"start":7921,"enrollment":9,"conditions":7922,"interventions":7923},"NCT04291001","Ovarian Function With ENG Implant and UPA Use",[88],"2022-10-10","2024-01-12","2020-09-04",[29],[7911],{"trials":7925,"activeCount":101},[],{"trials":7927,"activeCount":101},[],{"trials":7929,"activeCount":101},[],{"trials":7931,"activeCount":101},[],{"trials":7933,"activeCount":101},[],{"intervention":7935,"totalTrials":97,"cells":7936},"Alirocumab",{"EARLY_PHASE1":7937,"PHASE1":7949,"PHASE2":7951,"PHASE3":7953,"PHASE4":7955,"NA":7957},{"trials":7938,"activeCount":101},[7939],{"nctId":7940,"briefTitle":7941,"status":193,"phases":7942,"primaryCompletion":7943,"completion":7943,"start":7944,"enrollment":22,"conditions":7945,"interventions":7948},"NCT03507374","PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis",[88],"2020-04-17","2018-10-30",[34,7946,7947],"Intracranial Atherosclerosis","Intraplaque Hemorrhage",[7935],{"trials":7950,"activeCount":101},[],{"trials":7952,"activeCount":101},[],{"trials":7954,"activeCount":101},[],{"trials":7956,"activeCount":101},[],{"trials":7958,"activeCount":101},[],{"intervention":7960,"totalTrials":97,"cells":7961},"Daptomycin",{"EARLY_PHASE1":7962,"PHASE1":7974,"PHASE2":7976,"PHASE3":7978,"PHASE4":7980,"NA":7982},{"trials":7963,"activeCount":101},[7964],{"nctId":7965,"briefTitle":7966,"status":219,"phases":7967,"primaryCompletion":7968,"completion":3495,"start":4322,"enrollment":1393,"conditions":7969,"interventions":7972},"NCT02097953","Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin",[88],"2015-06",[7970,7971],"Drug Interactions","Pharmacokinetics",[7960,7973],"Rifampin",{"trials":7975,"activeCount":101},[],{"trials":7977,"activeCount":101},[],{"trials":7979,"activeCount":101},[],{"trials":7981,"activeCount":101},[],{"trials":7983,"activeCount":101},[],{"intervention":7973,"totalTrials":97,"cells":7985},{"EARLY_PHASE1":7986,"PHASE1":7992,"PHASE2":7994,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7987,"activeCount":101},[7988],{"nctId":7965,"briefTitle":7966,"status":219,"phases":7989,"primaryCompletion":7968,"completion":3495,"start":4322,"enrollment":1393,"conditions":7990,"interventions":7991},[88],[7970,7971],[7960,7973],{"trials":7993,"activeCount":101},[],{"trials":7995,"activeCount":101},[],{"trials":7997,"activeCount":101},[],{"trials":7999,"activeCount":101},[],{"trials":8001,"activeCount":101},[],{"intervention":8003,"totalTrials":97,"cells":8004},"Simvastatin",{"EARLY_PHASE1":8005,"PHASE1":8014,"PHASE2":8016,"PHASE3":8018,"PHASE4":8020,"NA":8022},{"trials":8006,"activeCount":101},[8007],{"nctId":8008,"briefTitle":8009,"status":219,"phases":8010,"primaryCompletion":6467,"completion":6467,"start":8011,"enrollment":1393,"conditions":8012,"interventions":8013},"NCT00769210","The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure",[88],"2005-05",[2240],[8003],{"trials":8015,"activeCount":101},[],{"trials":8017,"activeCount":101},[],{"trials":8019,"activeCount":101},[],{"trials":8021,"activeCount":101},[],{"trials":8023,"activeCount":101},[],{"intervention":8025,"totalTrials":97,"cells":8026},"Leuprolide Acetate - Early Puberty Leuprolide Visit",{"EARLY_PHASE1":8027,"PHASE1":8041,"PHASE2":8043,"PHASE3":8045,"PHASE4":8047,"NA":8049},{"trials":8028,"activeCount":101},[8029],{"nctId":8030,"briefTitle":8031,"status":219,"phases":8032,"primaryCompletion":3220,"completion":3288,"start":8033,"enrollment":3015,"conditions":8034,"interventions":8037},"NCT00734279","Follicle-Stimulating Hormone (FSH) and the Onset of Puberty",[88],"2006-03",[8035,8036],"Delayed Puberty","Precocious Puberty",[8025,8038,8039,8040],"Ganirelix - Early Puberty Ganirelix Visit","Ganirelix - Delayed Puberty Ganirelix Visit","Leuprolide Acetate- Delayed Puberty Leuprolide Visit",{"trials":8042,"activeCount":101},[],{"trials":8044,"activeCount":101},[],{"trials":8046,"activeCount":101},[],{"trials":8048,"activeCount":101},[],{"trials":8050,"activeCount":101},[],{"intervention":8038,"totalTrials":97,"cells":8052},{"EARLY_PHASE1":8053,"PHASE1":8059,"PHASE2":8061,"PHASE3":8063,"PHASE4":8065,"NA":8067},{"trials":8054,"activeCount":101},[8055],{"nctId":8030,"briefTitle":8031,"status":219,"phases":8056,"primaryCompletion":3220,"completion":3288,"start":8033,"enrollment":3015,"conditions":8057,"interventions":8058},[88],[8035,8036],[8025,8038,8039,8040],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[],{"trials":8064,"activeCount":101},[],{"trials":8066,"activeCount":101},[],{"trials":8068,"activeCount":101},[],{"intervention":8039,"totalTrials":97,"cells":8070},{"EARLY_PHASE1":8071,"PHASE1":8077,"PHASE2":8079,"PHASE3":8081,"PHASE4":8083,"NA":8085},{"trials":8072,"activeCount":101},[8073],{"nctId":8030,"briefTitle":8031,"status":219,"phases":8074,"primaryCompletion":3220,"completion":3288,"start":8033,"enrollment":3015,"conditions":8075,"interventions":8076},[88],[8035,8036],[8025,8038,8039,8040],{"trials":8078,"activeCount":101},[],{"trials":8080,"activeCount":101},[],{"trials":8082,"activeCount":101},[],{"trials":8084,"activeCount":101},[],{"trials":8086,"activeCount":101},[],{"intervention":8040,"totalTrials":97,"cells":8088},{"EARLY_PHASE1":8089,"PHASE1":8095,"PHASE2":8097,"PHASE3":8099,"PHASE4":8101,"NA":8103},{"trials":8090,"activeCount":101},[8091],{"nctId":8030,"briefTitle":8031,"status":219,"phases":8092,"primaryCompletion":3220,"completion":3288,"start":8033,"enrollment":3015,"conditions":8093,"interventions":8094},[88],[8035,8036],[8025,8038,8039,8040],{"trials":8096,"activeCount":101},[],{"trials":8098,"activeCount":101},[],{"trials":8100,"activeCount":101},[],{"trials":8102,"activeCount":101},[],{"trials":8104,"activeCount":101},[],{"intervention":8106,"totalTrials":97,"cells":8107},"Atorvastatin",{"EARLY_PHASE1":8108,"PHASE1":8121,"PHASE2":8123,"PHASE3":8125,"PHASE4":8127,"NA":8129},{"trials":8109,"activeCount":101},[8110],{"nctId":8111,"briefTitle":8112,"status":219,"phases":8113,"primaryCompletion":8114,"completion":8115,"start":8116,"enrollment":268,"conditions":8117,"interventions":8119},"NCT05342974","Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy",[88],"2023-12-31","2025-01-06","2022-04-19",[8118],"Abortion Early",[8106,8120],"Misoprostol",{"trials":8122,"activeCount":101},[],{"trials":8124,"activeCount":101},[],{"trials":8126,"activeCount":101},[],{"trials":8128,"activeCount":101},[],{"trials":8130,"activeCount":101},[],{"intervention":8132,"totalTrials":97,"cells":8133},"Real time enoxaparin dose adjustment",{"EARLY_PHASE1":8134,"PHASE1":8144,"PHASE2":8146,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8135,"activeCount":101},[8136],{"nctId":8137,"briefTitle":8138,"status":219,"phases":8139,"primaryCompletion":2907,"completion":8140,"start":3615,"enrollment":614,"conditions":8141,"interventions":8142},"NCT02704052","Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose",[88],"2018-10",[2359,5564,2357],[8132,8143],"Standard enoxaparin dose",{"trials":8145,"activeCount":101},[],{"trials":8147,"activeCount":101},[],{"trials":8149,"activeCount":101},[],{"trials":8151,"activeCount":101},[],{"trials":8153,"activeCount":101},[],{"intervention":8143,"totalTrials":97,"cells":8155},{"EARLY_PHASE1":8156,"PHASE1":8162,"PHASE2":8164,"PHASE3":8166,"PHASE4":8168,"NA":8170},{"trials":8157,"activeCount":101},[8158],{"nctId":8137,"briefTitle":8138,"status":219,"phases":8159,"primaryCompletion":2907,"completion":8140,"start":3615,"enrollment":614,"conditions":8160,"interventions":8161},[88],[2359,5564,2357],[8132,8143],{"trials":8163,"activeCount":101},[],{"trials":8165,"activeCount":101},[],{"trials":8167,"activeCount":101},[],{"trials":8169,"activeCount":101},[],{"trials":8171,"activeCount":101},[],{"intervention":8173,"totalTrials":97,"cells":8174},"Amiloride",{"EARLY_PHASE1":8175,"PHASE1":8186,"PHASE2":8188,"PHASE3":8190,"PHASE4":8192,"NA":8194},{"trials":8176,"activeCount":101},[8177],{"nctId":8178,"briefTitle":8179,"status":219,"phases":8180,"primaryCompletion":8181,"completion":8182,"start":8183,"enrollment":30,"conditions":8184,"interventions":8185},"NCT04181008","Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers",[88],"2022-08-30","2023-03-06","2020-09-28",[7971],[8173,8173,8173],{"trials":8187,"activeCount":101},[],{"trials":8189,"activeCount":101},[],{"trials":8191,"activeCount":101},[],{"trials":8193,"activeCount":101},[],{"trials":8195,"activeCount":101},[],{"intervention":8197,"totalTrials":97,"cells":8198},"18F-fluciclovine",{"EARLY_PHASE1":8199,"PHASE1":8211,"PHASE2":8213,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8200,"activeCount":101},[8201],{"nctId":8202,"briefTitle":8203,"status":219,"phases":8204,"primaryCompletion":8205,"completion":8205,"start":8206,"enrollment":397,"conditions":8207,"interventions":8210},"NCT04852523","18F-Fluciclovine PET\u002FCT in the Assessment of Pancreatic Transplants",[88],"2022-10-06","2021-09-16",[8208,8209],"Pancreatitis, Graft","Pancreatic Transplant Post-Transplant Dysfunction Rejection",[8197],{"trials":8212,"activeCount":101},[],{"trials":8214,"activeCount":101},[],{"trials":8216,"activeCount":101},[],{"trials":8218,"activeCount":101},[],{"trials":8220,"activeCount":101},[],{"intervention":8222,"totalTrials":97,"cells":8223},"Ferumoxytol",{"EARLY_PHASE1":8224,"PHASE1":8238,"PHASE2":8240,"PHASE3":8242,"PHASE4":8244,"NA":8246},{"trials":8225,"activeCount":101},[8226],{"nctId":8227,"briefTitle":8228,"status":219,"phases":8229,"primaryCompletion":8230,"completion":8230,"start":8231,"enrollment":3015,"conditions":8232,"interventions":8236},"NCT05357833","Novel Imaging Markers in SPMS",[88],"2023-09-01","2022-06-01",[8233,8234,8235],"Secondary Progressive Multiple Sclerosis","Multiple Sclerosis, Secondary Progressive","Multiple Sclerosis",[8222,8237],"Gadoteridol",{"trials":8239,"activeCount":101},[],{"trials":8241,"activeCount":101},[],{"trials":8243,"activeCount":101},[],{"trials":8245,"activeCount":101},[],{"trials":8247,"activeCount":101},[],{"intervention":8237,"totalTrials":97,"cells":8249},{"EARLY_PHASE1":8250,"PHASE1":8256,"PHASE2":8258,"PHASE3":8260,"PHASE4":8262,"NA":8264},{"trials":8251,"activeCount":101},[8252],{"nctId":8227,"briefTitle":8228,"status":219,"phases":8253,"primaryCompletion":8230,"completion":8230,"start":8231,"enrollment":3015,"conditions":8254,"interventions":8255},[88],[8233,8234,8235],[8222,8237],{"trials":8257,"activeCount":101},[],{"trials":8259,"activeCount":101},[],{"trials":8261,"activeCount":101},[],{"trials":8263,"activeCount":101},[],{"trials":8265,"activeCount":101},[],{"intervention":8267,"totalTrials":97,"cells":8268},"L-Citrulline",{"EARLY_PHASE1":8269,"PHASE1":8281,"PHASE2":8283,"PHASE3":8285,"PHASE4":8287,"NA":8289},{"trials":8270,"activeCount":101},[8271],{"nctId":8272,"briefTitle":8273,"status":193,"phases":8274,"primaryCompletion":8275,"completion":8275,"start":8276,"enrollment":1646,"conditions":8277,"interventions":8280},"NCT03542812","L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia",[88],"2022-08-31","2019-07-30",[8278,8279,1247],"Infant,Premature","Bronchopulmonary Dysplasia",[8267],{"trials":8282,"activeCount":101},[],{"trials":8284,"activeCount":101},[],{"trials":8286,"activeCount":101},[],{"trials":8288,"activeCount":101},[],{"trials":8290,"activeCount":101},[],{"intervention":8292,"totalTrials":97,"cells":8293},"Aspirin",{"EARLY_PHASE1":8294,"PHASE1":8305,"PHASE2":8307,"PHASE3":8309,"PHASE4":8311,"NA":8313},{"trials":8295,"activeCount":101},[8296],{"nctId":8297,"briefTitle":8298,"status":219,"phases":8299,"primaryCompletion":3742,"completion":3742,"start":8300,"enrollment":8301,"conditions":8302,"interventions":8304},"NCT04040465","Asprin Dosing Estimator in Healthy Adults",[88],"2021-02-15",57,[8303],"Aspirin Sensitivity",[8292],{"trials":8306,"activeCount":101},[],{"trials":8308,"activeCount":101},[],{"trials":8310,"activeCount":101},[],{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[],{"intervention":8316,"totalTrials":97,"cells":8317},"Atropine sulfate gel",{"EARLY_PHASE1":8318,"PHASE1":8331,"PHASE2":8333,"PHASE3":8335,"PHASE4":8337,"NA":8339},{"trials":8319,"activeCount":101},[8320],{"nctId":8321,"briefTitle":8322,"status":219,"phases":8323,"primaryCompletion":8324,"completion":8325,"start":8326,"enrollment":1430,"conditions":8327,"interventions":8330},"NCT05164367","Pharmacokinetics of Atropine Oral Gel",[88],"2023-06-30","2024-12-10","2022-10-01",[8328,8329],"Cerebral Palsy","Sialorrhea",[8316],{"trials":8332,"activeCount":101},[],{"trials":8334,"activeCount":101},[],{"trials":8336,"activeCount":101},[],{"trials":8338,"activeCount":101},[],{"trials":8340,"activeCount":101},[],{"intervention":8342,"totalTrials":97,"cells":8343},"Cephalosporin or clindamycin\u002Fvancomycin antibiotics..",{"EARLY_PHASE1":8344,"PHASE1":8356,"PHASE2":8358,"PHASE3":8360,"PHASE4":8362,"NA":8364},{"trials":8345,"activeCount":101},[8346],{"nctId":8347,"briefTitle":8348,"status":219,"phases":8349,"primaryCompletion":8350,"completion":8350,"start":8351,"enrollment":1430,"conditions":8352,"interventions":8354},"NCT05849090","Vancomycin and Tobramycin Powder Use in Acute Open Fractures",[88],"2024-12-12","2023-03-27",[8353],"Infections",[8342,8355],"Vancomycin and Tobramycin antibiotics.",{"trials":8357,"activeCount":101},[],{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":101},[],{"trials":8363,"activeCount":101},[],{"trials":8365,"activeCount":101},[],{"intervention":8355,"totalTrials":97,"cells":8367},{"EARLY_PHASE1":8368,"PHASE1":8374,"PHASE2":8376,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8369,"activeCount":101},[8370],{"nctId":8347,"briefTitle":8348,"status":219,"phases":8371,"primaryCompletion":8350,"completion":8350,"start":8351,"enrollment":1430,"conditions":8372,"interventions":8373},[88],[8353],[8342,8355],{"trials":8375,"activeCount":101},[],{"trials":8377,"activeCount":101},[],{"trials":8379,"activeCount":101},[],{"trials":8381,"activeCount":101},[],{"trials":8383,"activeCount":101},[],{"intervention":7848,"totalTrials":97,"cells":8385},{"EARLY_PHASE1":8386,"PHASE1":8392,"PHASE2":8394,"PHASE3":8396,"PHASE4":8398,"NA":8400},{"trials":8387,"activeCount":101},[8388],{"nctId":7841,"briefTitle":7842,"status":193,"phases":8389,"primaryCompletion":7844,"completion":7844,"start":561,"enrollment":7845,"conditions":8390,"interventions":8391},[88],[18],[7848,7849,7850],{"trials":8393,"activeCount":101},[],{"trials":8395,"activeCount":101},[],{"trials":8397,"activeCount":101},[],{"trials":8399,"activeCount":101},[],{"trials":8401,"activeCount":101},[],{"intervention":7849,"totalTrials":97,"cells":8403},{"EARLY_PHASE1":8404,"PHASE1":8410,"PHASE2":8412,"PHASE3":8414,"PHASE4":8416,"NA":8418},{"trials":8405,"activeCount":101},[8406],{"nctId":7841,"briefTitle":7842,"status":193,"phases":8407,"primaryCompletion":7844,"completion":7844,"start":561,"enrollment":7845,"conditions":8408,"interventions":8409},[88],[18],[7848,7849,7850],{"trials":8411,"activeCount":101},[],{"trials":8413,"activeCount":101},[],{"trials":8415,"activeCount":101},[],{"trials":8417,"activeCount":101},[],{"trials":8419,"activeCount":101},[],{"intervention":8421,"totalTrials":97,"cells":8422},"Medrol",{"EARLY_PHASE1":8423,"PHASE1":8433,"PHASE2":8435,"PHASE3":8437,"PHASE4":8439,"NA":8441},{"trials":8424,"activeCount":101},[8425],{"nctId":8426,"briefTitle":8427,"status":219,"phases":8428,"primaryCompletion":8429,"completion":8429,"start":8430,"enrollment":8301,"conditions":8431,"interventions":8432},"NCT06453083","Medrol Dose Packs for Post-Operative Pain Control",[88],"2024-12-17","2023-01-13",[18],[8421],{"trials":8434,"activeCount":101},[],{"trials":8436,"activeCount":101},[],{"trials":8438,"activeCount":101},[],{"trials":8440,"activeCount":101},[],{"trials":8442,"activeCount":101},[],{"intervention":6425,"totalTrials":97,"cells":8444},{"EARLY_PHASE1":8445,"PHASE1":8451,"PHASE2":8453,"PHASE3":8455,"PHASE4":8457,"NA":8459},{"trials":8446,"activeCount":101},[8447],{"nctId":6417,"briefTitle":6418,"status":219,"phases":8448,"primaryCompletion":6412,"completion":6412,"start":6420,"enrollment":6421,"conditions":8449,"interventions":8450},[88],[6423],[6425,6404,6426],{"trials":8452,"activeCount":101},[],{"trials":8454,"activeCount":101},[],{"trials":8456,"activeCount":101},[],{"trials":8458,"activeCount":101},[],{"trials":8460,"activeCount":101},[],{"intervention":6426,"totalTrials":97,"cells":8462},{"EARLY_PHASE1":8463,"PHASE1":8469,"PHASE2":8471,"PHASE3":8473,"PHASE4":8475,"NA":8477},{"trials":8464,"activeCount":101},[8465],{"nctId":6417,"briefTitle":6418,"status":219,"phases":8466,"primaryCompletion":6412,"completion":6412,"start":6420,"enrollment":6421,"conditions":8467,"interventions":8468},[88],[6423],[6425,6404,6426],{"trials":8470,"activeCount":101},[],{"trials":8472,"activeCount":101},[],{"trials":8474,"activeCount":101},[],{"trials":8476,"activeCount":101},[],{"trials":8478,"activeCount":101},[],{"intervention":8480,"totalTrials":97,"cells":8481},"Sodium bicarbonate",{"EARLY_PHASE1":8482,"PHASE1":8490,"PHASE2":8492,"PHASE3":8494,"PHASE4":8496,"NA":8498},{"trials":8483,"activeCount":101},[8484],{"nctId":8485,"briefTitle":8486,"status":219,"phases":8487,"primaryCompletion":5110,"completion":5110,"start":3220,"enrollment":472,"conditions":8488,"interventions":8489},"NCT01225796","Study of Sodium Bicarbonate in Kidney Transplant Recipients",[88],[2409],[8480],{"trials":8491,"activeCount":101},[],{"trials":8493,"activeCount":101},[],{"trials":8495,"activeCount":101},[],{"trials":8497,"activeCount":101},[],{"trials":8499,"activeCount":101},[],{"intervention":8501,"totalTrials":97,"cells":8502},"20ml 0.25% bupivacaine-epinephrine",{"EARLY_PHASE1":8503,"PHASE1":8513,"PHASE2":8515,"PHASE3":8517,"PHASE4":8519,"NA":8521},{"trials":8504,"activeCount":101},[8505],{"nctId":8506,"briefTitle":8507,"status":219,"phases":8508,"primaryCompletion":8509,"completion":8509,"start":5109,"enrollment":8510,"conditions":8511,"interventions":8512},"NCT03070054","LIA in Hip Arthroscopy Patients",[88],"2020-03",74,[18],[8501],{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[],{"trials":8518,"activeCount":101},[],{"trials":8520,"activeCount":101},[],{"trials":8522,"activeCount":101},[],{"intervention":8524,"totalTrials":97,"cells":8525},"Technetium Tc 99M",{"EARLY_PHASE1":8526,"PHASE1":8536,"PHASE2":8538,"PHASE3":8540,"PHASE4":8542,"NA":8544},{"trials":8527,"activeCount":101},[8528],{"nctId":8529,"briefTitle":8530,"status":219,"phases":8531,"primaryCompletion":8532,"completion":209,"start":3495,"enrollment":171,"conditions":8533,"interventions":8535},"NCT04069429","Radiation Dose in Humans From Orally Administered Tc99m-Heparin",[88],"2020-09",[8534],"Eosinophilic Esophagitis",[8524],{"trials":8537,"activeCount":101},[],{"trials":8539,"activeCount":101},[],{"trials":8541,"activeCount":101},[],{"trials":8543,"activeCount":101},[],{"trials":8545,"activeCount":101},[],{"intervention":8547,"totalTrials":97,"cells":8548},"Abatacept 10 mg\u002Fkg",{"EARLY_PHASE1":8549,"PHASE1":8559,"PHASE2":8561,"PHASE3":8563,"PHASE4":8565,"NA":8567},{"trials":8550,"activeCount":101},[8551],{"nctId":8552,"briefTitle":8553,"status":205,"phases":8554,"primaryCompletion":313,"completion":313,"start":8555,"enrollment":101,"conditions":8556,"interventions":8558},"NCT04344873","Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach",[88],"2025-09-01",[3315,7614,8557],"Aging",[8547],{"trials":8560,"activeCount":101},[],{"trials":8562,"activeCount":101},[],{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[],{"trials":8568,"activeCount":101},[],{"intervention":8570,"totalTrials":97,"cells":8571},"Human Amniotic Membrane",{"EARLY_PHASE1":8572,"PHASE1":8582,"PHASE2":8584,"PHASE3":8586,"PHASE4":8588,"NA":8590},{"trials":8573,"activeCount":101},[8574],{"nctId":8575,"briefTitle":8576,"status":219,"phases":8577,"primaryCompletion":8578,"completion":8578,"start":8579,"enrollment":1313,"conditions":8580,"interventions":8581},"NCT04130061","Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation",[88],"2021-06-01","2019-10-11",[2656],[8570],{"trials":8583,"activeCount":101},[],{"trials":8585,"activeCount":101},[],{"trials":8587,"activeCount":101},[],{"trials":8589,"activeCount":101},[],{"trials":8591,"activeCount":101},[],{"intervention":8593,"totalTrials":397,"cells":8594},"Enoxaparin",{"EARLY_PHASE1":8595,"PHASE1":8597,"PHASE2":8599,"PHASE3":8626,"PHASE4":8628,"NA":8630},{"trials":8596,"activeCount":101},[],{"trials":8598,"activeCount":101},[],{"trials":8600,"activeCount":101},[8601,8608,8617],{"nctId":8602,"briefTitle":8603,"status":219,"phases":8604,"primaryCompletion":3615,"completion":5109,"start":2746,"enrollment":8605,"conditions":8606,"interventions":8607},"NCT02411292","Enoxaparin Metabolism in Reconstructive Surgery Patients",[90],110,[2357,2359,5564,5565],[8593],{"nctId":8609,"briefTitle":8610,"status":219,"phases":8611,"primaryCompletion":7779,"completion":8612,"start":8613,"enrollment":8614,"conditions":8615,"interventions":8616},"NCT03339349","Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma",[90],"2019-10-29","2017-11-15",80,[2357,7783,5564],[8593],{"nctId":8618,"briefTitle":8619,"status":219,"phases":8620,"primaryCompletion":8621,"completion":8621,"start":8622,"enrollment":315,"conditions":8623,"interventions":8625},"NCT06118957","Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery",[90],"2024-07-01","2023-10-11",[8624],"Thromboembolism",[8593],{"trials":8627,"activeCount":101},[],{"trials":8629,"activeCount":101},[],{"trials":8631,"activeCount":101},[8632],{"nctId":8633,"briefTitle":8634,"status":219,"phases":8635,"primaryCompletion":8636,"completion":8636,"start":8637,"enrollment":8638,"conditions":8639,"interventions":8642},"NCT04305756","Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery",[93],"2021-12-15","2020-06-12",146,[8624,8640,8641],"Postpartum DVT","Thrombosis",[8593],{"intervention":2138,"totalTrials":397,"cells":8644},{"EARLY_PHASE1":8645,"PHASE1":8647,"PHASE2":8649,"PHASE3":8651,"PHASE4":8653,"NA":8667},{"trials":8646,"activeCount":101},[],{"trials":8648,"activeCount":101},[],{"trials":8650,"activeCount":101},[],{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[8655,8659,8663],{"nctId":2258,"briefTitle":2259,"status":193,"phases":8656,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":1646,"conditions":8657,"interventions":8658},[92],[2214],[2138,2245,2266],{"nctId":2130,"briefTitle":2131,"status":193,"phases":8660,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":1430,"conditions":8661,"interventions":8662},[92],[2136],[1756,2138,2139],{"nctId":2674,"briefTitle":2675,"status":219,"phases":8664,"primaryCompletion":2677,"completion":2262,"start":2678,"enrollment":1224,"conditions":8665,"interventions":8666},[92],[2214],[2661,2138,2681],{"trials":8668,"activeCount":101},[8669],{"nctId":8670,"briefTitle":8671,"status":219,"phases":8672,"primaryCompletion":5135,"completion":5135,"start":8673,"enrollment":3015,"conditions":8674,"interventions":8675},"NCT01126359","Lidocaine Analgesia For Removal Of Wound Vac Dressings",[93],"2008-08",[18],[2138],{"intervention":8677,"totalTrials":273,"cells":8678},"Levonorgestrel IUD",{"EARLY_PHASE1":8679,"PHASE1":8681,"PHASE2":8683,"PHASE3":8685,"PHASE4":8687,"NA":8707},{"trials":8680,"activeCount":101},[],{"trials":8682,"activeCount":101},[],{"trials":8684,"activeCount":101},[],{"trials":8686,"activeCount":101},[],{"trials":8688,"activeCount":101},[8689,8696],{"nctId":8690,"briefTitle":8691,"status":219,"phases":8692,"primaryCompletion":2812,"completion":325,"start":1903,"enrollment":8693,"conditions":8694,"interventions":8695},"NCT01990703","BLIS - Breastfeeding Levonorgestrel IUD Study",[92],285,[29],[8677],{"nctId":8697,"briefTitle":8698,"status":219,"phases":8699,"primaryCompletion":8700,"completion":8701,"start":8702,"enrollment":8703,"conditions":8704,"interventions":8705},"NCT02175030","RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC",[92],"2020-02","2020-12","2016-08",711,[29],[8706,8677],"Copper IUD",{"trials":8708,"activeCount":101},[8709],{"nctId":8710,"briefTitle":8711,"status":219,"phases":8712,"primaryCompletion":4860,"completion":4860,"start":5221,"enrollment":8713,"conditions":8714,"interventions":8715},"NCT01963962","Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception",[],188,[144],[8706,8677],{"intervention":8717,"totalTrials":273,"cells":8718},"Adenosine",{"EARLY_PHASE1":8719,"PHASE1":8733,"PHASE2":8735,"PHASE3":8737,"PHASE4":8739,"NA":8741},{"trials":8720,"activeCount":101},[8721],{"nctId":8722,"briefTitle":8723,"status":3445,"phases":8724,"primaryCompletion":8725,"completion":8726,"start":8727,"enrollment":1962,"conditions":8728,"interventions":8730},"NCT04600115","New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)",[88],"2022-03-03","2023-03-03","2017-03-03",[8729],"MRI Scans",[8717,8731,8732],"Regadenoson","O-15 labeled radioactive water",{"trials":8734,"activeCount":101},[],{"trials":8736,"activeCount":101},[],{"trials":8738,"activeCount":101},[],{"trials":8740,"activeCount":101},[],{"trials":8742,"activeCount":101},[8743,8751],{"nctId":8744,"briefTitle":8745,"status":219,"phases":8746,"primaryCompletion":6805,"completion":6805,"start":4398,"enrollment":361,"conditions":8747,"interventions":8750},"NCT00859833","Effects of Body Mass Index on the Hyperemic Response to Regadenoson",[93],[32,8748,8749],"Endothelial Dysfunction","Decreased Vascular Flow",[8717,8731],{"nctId":8752,"briefTitle":8753,"status":205,"phases":8754,"primaryCompletion":8755,"completion":8755,"start":8756,"enrollment":101,"conditions":8757,"interventions":8758},"NCT02608944","Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging",[93],"2019-06-12","2012-09-30",[8729],[8717,8731,8732],{"intervention":8731,"totalTrials":273,"cells":8760},{"EARLY_PHASE1":8761,"PHASE1":8767,"PHASE2":8769,"PHASE3":8771,"PHASE4":8773,"NA":8775},{"trials":8762,"activeCount":101},[8763],{"nctId":8722,"briefTitle":8723,"status":3445,"phases":8764,"primaryCompletion":8725,"completion":8726,"start":8727,"enrollment":1962,"conditions":8765,"interventions":8766},[88],[8729],[8717,8731,8732],{"trials":8768,"activeCount":101},[],{"trials":8770,"activeCount":101},[],{"trials":8772,"activeCount":101},[],{"trials":8774,"activeCount":101},[],{"trials":8776,"activeCount":101},[8777,8781],{"nctId":8744,"briefTitle":8745,"status":219,"phases":8778,"primaryCompletion":6805,"completion":6805,"start":4398,"enrollment":361,"conditions":8779,"interventions":8780},[93],[32,8748,8749],[8717,8731],{"nctId":8752,"briefTitle":8753,"status":205,"phases":8782,"primaryCompletion":8755,"completion":8755,"start":8756,"enrollment":101,"conditions":8783,"interventions":8784},[93],[8729],[8717,8731,8732],{"intervention":6683,"totalTrials":378,"cells":8786},{"EARLY_PHASE1":8787,"PHASE1":8789,"PHASE2":8795,"PHASE3":8797,"PHASE4":8799,"NA":8801},{"trials":8788,"activeCount":101},[],{"trials":8790,"activeCount":101},[8791],{"nctId":6676,"briefTitle":6677,"status":193,"phases":8792,"primaryCompletion":3598,"completion":3598,"start":2454,"enrollment":378,"conditions":8793,"interventions":8794},[89],[6680],[6669,6682,6683],{"trials":8796,"activeCount":101},[],{"trials":8798,"activeCount":101},[],{"trials":8800,"activeCount":101},[],{"trials":8802,"activeCount":101},[8803],{"nctId":8804,"briefTitle":8805,"status":205,"phases":8806,"primaryCompletion":3615,"completion":3615,"start":4794,"enrollment":101,"conditions":8807,"interventions":8810},"NCT02429453","FFP Versus PCC in Intracranial Hemorrhage",[93],[8808,8809],"Intracranial Hemorrhage, Traumatic","Intracranial Hemorrhage, Spontaneous",[8811,6683],"Four Factor Prothrombin Complex Concentrate",{"intervention":8813,"totalTrials":378,"cells":8814},"Uridine",{"EARLY_PHASE1":8815,"PHASE1":8817,"PHASE2":8819,"PHASE3":8828,"PHASE4":8830,"NA":8832},{"trials":8816,"activeCount":101},[],{"trials":8818,"activeCount":101},[],{"trials":8820,"activeCount":101},[8821],{"nctId":8822,"briefTitle":8823,"status":219,"phases":8824,"primaryCompletion":2857,"completion":2857,"start":7612,"enrollment":3863,"conditions":8825,"interventions":8827},"NCT00841269","Oral Uridine for Treatment of Bipolar Depression in Adolescents",[90],[8826],"Bipolar Disorder",[8813],{"trials":8829,"activeCount":101},[],{"trials":8831,"activeCount":101},[],{"trials":8833,"activeCount":101},[8834],{"nctId":8835,"briefTitle":8836,"status":219,"phases":8837,"primaryCompletion":8838,"completion":8838,"start":2879,"enrollment":7144,"conditions":8839,"interventions":8842},"NCT01805440","Uridine Adolescent Bipolar Depression Randomized Controlled Trial",[93],"2015-12",[8826,8840,8841],"Bipolar Depression","Manic Depression",[8813],{"intervention":8706,"totalTrials":378,"cells":8844},{"EARLY_PHASE1":8845,"PHASE1":8847,"PHASE2":8849,"PHASE3":8851,"PHASE4":8853,"NA":8859},{"trials":8846,"activeCount":101},[],{"trials":8848,"activeCount":101},[],{"trials":8850,"activeCount":101},[],{"trials":8852,"activeCount":101},[],{"trials":8854,"activeCount":101},[8855],{"nctId":8697,"briefTitle":8698,"status":219,"phases":8856,"primaryCompletion":8700,"completion":8701,"start":8702,"enrollment":8703,"conditions":8857,"interventions":8858},[92],[29],[8706,8677],{"trials":8860,"activeCount":101},[8861],{"nctId":8710,"briefTitle":8711,"status":219,"phases":8862,"primaryCompletion":4860,"completion":4860,"start":5221,"enrollment":8713,"conditions":8863,"interventions":8864},[],[144],[8706,8677],{"intervention":8120,"totalTrials":378,"cells":8866},{"EARLY_PHASE1":8867,"PHASE1":8873,"PHASE2":8875,"PHASE3":8877,"PHASE4":8879,"NA":8881},{"trials":8868,"activeCount":101},[8869],{"nctId":8111,"briefTitle":8112,"status":219,"phases":8870,"primaryCompletion":8114,"completion":8115,"start":8116,"enrollment":268,"conditions":8871,"interventions":8872},[88],[8118],[8106,8120],{"trials":8874,"activeCount":101},[],{"trials":8876,"activeCount":101},[],{"trials":8878,"activeCount":101},[],{"trials":8880,"activeCount":101},[],{"trials":8882,"activeCount":101},[8883],{"nctId":8884,"briefTitle":8885,"status":219,"phases":8886,"primaryCompletion":2304,"completion":2304,"start":2096,"enrollment":7896,"conditions":8887,"interventions":8888},"NCT00886834","Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women",[93],[29],[8120],{"intervention":8890,"totalTrials":378,"cells":8891},"Sotalol",{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8896,"PHASE3":8898,"PHASE4":8904,"NA":8906},{"trials":8893,"activeCount":101},[],{"trials":8895,"activeCount":101},[],{"trials":8897,"activeCount":101},[],{"trials":8899,"activeCount":101},[8900],{"nctId":3308,"briefTitle":3309,"status":219,"phases":8901,"completion":3311,"start":3312,"conditions":8902,"interventions":8903},[91],[3314,3315,3316,3317,3318,3319,3320],[3297,3322,3323,3324,3325],{"trials":8905,"activeCount":101},[],{"trials":8907,"activeCount":101},[8908],{"nctId":8909,"briefTitle":8910,"status":219,"phases":8911,"primaryCompletion":8912,"completion":8912,"start":1775,"enrollment":8913,"conditions":8914,"interventions":8916},"NCT05247320","Prospective Evaluation Analysis and Kinetics Registry",[],"2023-08-30",167,[8915],"Atrial Arrhythmia",[8890],{"intervention":3685,"totalTrials":378,"cells":8918},{"EARLY_PHASE1":8919,"PHASE1":8921,"PHASE2":8923,"PHASE3":8929,"PHASE4":8931,"NA":8933},{"trials":8920,"activeCount":101},[],{"trials":8922,"activeCount":101},[],{"trials":8924,"activeCount":101},[8925],{"nctId":3678,"briefTitle":3679,"status":193,"phases":8926,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":30,"conditions":8927,"interventions":8928},[90],[21],[3685,3629],{"trials":8930,"activeCount":101},[],{"trials":8932,"activeCount":101},[],{"trials":8934,"activeCount":101},[8935],{"nctId":8936,"briefTitle":8937,"status":219,"phases":8938,"primaryCompletion":8939,"completion":8940,"start":5109,"enrollment":4059,"conditions":8941,"interventions":8944},"NCT02778971","Implications for Management of PET Amyloid Classification Technology",[],"2018-06","2022-09",[8942,8943,4690],"Mild Cognitive Impairment","Dementia",[3685],{"intervention":8946,"totalTrials":378,"cells":8947},"Copper T380 IUD",{"EARLY_PHASE1":8948,"PHASE1":8950,"PHASE2":8952,"PHASE3":8954,"PHASE4":8956,"NA":8958},{"trials":8949,"activeCount":101},[],{"trials":8951,"activeCount":101},[],{"trials":8953,"activeCount":101},[],{"trials":8955,"activeCount":101},[],{"trials":8957,"activeCount":101},[],{"trials":8959,"activeCount":101},[8960,8968],{"nctId":8961,"briefTitle":8962,"status":219,"phases":8963,"primaryCompletion":2096,"completion":7612,"start":2454,"enrollment":8301,"conditions":8964,"interventions":8966},"NCT00669396","Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception",[93],[8965],"Pregnancy",[8946,8967],"levonorgestrel",{"nctId":8969,"briefTitle":8970,"status":219,"phases":8971,"primaryCompletion":6145,"completion":6145,"start":562,"enrollment":8972,"conditions":8973,"interventions":8974},"NCT00966771","The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception",[],548,[8965],[8946,8975],"Oral levonorgestrel",{"intervention":8967,"totalTrials":378,"cells":8977},{"EARLY_PHASE1":8978,"PHASE1":8980,"PHASE2":8982,"PHASE3":8984,"PHASE4":8986,"NA":8995},{"trials":8979,"activeCount":101},[],{"trials":8981,"activeCount":101},[],{"trials":8983,"activeCount":101},[],{"trials":8985,"activeCount":101},[],{"trials":8987,"activeCount":101},[8988],{"nctId":8989,"briefTitle":8990,"status":219,"phases":8991,"primaryCompletion":4391,"completion":4391,"start":5136,"enrollment":3053,"conditions":8992,"interventions":8993},"NCT00131885","Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel",[92],[29],[8994],"Levonorgestrel",{"trials":8996,"activeCount":101},[8997],{"nctId":8961,"briefTitle":8962,"status":219,"phases":8998,"primaryCompletion":2096,"completion":7612,"start":2454,"enrollment":8301,"conditions":8999,"interventions":9000},[93],[8965],[8946,8967],{"intervention":8732,"totalTrials":378,"cells":9002},{"EARLY_PHASE1":9003,"PHASE1":9009,"PHASE2":9011,"PHASE3":9013,"PHASE4":9015,"NA":9017},{"trials":9004,"activeCount":101},[9005],{"nctId":8722,"briefTitle":8723,"status":3445,"phases":9006,"primaryCompletion":8725,"completion":8726,"start":8727,"enrollment":1962,"conditions":9007,"interventions":9008},[88],[8729],[8717,8731,8732],{"trials":9010,"activeCount":101},[],{"trials":9012,"activeCount":101},[],{"trials":9014,"activeCount":101},[],{"trials":9016,"activeCount":101},[],{"trials":9018,"activeCount":101},[9019],{"nctId":8752,"briefTitle":8753,"status":205,"phases":9020,"primaryCompletion":8755,"completion":8755,"start":8756,"enrollment":101,"conditions":9021,"interventions":9022},[93],[8729],[8717,8731,8732],{"intervention":9024,"totalTrials":378,"cells":9025},"Ketamine",{"EARLY_PHASE1":9026,"PHASE1":9039,"PHASE2":9041,"PHASE3":9043,"PHASE4":9045,"NA":9047},{"trials":9027,"activeCount":101},[9028],{"nctId":9029,"briefTitle":9030,"status":193,"phases":9031,"primaryCompletion":9032,"completion":9033,"start":9034,"enrollment":378,"conditions":9035,"interventions":9038},"NCT06001372","Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers",[88],"2023-12-22","2024-03-12","2023-10-13",[9036,6522,9037],"Gastrointestinal Cancer","Anxiety",[9024],{"trials":9040,"activeCount":101},[],{"trials":9042,"activeCount":101},[],{"trials":9044,"activeCount":101},[],{"trials":9046,"activeCount":101},[],{"trials":9048,"activeCount":101},[9049],{"nctId":9050,"briefTitle":9051,"status":205,"phases":9052,"primaryCompletion":561,"completion":9053,"start":2577,"enrollment":101,"conditions":9054,"interventions":9056},"NCT01169025","Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients",[93],"2014-10",[9055,18],"Trauma",[9024,9057],"Fentanyl",{"intervention":9059,"totalTrials":97,"cells":9060},"ACEI\u002FARB",{"EARLY_PHASE1":9061,"PHASE1":9063,"PHASE2":9065,"PHASE3":9067,"PHASE4":9069,"NA":9071},{"trials":9062,"activeCount":101},[],{"trials":9064,"activeCount":101},[],{"trials":9066,"activeCount":101},[],{"trials":9068,"activeCount":101},[],{"trials":9070,"activeCount":101},[],{"trials":9072,"activeCount":101},[9073],{"nctId":9074,"briefTitle":9075,"status":219,"phases":9076,"primaryCompletion":9077,"completion":9078,"start":9079,"enrollment":9080,"conditions":9081,"interventions":9083},"NCT04467931","ACEI or ARB and COVID-19 Severity and Mortality in US Veterans",[],"2020-10-21","2020-12-31","2020-01-19",22213,[7872,9082],"COVID",[9059,9084,9085,9086],"Non-ACEI\u002FARB","ACEI","ARB",{"intervention":9084,"totalTrials":97,"cells":9088},{"EARLY_PHASE1":9089,"PHASE1":9091,"PHASE2":9093,"PHASE3":9095,"PHASE4":9097,"NA":9099},{"trials":9090,"activeCount":101},[],{"trials":9092,"activeCount":101},[],{"trials":9094,"activeCount":101},[],{"trials":9096,"activeCount":101},[],{"trials":9098,"activeCount":101},[],{"trials":9100,"activeCount":101},[9101],{"nctId":9074,"briefTitle":9075,"status":219,"phases":9102,"primaryCompletion":9077,"completion":9078,"start":9079,"enrollment":9080,"conditions":9103,"interventions":9104},[],[7872,9082],[9059,9084,9085,9086],{"intervention":9085,"totalTrials":97,"cells":9106},{"EARLY_PHASE1":9107,"PHASE1":9109,"PHASE2":9111,"PHASE3":9113,"PHASE4":9115,"NA":9117},{"trials":9108,"activeCount":101},[],{"trials":9110,"activeCount":101},[],{"trials":9112,"activeCount":101},[],{"trials":9114,"activeCount":101},[],{"trials":9116,"activeCount":101},[],{"trials":9118,"activeCount":101},[9119],{"nctId":9074,"briefTitle":9075,"status":219,"phases":9120,"primaryCompletion":9077,"completion":9078,"start":9079,"enrollment":9080,"conditions":9121,"interventions":9122},[],[7872,9082],[9059,9084,9085,9086],{"intervention":9086,"totalTrials":97,"cells":9124},{"EARLY_PHASE1":9125,"PHASE1":9127,"PHASE2":9129,"PHASE3":9131,"PHASE4":9133,"NA":9135},{"trials":9126,"activeCount":101},[],{"trials":9128,"activeCount":101},[],{"trials":9130,"activeCount":101},[],{"trials":9132,"activeCount":101},[],{"trials":9134,"activeCount":101},[],{"trials":9136,"activeCount":101},[9137],{"nctId":9074,"briefTitle":9075,"status":219,"phases":9138,"primaryCompletion":9077,"completion":9078,"start":9079,"enrollment":9080,"conditions":9139,"interventions":9140},[],[7872,9082],[9059,9084,9085,9086],{"intervention":9142,"totalTrials":97,"cells":9143},"Intra articular PRP",{"EARLY_PHASE1":9144,"PHASE1":9146,"PHASE2":9148,"PHASE3":9150,"PHASE4":9152,"NA":9154},{"trials":9145,"activeCount":101},[],{"trials":9147,"activeCount":101},[],{"trials":9149,"activeCount":101},[],{"trials":9151,"activeCount":101},[],{"trials":9153,"activeCount":101},[],{"trials":9155,"activeCount":101},[9156],{"nctId":9157,"briefTitle":9158,"status":219,"phases":9159,"primaryCompletion":9160,"completion":9160,"start":9161,"enrollment":35,"conditions":9162,"interventions":9165},"NCT06543368","Low-Cost Platelet-Rich Plasma for Hemarthropathy",[93],"2025-05-05","2024-07-23",[9163,9164],"Hemarthrosis","Hemophilia",[9142],{"intervention":9167,"totalTrials":97,"cells":9168},"phenylephrine",{"EARLY_PHASE1":9169,"PHASE1":9171,"PHASE2":9173,"PHASE3":9175,"PHASE4":9177,"NA":9179},{"trials":9170,"activeCount":101},[],{"trials":9172,"activeCount":101},[],{"trials":9174,"activeCount":101},[],{"trials":9176,"activeCount":101},[],{"trials":9178,"activeCount":101},[],{"trials":9180,"activeCount":101},[9181],{"nctId":9182,"briefTitle":9183,"status":219,"phases":9184,"primaryCompletion":5381,"completion":8673,"start":9185,"enrollment":30,"conditions":9186,"interventions":9187},"NCT00585091","The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment",[93],"2003-10",[2240],[9167],{"intervention":9189,"totalTrials":97,"cells":9190},"Remimazolam 20 MG [Byfavo]",{"EARLY_PHASE1":9191,"PHASE1":9193,"PHASE2":9195,"PHASE3":9197,"PHASE4":9199,"NA":9201},{"trials":9192,"activeCount":101},[],{"trials":9194,"activeCount":101},[],{"trials":9196,"activeCount":101},[],{"trials":9198,"activeCount":101},[],{"trials":9200,"activeCount":101},[],{"trials":9202,"activeCount":101},[9203],{"nctId":9204,"briefTitle":9205,"status":219,"phases":9206,"primaryCompletion":9207,"completion":9207,"start":9208,"enrollment":1962,"conditions":9209,"interventions":9212},"NCT05415202","Remimazolam Sedation for Nerve Blocks",[],"2022-08-01","2022-06-06",[9210,9211],"Procedural Anxiety","Procedural Pain",[9189],{"intervention":9214,"totalTrials":97,"cells":9215},"liposomal bupivacaine\u002Fplain bupivacaine peri-articular",{"EARLY_PHASE1":9216,"PHASE1":9218,"PHASE2":9220,"PHASE3":9222,"PHASE4":9224,"NA":9226},{"trials":9217,"activeCount":101},[],{"trials":9219,"activeCount":101},[],{"trials":9221,"activeCount":101},[],{"trials":9223,"activeCount":101},[],{"trials":9225,"activeCount":101},[],{"trials":9227,"activeCount":101},[9228],{"nctId":9229,"briefTitle":9230,"status":219,"phases":9231,"primaryCompletion":2812,"completion":2812,"start":9232,"enrollment":9,"conditions":9233,"interventions":9235},"NCT02626559","Serum Bupivacaine Concentration Levels After Injection of Liposomal Bupivacaine Into the Knee",[],"2015-11",[9234],"Anesthesia, Local",[9214],{"intervention":9237,"totalTrials":97,"cells":9238},"Clomiphene",{"EARLY_PHASE1":9239,"PHASE1":9241,"PHASE2":9243,"PHASE3":9245,"PHASE4":9247,"NA":9249},{"trials":9240,"activeCount":101},[],{"trials":9242,"activeCount":101},[],{"trials":9244,"activeCount":101},[],{"trials":9246,"activeCount":101},[],{"trials":9248,"activeCount":101},[],{"trials":9250,"activeCount":101},[9251],{"nctId":9252,"briefTitle":9253,"status":219,"phases":9254,"primaryCompletion":4688,"completion":4688,"start":4663,"enrollment":22,"conditions":9255,"interventions":9257},"NCT01291056","Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation",[93],[9256],"Mood",[9237],{"intervention":9259,"totalTrials":97,"cells":9260},"Midodrine",{"EARLY_PHASE1":9261,"PHASE1":9263,"PHASE2":9265,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9262,"activeCount":101},[],{"trials":9264,"activeCount":101},[],{"trials":9266,"activeCount":101},[],{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"trials":9272,"activeCount":101},[9273],{"nctId":9274,"briefTitle":9275,"status":205,"phases":9276,"primaryCompletion":9277,"completion":9277,"start":9277,"enrollment":101,"conditions":9278,"interventions":9279},"NCT02383121","Midodrine for Ischemic Stroke With Penumbra",[],"2017-05-10",[34],[9259],{"intervention":9281,"totalTrials":97,"cells":9282},"PRP",{"EARLY_PHASE1":9283,"PHASE1":9285,"PHASE2":9287,"PHASE3":9289,"PHASE4":9291,"NA":9293},{"trials":9284,"activeCount":101},[],{"trials":9286,"activeCount":101},[],{"trials":9288,"activeCount":101},[],{"trials":9290,"activeCount":101},[],{"trials":9292,"activeCount":101},[],{"trials":9294,"activeCount":101},[9295],{"nctId":9296,"briefTitle":9297,"status":219,"phases":9298,"primaryCompletion":9299,"completion":9300,"start":956,"enrollment":361,"conditions":9301,"interventions":9303},"NCT06332352","Intra-articular Platelet-Rich Plasma for Acetabular Labral Tears",[93],"2026-01-31","2026-03-01",[9302],"Acetabular Labrum Tear",[9281],{"intervention":9305,"totalTrials":97,"cells":9306},"Imiquimod Cream",{"EARLY_PHASE1":9307,"PHASE1":9309,"PHASE2":9311,"PHASE3":9313,"PHASE4":9315,"NA":9317},{"trials":9308,"activeCount":101},[],{"trials":9310,"activeCount":101},[],{"trials":9312,"activeCount":101},[],{"trials":9314,"activeCount":101},[],{"trials":9316,"activeCount":101},[],{"trials":9318,"activeCount":101},[9319],{"nctId":9320,"briefTitle":9321,"status":219,"phases":9322,"primaryCompletion":3148,"completion":3148,"start":9323,"enrollment":4399,"conditions":9324,"interventions":9326},"NCT00707174","Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna",[93],"2005-03",[15,9325],"Lentigo Maligna",[9305,9327],"Tazarotene Cream 0.1%",{"intervention":9327,"totalTrials":97,"cells":9329},{"EARLY_PHASE1":9330,"PHASE1":9332,"PHASE2":9334,"PHASE3":9336,"PHASE4":9338,"NA":9340},{"trials":9331,"activeCount":101},[],{"trials":9333,"activeCount":101},[],{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[],{"trials":9341,"activeCount":101},[9342],{"nctId":9320,"briefTitle":9321,"status":219,"phases":9343,"primaryCompletion":3148,"completion":3148,"start":9323,"enrollment":4399,"conditions":9344,"interventions":9345},[93],[15,9325],[9305,9327],{"intervention":9347,"totalTrials":97,"cells":9348},"Copper T-380 IUD",{"EARLY_PHASE1":9349,"PHASE1":9351,"PHASE2":9353,"PHASE3":9355,"PHASE4":9357,"NA":9359},{"trials":9350,"activeCount":101},[],{"trials":9352,"activeCount":101},[],{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[],{"trials":9360,"activeCount":101},[9361],{"nctId":9362,"briefTitle":9363,"status":219,"phases":9364,"primaryCompletion":9365,"completion":9365,"start":6763,"enrollment":9366,"conditions":9367,"interventions":9371},"NCT02076217","Quick Start of Highly Effective Contraception",[],"2021-10",270,[9368,9369,29,9370,144],"IUD","Contraceptive Implant","Birth Control",[9347,9372,9373],"LNG IUD","Depo-Provera",{"intervention":9372,"totalTrials":97,"cells":9375},{"EARLY_PHASE1":9376,"PHASE1":9378,"PHASE2":9380,"PHASE3":9382,"PHASE4":9384,"NA":9386},{"trials":9377,"activeCount":101},[],{"trials":9379,"activeCount":101},[],{"trials":9381,"activeCount":101},[],{"trials":9383,"activeCount":101},[],{"trials":9385,"activeCount":101},[],{"trials":9387,"activeCount":101},[9388],{"nctId":9362,"briefTitle":9363,"status":219,"phases":9389,"primaryCompletion":9365,"completion":9365,"start":6763,"enrollment":9366,"conditions":9390,"interventions":9391},[],[9368,9369,29,9370,144],[9347,9372,9373],{"intervention":9373,"totalTrials":97,"cells":9393},{"EARLY_PHASE1":9394,"PHASE1":9396,"PHASE2":9398,"PHASE3":9400,"PHASE4":9402,"NA":9404},{"trials":9395,"activeCount":101},[],{"trials":9397,"activeCount":101},[],{"trials":9399,"activeCount":101},[],{"trials":9401,"activeCount":101},[],{"trials":9403,"activeCount":101},[],{"trials":9405,"activeCount":101},[9406],{"nctId":9362,"briefTitle":9363,"status":219,"phases":9407,"primaryCompletion":9365,"completion":9365,"start":6763,"enrollment":9366,"conditions":9408,"interventions":9409},[],[9368,9369,29,9370,144],[9347,9372,9373],{"intervention":9411,"totalTrials":97,"cells":9412},"SoluMedrol",{"EARLY_PHASE1":9413,"PHASE1":9415,"PHASE2":9417,"PHASE3":9419,"PHASE4":9421,"NA":9423},{"trials":9414,"activeCount":101},[],{"trials":9416,"activeCount":101},[],{"trials":9418,"activeCount":101},[],{"trials":9420,"activeCount":101},[],{"trials":9422,"activeCount":101},[],{"trials":9424,"activeCount":101},[9425],{"nctId":9426,"briefTitle":9427,"status":193,"phases":9428,"primaryCompletion":9429,"completion":9430,"start":9053,"enrollment":2025,"conditions":9431,"interventions":9432},"NCT02296346","Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis",[93],"2017-06-13","2018-05-10",[8233],[9411],{"intervention":9434,"totalTrials":97,"cells":9435},"Linezolid or Vancomycin",{"EARLY_PHASE1":9436,"PHASE1":9438,"PHASE2":9440,"PHASE3":9442,"PHASE4":9444,"NA":9446},{"trials":9437,"activeCount":101},[],{"trials":9439,"activeCount":101},[],{"trials":9441,"activeCount":101},[],{"trials":9443,"activeCount":101},[],{"trials":9445,"activeCount":101},[],{"trials":9447,"activeCount":101},[9448],{"nctId":9449,"briefTitle":9450,"status":219,"phases":9451,"primaryCompletion":3101,"completion":3101,"start":2721,"enrollment":304,"conditions":9452,"interventions":9454},"NCT00811980","The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents",[],[9453],"Sepsis",[9434],{"intervention":9456,"totalTrials":97,"cells":9457},"Lucentis",{"EARLY_PHASE1":9458,"PHASE1":9460,"PHASE2":9462,"PHASE3":9464,"PHASE4":9466,"NA":9468},{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[],{"trials":9463,"activeCount":101},[],{"trials":9465,"activeCount":101},[],{"trials":9467,"activeCount":101},[],{"trials":9469,"activeCount":101},[9470],{"nctId":9471,"briefTitle":9472,"status":193,"phases":9473,"primaryCompletion":9474,"completion":2719,"start":7870,"enrollment":9475,"conditions":9476,"interventions":9478},"NCT00474695","Study Evaluating Genotypes Using Lucentis",[],"2009-06",65,[9477],"Age-Related Maculopathy",[9456],{"intervention":8811,"totalTrials":97,"cells":9480},{"EARLY_PHASE1":9481,"PHASE1":9483,"PHASE2":9485,"PHASE3":9487,"PHASE4":9489,"NA":9491},{"trials":9482,"activeCount":101},[],{"trials":9484,"activeCount":101},[],{"trials":9486,"activeCount":101},[],{"trials":9488,"activeCount":101},[],{"trials":9490,"activeCount":101},[],{"trials":9492,"activeCount":101},[9493],{"nctId":8804,"briefTitle":8805,"status":205,"phases":9494,"primaryCompletion":3615,"completion":3615,"start":4794,"enrollment":101,"conditions":9495,"interventions":9496},[93],[8808,8809],[8811,6683],{"intervention":9498,"totalTrials":97,"cells":9499},"PENNSAID",{"EARLY_PHASE1":9500,"PHASE1":9502,"PHASE2":9504,"PHASE3":9506,"PHASE4":9508,"NA":9510},{"trials":9501,"activeCount":101},[],{"trials":9503,"activeCount":101},[],{"trials":9505,"activeCount":101},[],{"trials":9507,"activeCount":101},[],{"trials":9509,"activeCount":101},[],{"trials":9511,"activeCount":101},[9512],{"nctId":9513,"briefTitle":9514,"status":205,"phases":9515,"primaryCompletion":2095,"completion":2095,"start":9516,"enrollment":101,"conditions":9517,"interventions":9519},"NCT01350622","Efficacy of PENNSAID® for Pain Management in the Emergency Department",[93],"2011-12",[18,9518],"Ankle Sprain",[9498,9520],"Diclofenac hydroxyethylpyrrolidine",{"intervention":9520,"totalTrials":97,"cells":9522},{"EARLY_PHASE1":9523,"PHASE1":9525,"PHASE2":9527,"PHASE3":9529,"PHASE4":9531,"NA":9533},{"trials":9524,"activeCount":101},[],{"trials":9526,"activeCount":101},[],{"trials":9528,"activeCount":101},[],{"trials":9530,"activeCount":101},[],{"trials":9532,"activeCount":101},[],{"trials":9534,"activeCount":101},[9535],{"nctId":9513,"briefTitle":9514,"status":205,"phases":9536,"primaryCompletion":2095,"completion":2095,"start":9516,"enrollment":101,"conditions":9537,"interventions":9538},[93],[18,9518],[9498,9520],{"intervention":9540,"totalTrials":97,"cells":9541},"Isoniazid",{"EARLY_PHASE1":9542,"PHASE1":9544,"PHASE2":9546,"PHASE3":9548,"PHASE4":9550,"NA":9552},{"trials":9543,"activeCount":101},[],{"trials":9545,"activeCount":101},[],{"trials":9547,"activeCount":101},[],{"trials":9549,"activeCount":101},[],{"trials":9551,"activeCount":101},[],{"trials":9553,"activeCount":101},[9554],{"nctId":9555,"briefTitle":9556,"status":193,"phases":9557,"primaryCompletion":8838,"completion":8838,"start":2813,"enrollment":3015,"conditions":9558,"interventions":9561},"NCT01550705","Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria",[93],[9559,9560],"Erythropoietic Protoporphyria (EPP)","X Linked Erythropoietic Protoporphyria",[9540],{"intervention":9563,"totalTrials":97,"cells":9564},"Pioglitazone",{"EARLY_PHASE1":9565,"PHASE1":9567,"PHASE2":9569,"PHASE3":9571,"PHASE4":9573,"NA":9575},{"trials":9566,"activeCount":101},[],{"trials":9568,"activeCount":101},[],{"trials":9570,"activeCount":101},[],{"trials":9572,"activeCount":101},[],{"trials":9574,"activeCount":101},[],{"trials":9576,"activeCount":101},[9577],{"nctId":9578,"briefTitle":9579,"status":219,"phases":9580,"primaryCompletion":8838,"completion":8838,"start":4391,"enrollment":4048,"conditions":9581,"interventions":9583},"NCT01301027","Effect of Adipokines in Hemodialysis Patients",[93],[9582],"End Stage Renal Disease",[9563],{"intervention":9585,"totalTrials":97,"cells":9586},"ZTlido 1.8 % Topical System",{"EARLY_PHASE1":9587,"PHASE1":9589,"PHASE2":9591,"PHASE3":9593,"PHASE4":9595,"NA":9597},{"trials":9588,"activeCount":101},[],{"trials":9590,"activeCount":101},[],{"trials":9592,"activeCount":101},[],{"trials":9594,"activeCount":101},[],{"trials":9596,"activeCount":101},[],{"trials":9598,"activeCount":101},[9599],{"nctId":9600,"briefTitle":9601,"status":219,"phases":9602,"primaryCompletion":9603,"completion":9603,"start":8230,"enrollment":9604,"conditions":9605,"interventions":9607},"NCT06030297","Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.",[93],"2026-02-09",75,[9606],"Peripheral Neuropathy",[9585],{"intervention":9609,"totalTrials":97,"cells":9610},"Dietary and Exercise Intervention",{"EARLY_PHASE1":9611,"PHASE1":9613,"PHASE2":9615,"PHASE3":9617,"PHASE4":9619,"NA":9621},{"trials":9612,"activeCount":101},[],{"trials":9614,"activeCount":101},[],{"trials":9616,"activeCount":101},[],{"trials":9618,"activeCount":101},[],{"trials":9620,"activeCount":101},[],{"trials":9622,"activeCount":101},[9623],{"nctId":9624,"briefTitle":9625,"status":219,"phases":9626,"primaryCompletion":9627,"completion":9627,"start":9628,"enrollment":171,"conditions":9629,"interventions":9632},"NCT06002269","A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients",[93],"2025-07-08","2024-06-04",[259,9630,9631],"Cystectomy","Chemotherapy",[9609],{"intervention":9634,"totalTrials":97,"cells":9635},"LDE225",{"EARLY_PHASE1":9636,"PHASE1":9638,"PHASE2":9640,"PHASE3":9642,"PHASE4":9644,"NA":9646},{"trials":9637,"activeCount":101},[],{"trials":9639,"activeCount":101},[],{"trials":9641,"activeCount":101},[],{"trials":9643,"activeCount":101},[],{"trials":9645,"activeCount":101},[],{"trials":9647,"activeCount":101},[9648],{"nctId":9649,"briefTitle":9650,"status":205,"phases":9651,"primaryCompletion":9053,"completion":9053,"start":1903,"enrollment":101,"conditions":9652,"interventions":9654},"NCT01911416","A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer",[93],[9653],"Pancreatic Ductal Adenocarcinoma",[9634],{"intervention":9057,"totalTrials":97,"cells":9656},{"EARLY_PHASE1":9657,"PHASE1":9659,"PHASE2":9661,"PHASE3":9663,"PHASE4":9665,"NA":9667},{"trials":9658,"activeCount":101},[],{"trials":9660,"activeCount":101},[],{"trials":9662,"activeCount":101},[],{"trials":9664,"activeCount":101},[],{"trials":9666,"activeCount":101},[],{"trials":9668,"activeCount":101},[9669],{"nctId":9050,"briefTitle":9051,"status":205,"phases":9670,"primaryCompletion":561,"completion":9053,"start":2577,"enrollment":101,"conditions":9671,"interventions":9672},[93],[9055,18],[9024,9057],{"intervention":8975,"totalTrials":97,"cells":9674},{"EARLY_PHASE1":9675,"PHASE1":9677,"PHASE2":9679,"PHASE3":9681,"PHASE4":9683,"NA":9685},{"trials":9676,"activeCount":101},[],{"trials":9678,"activeCount":101},[],{"trials":9680,"activeCount":101},[],{"trials":9682,"activeCount":101},[],{"trials":9684,"activeCount":101},[],{"trials":9686,"activeCount":101},[9687],{"nctId":8969,"briefTitle":8970,"status":219,"phases":9688,"primaryCompletion":6145,"completion":6145,"start":562,"enrollment":8972,"conditions":9689,"interventions":9690},[],[8965],[8946,8975],{"intervention":9692,"totalTrials":97,"cells":9693},"Acitretin 25Mg Oral",{"EARLY_PHASE1":9694,"PHASE1":9696,"PHASE2":9698,"PHASE3":9700,"PHASE4":9702,"NA":9704},{"trials":9695,"activeCount":101},[],{"trials":9697,"activeCount":101},[],{"trials":9699,"activeCount":101},[],{"trials":9701,"activeCount":101},[],{"trials":9703,"activeCount":101},[],{"trials":9705,"activeCount":101},[9706],{"nctId":9707,"briefTitle":9708,"status":193,"phases":9709,"primaryCompletion":4861,"completion":7466,"start":4663,"enrollment":2025,"conditions":9710,"interventions":9712},"NCT01094717","Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis",[93],[9711],"Psoriasis",[9692,9713],"Tazarotene 0.1% Gel,Top",{"intervention":9713,"totalTrials":97,"cells":9715},{"EARLY_PHASE1":9716,"PHASE1":9718,"PHASE2":9720,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9717,"activeCount":101},[],{"trials":9719,"activeCount":101},[],{"trials":9721,"activeCount":101},[],{"trials":9723,"activeCount":101},[],{"trials":9725,"activeCount":101},[],{"trials":9727,"activeCount":101},[9728],{"nctId":9707,"briefTitle":9708,"status":193,"phases":9729,"primaryCompletion":4861,"completion":7466,"start":4663,"enrollment":2025,"conditions":9730,"interventions":9731},[93],[9711],[9692,9713],{"intervention":9733,"totalTrials":97,"cells":9734},"interscalene nerve block with 0.25% bupivacaine",{"EARLY_PHASE1":9735,"PHASE1":9737,"PHASE2":9739,"PHASE3":9741,"PHASE4":9743,"NA":9745},{"trials":9736,"activeCount":101},[],{"trials":9738,"activeCount":101},[],{"trials":9740,"activeCount":101},[],{"trials":9742,"activeCount":101},[],{"trials":9744,"activeCount":101},[],{"trials":9746,"activeCount":101},[9747],{"nctId":9748,"briefTitle":9749,"status":219,"phases":9750,"primaryCompletion":4300,"completion":4300,"start":4391,"enrollment":361,"conditions":9751,"interventions":9753},"NCT01429584","The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function",[93],[9752],"Diaphragm Paralysis",[9733,9754],"interscalene block with 0.125% bupivacaine",{"intervention":9754,"totalTrials":97,"cells":9756},{"EARLY_PHASE1":9757,"PHASE1":9759,"PHASE2":9761,"PHASE3":9763,"PHASE4":9765,"NA":9767},{"trials":9758,"activeCount":101},[],{"trials":9760,"activeCount":101},[],{"trials":9762,"activeCount":101},[],{"trials":9764,"activeCount":101},[],{"trials":9766,"activeCount":101},[],{"trials":9768,"activeCount":101},[9769],{"nctId":9748,"briefTitle":9749,"status":219,"phases":9770,"primaryCompletion":4300,"completion":4300,"start":4391,"enrollment":361,"conditions":9771,"interventions":9772},[93],[9752],[9733,9754],{"intervention":9774,"totalTrials":97,"cells":9775},"Ibuprofen",{"EARLY_PHASE1":9776,"PHASE1":9778,"PHASE2":9780,"PHASE3":9782,"PHASE4":9784,"NA":9786},{"trials":9777,"activeCount":101},[],{"trials":9779,"activeCount":101},[],{"trials":9781,"activeCount":101},[],{"trials":9783,"activeCount":101},[],{"trials":9785,"activeCount":101},[],{"trials":9787,"activeCount":101},[9788],{"nctId":9789,"briefTitle":9790,"status":193,"phases":9791,"primaryCompletion":5086,"completion":5086,"start":2721,"enrollment":30,"conditions":9792,"interventions":9795},"NCT00833365","Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure",[93],[9793,9794],"Patent Ductus Arteriosus","Prematurity",[9774,9774],{"intervention":9797,"totalTrials":97,"cells":9798},"Febuxostat",{"EARLY_PHASE1":9799,"PHASE1":9801,"PHASE2":9803,"PHASE3":9805,"PHASE4":9807,"NA":9809},{"trials":9800,"activeCount":101},[],{"trials":9802,"activeCount":101},[],{"trials":9804,"activeCount":101},[],{"trials":9806,"activeCount":101},[],{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[9811],{"nctId":9812,"briefTitle":9813,"status":219,"phases":9814,"primaryCompletion":9815,"completion":2653,"start":4688,"enrollment":8614,"conditions":9816,"interventions":9819},"NCT01350388","Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease",[93],"2013-10",[9817,9818],"Chronic Kidney Disease","Diabetes",[9797]]